Document:

EX-10.9

 Exhibit 10.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 CO-DEVELOPMENT AND
LICENSE AGREEMENT 
 among 

NOVOCODEX BIOPHARMACEUTICALS LTD. 

and 
 AMBRX, INC. 

Dated as of 22 October, 2019 

  
 1 

 This CO-DEVELOPMENT AND LICENSE
AGREEMENT (this “Agreement”), effective as of 22 October, 2019 (the “Effective Date”), is between, Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North
Torrey Pines Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and NovoCodex Biopharmaceuticals Ltd., a company registered under the laws of the
People’s Republic of China, with its registered address in Shaoxing, China, for and on behalf of itself and its Affiliates (together with its Affiliates, “Novocodex”). Novocodex currently is majority owned by Zhejiang Medicine
Co. Ltd., a company registered with address in Shaoxing, China. Ambrx and Novocodex may each be referred to herein individually as a “Party” or, collectively, as the “Parties.” 

RECITALS 

WHEREAS, Ambrx owns and/or controls Ambrx Background Technology (as hereinafter defined) and has rights to Licensed
Intellectual Property Rights (as hereinafter defined) with respect to the Program (as hereinafter defined); 

WHEREAS, Novocodex is a pharmaceutical company engaged in research, development, and commercialization of pharmaceutical
products, including the human therapeutic products in the Territory (as hereinafter defined); 
 WHEREAS, Novocodex
desires to obtain an exclusive license under the Ambrx Existing Patent Rights in the Territory upon the terms and conditions set forth herein, and Ambrx desires to grant such a license, in order for Novocodex, to develop, make, use, sell, offer for
sale the Licensed Products (as hereinafter defined) for the prevention or treatment of human diseases and human conditions in the Territory; and 

WHEREAS, Novocodex desires to obtain assistance from Ambrx and Ambrx desires to offer such assistance to Novocodex to
develop the Program and the Licensed Products in the Territory under world-class standards. 
 NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 As used in this Agreement, the following terms shall have those meanings set forth in this ARTICLE 1 unless the
context dictates otherwise. 
  

	1.1	 “Anti-CD70-ADC” shall mean an Antibody Drug
Conjugate (ADC) which is capable of binding primarily to CD70 and being conjugated to one cytotoxic payload. For clarity, Anti-CD70-ADC includes ADC that has been conjugated to one cytotoxic payload.

  

	1.2	 “ARX305” shall mean the Anti-CD70-ADC with the
structure depicted in Exhibit 1.1, also known as ARX305. 

  
 2 

	1.3	 “Affiliate” shall mean, with respect to any Person, any other Person that directly or
indirectly controls, is controlled by, or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of
such Person, whether through the ownership of fifty percent (50%) or more of the voting securities of such Person by voting agreement, by contract or otherwise. 

 

	1.4	 “Ambrx Background Technology” shall mean Know-How and
Ambrx Patent Rights, including inventions, discoveries, improvements, processes, methods, protocols, formulas, compositions, data, inventions, know-how and/or trade secrets, patentable or otherwise, which are
owned and/or Controlled by Ambrx or any of its Affiliates as of the Effective Date or during the Term of this Agreement. 

  

	1.5	 “Ambrx Existing Patent Rights” shall mean all Patent Rights in the Territory owned or
Controlled by or licensed to Ambrx as of the Effective Date which is related to ARX305 as shown in Exhibit 1.5. 

  

	1.6	 “Ambrx Improvements” shall mean all Patent Rights and
Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by one or more employees or Third Parties working on behalf of Ambrx, in connection with the
development of Licensed Products or in the course of engaging in the Program during the Term of this Agreement without involvement of any employees from Novocodex. 

 

	1.7	 “Ambrx Know-How” shall mean all Confidential
Information & Materials, technical knowledge, materials, cells or cell lines, software, trade secrets, Know-How, process technology and other knowledge, information, or technology in possession of
Ambrx and its Affiliate, as of the Effective Date and during the Royalty Term, concerning subject matter relating to Licensed Products and which are necessary for the development, manufacture, use or sale of Licensed Products in the Field in the
Territory. 

  

	1.8	 “Ambrx Patent Rights” shall mean any Patent Rights Controlled or owned by Ambrx as of the
Effective Date or during the Term of this Agreement in addition to Ambrx Existing Patent Rights. 

  

	1.9	 “Antibody” or “Antibodies” shall mean a full length antibody which is a
“Y”-shaped protein consisting of four polypeptide chains: two identical heavy chains and two identical light chains connected by disulfide bonds, capable of binding to an antigen, whether polyclonal, monoclonal, human, humanized, chimeric,
murine, synthetic or from any other source. 

  

	1.10	 “Antibody Drug Conjugate” or “ADC” shall mean an Antibody which
1) has undergone modification through [***], 2) provides one or more specific site(s) in the amino acid sequence of the Antibody suitable for conjugation, and 3) is suitable and capable of [***]. 

  
 3 

 For clarity, ADC includes an Antibody that has been conjugated, linked or attached to one or
more cytotoxic payload(s) via one or more specific site(s). 
  

	1.11	 “Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to
any of the Parties or their respective Affiliates in carrying out activities hereunder or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject by law or by agreement, and shall include all
statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, policies, directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local
authority or other governmental entity in such jurisdictions. 

  

	1.12	 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar
months ending on March 31, June 30, September 30 and December 31. 

  

	1.13	 “Calendar Year” shall mean each successive period of twelve (12) months commencing on
January 1 and ending on December 31. 

  

	1.14	 “CD70” shall mean the protein encoded by the CD70 (Cluster of Differentiation 70, Entrez Gene:
970) gene which is known to be a cytokine in the tumor necrosis factor (TNF) ligand family. 

  

	1.15	 “cGMP” or “Current Good Manufacturing Practice” shall mean the
applicable then-current standards for manufacturing of pharmaceuticals or biologicals, as set forth in the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301, as amended from time to time, together with any similar
standards of good manufacturing practice as required by the FDA and other relevant Regulatory Authority. 

  

	1.16	 “China GAAP” shall mean Generally Accepted Accounting Principles for the People’s
Republic of China. 

  

	1.17	 “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a
Party with respect to any objective, [***]. 

  

	1.18	 “Confidential Information & Materials” shall mean any and all
proprietary and/or confidential information, materials, and data, including all scientific, pre-clinical, clinical, 

  
 4 

	 	
regulatory, process, formulation, manufacturing, marketing, financial and commercial information or data, compounds, cells, cell lines, whether communicated in writing or orally or by any other
method, which are provided by one Party to the other Party prior to or during the Term of this Agreement. 

  

	1.19	 “Control”, “Controls” or “Controlled by” shall mean with
respect to any Patent Rights, Know-How, Confidential Information & Materials, or other intellectual property assets or other items or rights, as applicable, the possession of (whether by ownership or
license or other right, other than pursuant to a license under this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, such item or right as provided for herein without violating the terms of any agreement and
without additional payments or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense. 

 

	1.20	 “Covered By” shall mean, with respect to Patent Rights: materials, products and services
developed, manufactured, used, sold or provided by Novocodex, which but for the License, would infringe a Valid Claim of such Patent Rights in the Territory in which such products or services are developed, used, manufactured, sold or provided by
Novocodex, respectively. 

  

	1.21	 “Effective Date” shall mean the date first set forth above. 

 

	1.22	 “FDA” shall mean the United States Food and Drug Administration, or any successor thereto.

  

	1.23	 “Field” shall mean all human indications and uses, such as diagnosis, prevention, and
treatment of human diseases and conditions associated with anti-CD70. For clarity, the Field is for human use only and excludes all non-human indications and uses. 

 

	1.24	 “First Commercial Sale” shall mean, with respect to Licensed Product, the first sale to the
general public of such Licensed Product in the Territory after all required marketing and pricing approvals have been granted, or otherwise permitted, by the governing health authority of Territory such as NMPA. “First Commercial Sale”
shall not include the provision of any Licensed Product for use in clinical trials or for compassionate use, in each case, if such use is not compensated, prior to the receipt of necessary Marketing Authorization. 

 

	1.25	 “Full Time Equivalent” or “FTE” shall mean a dedicated full-time employee or
contractor of Ambrx, as the case may be, or in the case of less than a full-time dedicated person, a full-time, equivalent person year, each based upon the total of one thousand six hundred eighty (1680) hours per year of work on activities
hereunder. 

  

	1.26	 “FTE Rate” means the yearly rate at which Novocodex will fund Ambrx FTEs for labor and
services. 

  

	1.27	 “Generic/Biosimilar Competition” shall mean the sale of products containing ARX305 in the
Territory by a Third Party. 

  
 5 

	1.28	 “Global Development Plan” means the plan setting forth the
pre-clinical, clinical, manufacturing and regulatory activities and timelines relating to the development of Licensed Products in the Field. An initial draft of the Global Development Plan is set forth on
Exhibit 1.28. 

  

	1.29	 “Joint Development Technology” or “Joint Improvements” shall mean all
inventions and Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by, on one hand, one or more employees or Third Parties working on behalf of
Novocodex, on the one hand, with one or more employees or Third Parties working on behalf of Ambrx, on the other hand, in connection with the development of Licensed Products or in the course of engaging in the Program, as well as any and all Patent
Rights covering the same. 

  

	1.30	 “Joint Steering Committee” shall mean the entity organized and acting pursuant to ARTICLE 3.

  

	1.31	 “Know-How” shall mean unpatented technical and other
information or materials which are not in the public domain including information comprising or relating to discoveries, inventions, data, designs, formulae, methods, models, assays, research plans, procedures, designs for experiments and tests and
results of experimentation and testing (including results of research or development or Anti-CD70-ADC Program), cells or cell lines (including cells or cell lines producing Anti-CD70 Antibody or Anti-CD70
ADC), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or
summaries and information contained in submissions to and information from ethical committees and regulatory authorities. Know-How includes rights protecting Know-How.
The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, and/or a development relating to the item, is (and remains) not known to the public. 

 

	1.32	 “License” shall mean all of the rights granted by Ambrx to Novocodex by this Agreement under
the Licensed Intellectual Property Rights pursuant to Sections 2.1.1 and 2.1.2. 

  

	1.33	 “Licensed Intellectual Property Rights” shall mean (a) Ambrx Know-How; and (b) Ambrx Existing Patent Rights. 

  

	1.34	 “Licensed Product” shall mean any pharmaceutical product containing ARX305 as an active
pharmaceutical ingredient, that meets any of the following criteria: (i) the development, use, manufacture or sale of such product is or will be Covered By a Valid Claim of any Ambrx Existing Patent Rights and/or Ambrx Patent Rights; or
(ii) such product (a) is not described in clause (i) above and (b) is developed, manufactured, sold or provided using Ambrx Know-How. 

  
 6 

	1.35	 “Marketing Authorization” shall mean all approvals from NMPA necessary to market and sell a
Licensed Product in the Territory or a Regulatory Authority in a corresponding jurisdiction outside the Territory. 

  

	1.36	 “Net Sales” shall mean: 

(I) to Ambrx, the “for profit” licensing revenue Ambrx received from a Third Party by transferring, assigning or licensing Phase I
Clinical Data to such Third Party, [***]; and 
 (II) to Novocodex, the gross invoice price (not including value added taxes, sales taxes, or
similar taxes) of Licensed Product sold by Novocodex or its Affiliate or sublicensee to the first Third Party in which Novocodex or its Affiliate or sublicensee has no equity interest after deducting, if not previously deducted, from the amount
invoiced or received: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; and 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; and 

  

	 	(i)	 [***]. 

Any individual items that are estimated and deducted in calculating Net Sales shall be periodically (but at least on a calendar quarter basis)
trued up and adjusted by Novocodex consistent with its customary practices and in accordance with China GAAP. Any deductions subsequently reversed shall be included in Net Sales for the royalty period in which such deductions are reversed. In no
event shall the total amount of deductions 

  
 7 

 
made in accordance with Items 1.36(II)(e) through (i) above during any period exceed [***]% of the gross invoice price for such period. The calculation of Net Sales hereunder shall be in
accordance with China GAAP and Novocodex’s and/or its Affiliates’ customary accounting policies, applied consistently across periods, and 

(1) Transfer or sale of a Licensed Product within Novocodex, between Novocodex and an Affiliate, or between Novocodex and a non-Affiliate Third Party in which Novocodex has equity interest shall not be considered a sale, commercial use or disposition for the purpose of the foregoing paragraphs; 

(2) in the event that Novocodex has to transfer or sell any Licensed Product to a non-Affiliate Third
Party in which Novocodex has equity interest, Novocodex and Ambrx shall jointly discuss and determine the value of Net Sales; and 
 (3) in
the event that Novocodex receives consideration for any Licensed Products in the case of transactions not at arm’s length with a non-Affiliate of Novocodex, Net Sales will be calculated [***]. 

 

	1.37	 “NMPA” shall mean National Medical and Pharmaceutical Administration in the People’s
Republic of China, or any successor thereto. 

  

	1.38	 “Novocodex Improvements” shall mean all Patent Rights and
Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by one or more employees or Third Parties working on behalf of Novocodex, in connection with
the development of Licensed Products or in the course of engaging in the Program without any involvement with employee(s) of Ambrx. 

  

	1.39	 “Patent Rights” shall mean any and all rights under any of the following, whether existing now
or in the future, and whether or not filed: (i) a United States, international or foreign patent, utility model, design registration, certificate of invention, patent of addition or substitution, or other governmental grant for the protection
of inventions or industrial designs anywhere in the world, including any reissue, renewal, re-examination or extension thereof; and (ii) any application for any of the foregoing, including any
international, provisional, divisional, continuation, continuation-in-part, or continued prosecution application. 

 

	1.40	 “Person” shall mean any natural person, corporation, firm, business trust, joint venture,
association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. 

  

	1.41	 “Phase I Clinical Data” shall mean data, information, or regulatory filings related to Phase I
Clinical Trial in a country that would satisfy the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent thereof. 

  

	1.42	 “Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent thereof. 

  
 8 

	1.43	 “Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 CFR 312.21(b), as may be amended, or the foreign equivalent thereof. 

  

	1.44	 “Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 CFR 312.21(c), as may be amended, or the foreign equivalent thereof. 

  

	1.45	 “Program” shall mean development, preclinical and clinical activities directed by the Joint
Steering Committee and undertaken by the Parties to develop ARX305 into a therapeutic product. 

  

	1.46	 “Regulatory Authority” shall mean any applicable government regulatory authority involved in
granting approvals for the manufacturing, marketing, reimbursement and/or pricing of the Licensed Product or ARX305 in the Territory or outside the Territory, including, in the Territory, NMPA, and in the United States, the FDA and any successor
governmental authority having substantially the same function. 

  

	1.47	 “Royalty Term” shall have the meaning set forth in Section 6.5. 

 

	1.48	 “Territory” shall mean all cities, zones, provinces, territories and other divisions or
regions in and throughout the People’s Republic of China. 

  

	1.49	 “Third Party” shall mean a person or entity other than Ambrx, Novocodex or their Affiliates.

  

	1.50	 “Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent
Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
(ii) rendered unenforceable through disclaimer or otherwise, (iii) abandoned or (iv) permanently lost through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending
patent application within the Patent Rights that (i) has been asserted and continues to be prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling. 

ARTICLE 2 
 LICENSE;
DEVELOPMENT AND COMMERCIALIZATION 
  

	2.1	 EXCLUSIVE LICENSE GRANT BY AMBRX. 

 

	2.1.1	 Subject to terms and conditions of this Agreement, including the rights retained by Ambrx in Sections 2.1.3
& 2.1.4, Ambrx hereby grants to Novocodex an exclusive right and license in the Field throughout the Territory, with the right to grant sublicenses subject to Section 2.9.1, under Ambrx Existing Patent Rights to develop, have developed,

  
 9 

	 	
use, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products during the Term of this Agreement. 

 

	2.1.2	 Subject to terms and conditions of this Agreement, including the rights retained by Ambrx in Sections 2.1.3
& 2.1.4, Ambrx hereby grants to Novocodex an exclusive right and license in the Field throughout the Territory, with the right to grant sublicenses subject to Section 2.9.1, under Ambrx Know-How to
develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products during the Term of this Agreement. 

  

	2.1.3	 Ambrx shall retain non-exclusive and sublicensable rights under the
foregoing Licenses in Section 2.1.1 and 2.1.2 solely as are necessary to perform documented research activities in the Territory and Ambrx shall notify Novocodex in writing thirty (30) days in advance of such activities.

  

	2.1.4	 Ambrx shall retain all rights under Licensed Intellectual Property Rights unless otherwise specifically and
expressly set forth in this Agreement. 

  

	2.1.5	 Ambrx agrees that during the Term of this Agreement, it will not grant any exclusive right and license under
Ambrx Existing Patent Rights to any Third Party to develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold any product containing any Anti-CD70-ADC for use in the Field
and in the Territory. 

  

	2.2	 NON-EXCLUSIVE LICENSE GRANT BY AMBRX. Ambrx hereby grants to Novocodex a non-exclusive right and license in the
Field in any mutually approved jurisdiction outside the Territory, under the Licensed Intellectual Property Rights, for the sole purpose of conducting regulatory activities for Phase I Clinical Data in said jurisdiction for the Licensed Products;
provided that the Joint Steering Committee may amend such jurisdiction from time to time. 

  

	2.3	 NON-EXCLUSIVE SUBLICENSE GRANT BY AMBRX. In the event that, during the
term of this Agreement and after the Effective Date, Ambrx licenses from any Third Party rights in the Field to any Valid Claim of any issued patent or patent application issued to a Third Party that shall be necessary for Novocodex’s exercise
of its rights pursuant to Section 2.1 herein (an “Ambrx Third Party License”) in the Territory, Ambrx shall promptly notify Novocodex of the terms of such Ambrx Third Party License and the rights covered by such license. Upon
request by Novocodex, and to the extent not prohibited by such Ambrx Third Party License, Ambrx shall grant to Novocodex, and does hereby grant to Novocodex, a non-exclusive right and sublicense (if permitted
by the Third Party) in the Field throughout the Territory, with the right to grant further sublicenses subject to Section 2.9.1, under the rights granted to Ambrx in the Ambrx Third Party License. Ambrx shall use reasonable efforts to secure
the right to grant the sublicense under this Section in any Ambrx Third Party License. If Novocodex is required to pay certain royalty payment to such a Third Party under Ambrx Third Party License, Novocodex is entitled to offset such royalty
payment pursuant to the terms in Section 6.7. 

  
 10 

	2.4	 NON-EXCLUSIVE LICENSE GRANT BY AMBRX. Ambrx hereby grants to Novocodex
a non-exclusive, sub-licensable subject to Section 2.9.1, royalty-free right and license in the Territory, under Ambrx’s interest in the Ambrx Improvements, to use, develop and exploit Ambrx
Improvements only for Licensed Products. 

  

	2.5	 NO ASSERTION BY AMBRX. So long as Novocodex is in compliance with the terms and conditions of this Agreement,
Ambrx shall not assert against any claims for infringement of any Ambrx Background Technology owned or Controlled by Ambrx covering Novocodex’s permitted exercise of its rights hereunder solely for the purpose of developing, making, having
made, using, selling, offering for sale, having sold any Licensed Product in the Field in the Territory during the Term of this Agreement or solely for the purpose of engaging in permitted regulatory activities for Phase I Clinical Data in an ex-China territory such as the USA or a mutually approved jurisdiction outside the Territory pursuant to Section 2.2. 

  

	2.6	 EXCLUSIVE LICENSE GRANT BY NOVOCODEX. As the consideration to the rights granted by Ambrx under Sections 2.1,
2.2, 2.3 and 2.4 and Ambrx’s agreement not to sue under Section 2.5, Novocodex hereby grants to Ambrx an exclusive (even as to Novocodex), sub-licensable, royalty-free right and license in the world outside the Territory, under
Novocodex’s interest in the Novocodex Improvements and Joint Improvements, to use, develop and exploit Novocodex Improvements and Joint Improvements. 

  

	2.7	 NON-EXCLUSIVE LICENSE GRANT BY NOVOCODEX. As the consideration to the rights granted by Ambrx under Sections
2.1, 2.2, 2.3 and 2.4 and Ambrx’s agreement not to sue under Section 2.5, Novocodex hereby grants to Ambrx a non-exclusive, sub-licensable, royalty-free right and license in the Territory, under
Novocodex’s interest in the Novocodex Improvements, to use, develop and exploit Novocodex Improvements. 

  

	2.8	 TRANSFER OR EXCLUSIVE LICENSE GRANT BY NOVOCODEX REGARDING PHASE I CLINICAL DATA. To the extent permissible by
Applicable Law, Novocodex shall transfer and assign to Ambrx ownership of all preclinical, clinical, regulatory filings, and Phase I Clinical Data in any mutually approved jurisdiction outside the Territory, provided however, if such transfer and
assignment is not legally permitted, Novocodex hereby grants to Ambrx an exclusive (even as to Novocodex), sub-licensable, transferable, perpetual, irrevocable,
non-terminable, royalty-bearing right and license in the world outside the Territory, under Novocodex’s interest in information including regulatory filings and Phase I Clinical Data, to use, reference,
develop and exploit such information by Ambrx, its Affiliate or a Third Party authorized by Ambrx. Novocodex shall make reasonable effort to perfect such transfer, assignment or exclusive license under this Section. 

 

	2.9	 SUBLICENSES. 

  

	2.9.1	 Any sublicense by Novocodex of the rights granted to Novocodex under this Agreement shall obtain written
approval from the Joint Steering Committee first, and then Ambrx’s prior written consent (not unreasonably withheld or delayed), be consistent with the terms 

  
 11 

	 	
of this Agreement, and include an obligation for the sublicensee to comply with the applicable obligations of the sublicensing Party set forth in this Agreement. Novocodex shall not grant any
sublicense hereunder that would impose obligations on Ambrx greater than those obligations of Ambrx contained in this Agreement. Novocodex shall provide to Ambrx a copy of each sublicense hereunder, which shall permit verification by Ambrx of
compliance with the provisions of this Agreement. Parties expressly agree that Ambrx 1) shall reasonably withhold the written consent if Novocodex sublicenses its substantially entire rights and interests granted herein to a Third Party unless
Parties negotiate in good faith to reach an agreement prior to such sublicense, and 2) shall not unreasonably withhold such consent if Novocodex enters such sublicense for the purpose of distributing or supplying Licensed Products in the Territory
or otherwise expressed approved herein or by the Joint Steering Committee. 

  

	2.9.2	 With respect to any sublicense by one Party of the rights granted to said Party under this ARTICLE 2, said
Party shall not grant any sublicense hereunder that would impose obligations on the other Party greater than those obligations of the other Party contained in this Agreement. 

 

	2.10	 NO OTHER GRANT OF RIGHTS. Except as expressly provided herein, nothing in this Agreement will be construed to
confer any ownership interest, license or other rights upon Novocodex by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of Ambrx, or any other entity, regardless of whether
such technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Ambrx Background Technology or Licensed Intellectual Property Rights. 

ARTICLE 3 
 JOINT
STEERING COMMITTEE 
  

	3.1	 MEMBERS. Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Steering
Committee (the “Joint Steering Committee”), which shall comprise six (6) members, three (3) designated by Novocodex and three (3) by Ambrx (or such other number as the Parties may agree in writing). The initial
members of the Joint Steering Committee are set forth on Exhibit 3.1. Any member of the Joint Steering Committee may be represented at any meeting by a designee who is appointed by the Party designating such member for such meeting and who has
authority to act on behalf of such member, as evidenced by written notice from the Party designating such member to the chairperson of the Joint Steering Committee. The chairperson of the Joint Steering Committee shall be one of the members
designated by Ambrx. The initial chairperson is designated on Exhibit 3.1. Each Party shall be free to replace its representative members with new appointees who have authority to act on behalf of such Party on the Joint Steering
Committee, on written notice to the other Party. 

  
 12 

	3.2	 RESPONSIBILITIES. The Joint Steering Committee shall be responsible for (a) maximizing the global
opportunity and profitability of the Licensed Product while aligning the strategic, logistical and financial considerations of each Party; (b) reviewing and discussing the implementation of the Global Development Plan; (c) reviewing,
discussing and approving amendments and updates to the Global Development Plan; (d) directing development activities for the Licensed Product in accordance with the Global Development Plan; (e) aligning cGMP manufacturing activities and
investments to provide Licensed Products and ARX305 for clinical trials and commercial supply in accordance with the Global Development Plan. 

  

	3.3	 MEETINGS. The Joint Steering Committee shall meet as frequently as the Parties deem appropriate during the
first three-year period following the Effective Date but no less frequently than once a Calendar Quarter (or more frequently, as agreed upon by the Parties) thereafter, on such dates and at such times as the Parties shall agree, on ten
(10) days’ written notice to the other Party unless such notice is waived by the other Party. The Joint Steering Committee may convene or be polled or consulted from time to time by means of telecommunications, video conferences or
correspondence, as deemed necessary or appropriate by the Parties. To the extent that meetings are held in person, they shall alternate between the offices of the Parties unless the Parties otherwise agree. The chairperson shall be responsible for
sending notices of meetings to all members. 

  

	3.4	 DECISIONS. 

  

	3.4.1	 A quorum for a meeting of the Joint Steering Committee shall require the presence of at least two
(2) Ambrx members (or designees) and at least two (2) Novocodex members (or designees) in person or by telephone. All decisions made or actions taken by the Joint Steering Committee shall be made unanimously by its members, with the Ambrx
members present at a meeting cumulatively having one (1) vote and the Novocodex members present at a meeting cumulatively having one (1) vote. 

  

	3.4.2	 In the event that unanimity cannot be reached by the Joint Steering Committee with respect to a matter that is
a subject of its decision-making authority within thirty (30) days after the matter is first brought before the Joint Steering Committee, then the matter shall be decided unanimously by the Chairperson of Novocodex and the CEO of Ambrx or by
their designated representatives. If the Chairperson of Novocodex and the CEO of Ambrx or their designated representatives cannot reach an unanimous decision within thirty (30) days after the matter is first brought to them, then [***] shall
have the final decision making authority for [***]; provided that [***] final decisions do not obligate [***] to [***]. 

  

	3.5	 MINUTES. Within fifteen (15) days after each Joint Steering Committee meeting, the chairperson of the
Joint Steering Committee shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint

  
 13 

	 	
Steering Committee at such meeting. The chairperson of the Joint Steering Committee shall be responsible for circulation of all draft and final minutes. Draft minutes shall be circulated to all
members of the Joint Steering Committee sufficiently in advance of the next meeting to allow review and comment prior to the meeting. Minutes shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be
distributed to the members of the Joint Steering Committee. 

  

	3.6	 WITHDRAWAL. At any time during the Term and for any reason, either Party shall have the right to withdraw from
participation in the Joint Steering Committee upon written notice to the other Party (a “Withdrawal Notice”), which shall be effective immediately upon receipt. Following the issuance of a Withdrawal Notice and subject
to this Section 3.6 the withdrawing Party’s representatives on the Joint Steering Committee shall not participate in any meetings of the Joint Steering Committee. If, at any time, following the issuance of a Withdrawal Notice, the
withdrawing Party wishes to resume participation in the Joint Steering Committee, the withdrawing Party shall notify the other Party in writing and, thereafter, the withdrawing Party’s representatives on the Joint Steering Committee shall be
entitled to attend any subsequent meeting of, and to participate in the activities of, the Joint Steering Committee as if a Withdrawal Notice had not been issued by the withdrawing Party. Following the withdrawing Party’s issuance of a
Withdrawal Notice, unless and until the withdrawing Party resumes participation in the Joint Steering Committee in accordance with this Section 3.6: (i) all meetings of the Joint Steering Committee shall be held at the other Party’s
facilities; and (ii) the withdrawing Party shall have the right to continue to receive the minutes of the meetings of the Joint Steering Committee, but shall not have the right to approve the minutes for any such meeting held after the
withdrawing Party’s issuance of the Withdrawal Notice. In any event, withdrawal from the Joint Steering Committee shall not impair Novocodex and Ambrx’s rights to receive reports or disclosures under Section 3.5. 

  

	3.7	 TERM. The Joint Steering Committee shall exist until the earlier of (i) expiration of the Royalty Term for
all Licensed Products and (ii) the grant of an exclusive license by Ambrx to a Third Party to develop, manufacture, use, sell or otherwise commercialize the Licensed Product in any country outside the Territory. 

ARTICLE 4 
 DEVELOPMENT,
MANUFACTURING AND COMMERCIALIZATION 
  

	4.1	 DEVELOPMENT OVERVIEW. The Parties shall collaborate in the development of Licensed Products up until the
completion of Phase I Clinical Trials in the Field globally in accordance with the Global Development Plan and Section 4.3 below. Thereafter, the Parties may continue the development collaboration or conduct development activities in their
respective territories separately in accordance with Section 4.4 below. 

  

	4.2	 GLOBAL DEVELOPMENT PLAN. Within sixty (60) days after the Effective Date, the Joint Steering Committee
shall adopt a written plan for development of Licensed Products up until the completion of Phase I Clinical Trials in the Field globally in a 

  
 14 

	 	
collaborative manner (which shall be attached hereto as Exhibit 1.28), which shall include, but not be limited to (i) the indication(s) to be developed, (ii) the proposed global
development activities and allocation thereof between the Parties, (iii) the timeline and budget, (iv) manufacturing process development, (v) clinical supply arrangement, and (vi) the Phase I clinical activities and such other
matters that the Parties may want to include (the “Global Development Plan”). Either Party may propose to the Joint Steering Committee and the other Party, revisions to the Global Development Plan, with supporting evidence, such as
technical, clinical or regulatory reasons that underline the proposed revisions. The Joint Steering Committee may amend the Global Development Plan from time to time after the Effective Date, pursuant to the decision making mechanism as set forth in
Section 3.4.2. 

  

	4.3	 COLLABORATIONS UNDER THE GLOBAL DEVELOPMENT PLAN; FUNDING. 

 

	4.3.1	 Up until the completion of the global Phase I Clinical Trials of the Licensed Product, the Parties shall
collaborate in the development of the Licensed Product in accordance with the Global Development Plan, including budgets and timelines set forth in the Global Development Plan. Each Party shall use Commercially Reasonable Efforts to carry out the
activities assigned to it under the Global Development Plan and in accordance with the world-class standards. Novocodex shall, among other things, be responsible for funding the preparation of IND filing package(s) suitable for filings in the US and
the Territory. The Parties shall jointly be responsible for designing clinical trials and study protocols and overseeing the global Phase I Clinical Trial of the Licensed Product and the performance of other activities under the Global Development
Plan, with the priority to complete the Phase I activities, including dose-escalation and indication explorations, inside the Territory first. 

  

	4.3.2	 Novocodex shall be responsible for funding activities up to the end of the global Phase I Clinical Trial of the
Licensed Product in accordance with the Global Development Plan and shall fund or reimburse Ambrx for development costs incurred or to be incurred by Ambrx prior to the completion of the global Phase I Clinical Trial of the Licensed Product, with
the following exceptions: (i) with respect to Phase I Clinical Trial activities under the Global Development Plan conducted outside the Territory and clinical supply of drug substance for such Phase I Clinical Trial activities, Novocodex shall
fund or reimburse Ambrx for up to $[***] in costs and expenses (the “Cap”), and (ii) in the event that costs and expenses for Phase I Clinical Trial activities under the Global Development Plan conducted outside the Territory
are in excess of the Cap, Novocodex shall be responsible for [***]% and Ambrx shall be responsible for [***]% of the amount above the Cap (the “Cost Share”). For the sake of clarity, [***]. Novocodex shall promptly, within thirty
(30) days after the date of receipt of Ambrx’s invoices, fund or reimburse Ambrx the development costs incurred or to be 

  
 15 

	 	
incurred by Ambrx prior to the completion of the global Phase I Clinical Trial of the Licensed Product. 

  

	4.4	 OUTSIDE THE GLOBAL DEVELOPMENT PLAN. Other than rights and obligations set forth in the Global Development
Plan, Novocodex shall be solely responsible for conducting and paying for all development and commercialization of the Licensed Products in or for the Territory, and Ambrx shall be solely responsible for conducting and paying for the development and
commercialization of the Licensed Products outside the Territory. Subject to Section 3.4.2, Novocodex shall have decision making authority for (and an obligation to fund) additional activities not included in the Global Development Plan that
Novocodex deems necessary or desirable for the Territory; provided that such additional activities would not reasonably likely to affect the development or commercialization of the Licensed Product outside the Territory or outside the Field.

  

	4.5	 SAFETY DATA EXCHANGE. No later than initiation by Novocodex of a clinical trial in the Territory, Novocodex
shall enter into a safety data exchange agreement with Ambrx and/or its other licensee regarding the Licensed Product, which shall set forth standard operating procedures governing the collection, investigation, reporting, and exchange of
information concerning adverse drug reactions/experiences sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes. Such safety data exchange agreement shall identify which Party
shall be responsible for the timely reporting of all relevant adverse drug reactions/experiences, product quality, product complaints and safety data relating to Licensed Product to the appropriate Regulatory Authorities in and outside the Territory
in accordance with all Applicable Law. Such agreement shall allow each Party to comply with all regulatory and legal requirements regarding the management of safety data by providing for the exchange of relevant information in the appropriate format
within applicable timeframes. Unless otherwise mutually agreed by the Parties, Ambrx or its other licensee shall maintain a global safety database for the Licensed Product, and Novocodex shall maintain one or more safety database(s) for the Licensed
Product in the Field and the Territory. 

  

	4.6	 MANUFACTURING. The Parties shall collaborate in the manufacturing process development and the clinical supply
arrangement up until the completion of the global Phase 1 Clinical Trials in accordance with the Global Development Plan. Thereafter, the Parties may decide to continue to collaborate with clinical and commercial manufacturing and supply
arrangements or have separate arrangements; provided that the Licensed Product is manufactured at facilities that meet all applicable regulatory requirements and in accordance with cGMP and other Applicable Laws. 

 

	4.7	 COMMERCIALIZATION. Novocodex (itself and through its Affiliates and sublicensees, as applicable) shall be
solely responsible, at its own expense, for marketing, selling, offering for sale, distributing, promoting and otherwise commercializing Licensed Product in the Field in the Territory. 

 

	4.8	 COMPLIANCE WITH APPLICABLE LAWS. Novocodex shall conduct, and shall cause its Affiliates and sublicensees to
conduct all development, regulatory, 

  
 16 

	 	
manufacturing and commercialization activities with respect to ARX305 and Licensed Product in the Field in the Territory in compliance with this Agreement, all Applicable Laws and world-class
standards, including cGMP, good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted. 

ARTICLE 5 
 SUPPORT AND
ASSISTANCE 
  

	5.1	 EFFORTS BY AMBRX. Ambrx shall, either itself or through its Affiliates, use commercially reasonable efforts to
provide technical and consulting assistance or other services as requested by Novocodex, at Novocodex’s expense, which are necessary for Novocodex to exercise its rights and/or perform its obligations under this Agreement.

  

	5.2	 TECHNICAL ASSISTANCE: Parties agree that Ambrx will dispatch [***] during the [***] period following the
Effective Date, provided however, Novocodex may request [***] from Ambrx to provide technical and consulting assistance or other services to Novocodex, as necessary for Novocodex to perform its development activities under Section 4.1.

 ARTICLE 6 

MONETARY OBLIGATIONS, REPORTS AND AUDITS 
  

	6.1	 STARTUP PAYMENT. For the initiation of collaborative research, Novocodex shall pay to Ambrx within thirty
(30) days after receipt of invoice from Ambrx, a one-time payment in cash of Two Million Dollars ($2,000,000), which payment shall be non-refundable and non-creditable and not subject to set-off. 

  

	6.2	 FOLLOW-UP PAYMENTS. As set forth in the following table, Novocodex
shall make the following payments (the “Follow-up Payments”) to Ambrx upon achievement of each of the events set forth in the tables below (the
“Follow-up Events”) by Novocodex or its Affiliates or sublicensees. Each Follow-up Payment shall be payable by Novocodex to Ambrx within thirty
(30) days after the achievement of the corresponding Follow-up Event and receipt of invoice from Ambrx with respect to the Licensed Product. Such payments shall be
non-refundable and non-creditable and not subject to set-off. 

 

					
	
Follow-up Event
	  	 Follow-up Payment
	 
	 [***]
	  	 	[	***] 

  
 17 

					
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  

	6.3	 ROYALTIES PAYABLE BY NOVOCODEX. Subject to the terms and conditions of this Agreement, Novocodex shall pay
Ambrx royalties in an amount equal to the following percentage of Net Sales of Licensed Products sold by Novocodex or its Affiliates: 

  

	6.3.1	 [***] ([***]%) of such Net Sales in the Territory in each Calendar Year up to and including Net Sales of [***]
($[***]); 

  

	6.3.2	 [***] ([***]%) of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales
exceeding of [***] ($[***]) up to and including of [***] ($[***]); and 

  

	6.3.3	 [***] ([***]%) of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales
exceeding [***] ($[***]). 

  

	6.4	 KNOW-HOW ROYALTY. Notwithstanding the provisions of Section 6.3
above, in the event and after the manufacture, use or sale of Licensed Products by Novocodex or its Affiliates would not infringe a Valid Claim of the Ambrx Existing Patent Rights, or the Ambrx Existing Patent Rights covering the Licensed Products
are deemed invalid or have expired, the Net Sales of such Licensed Products in the Territory shall remain the same during the Royalty Term in determining the applicable royalty rate according to Section 6.3, provided however, the Net Sales of
such Licensed Products shall be [***] if Generic Competition exists. 

  

	6.5	 ROYALTY TERM. Royalties on Licensed Product at the rates set forth above shall be paid during the period which
shall commence with the First Commercial Sale of the Licensed Product and continue until the expiration of the later of: (i) the last-to-expire Valid Claim of Ambrx
Existing Patent Rights that would be infringed by the manufacture, use or sale of Licensed Product in the Territory; or (ii) the period of [***] ([***]) years following the First Commercial Sale of such Licensed Product in the Territory (the
“Royalty Term”). 

  

	6.6	 ROYALTIES PAYABLE BY AMBRX. Ambrx shall pay Novocodex royalties in an amount equal to the following percentage
of Net Sales of Phase I Clinical Data transferred or licensed by Ambrx to a Third Party: 

  
 18 

	6.6.1	 [***] ([***]%) of such Net Sales if Ambrx or its Affiliate(s) transfers or licenses Phase I Clinical Data
without making additional efforts as defined in Sections 6.6.2 to 6.6.4; 

  

	6.6.2	 [***] ([***]%) of such Net Sales if Ambrx or its Affiliate(s) transfers or licenses Phase I Clinical Data after
Ambrx initiates Phase II Clinical Trial outside the Territory; 

  

	6.6.3	 [***] ([***]%) of such Net Sales if Ambrx or its Affiliate(s) transfers or licenses Phase I Clinical Data after
Ambrx initiates Phase III Clinical Trial outside the Territory; and 

  

	6.6.4	 [***] ([***]%) of such Net Sales if Ambrx or its Affiliate(s) commercializes and sells a Licensed Product
outside the Territory, the Marketing Authorization of such Licensed Product is based on Phase I Clinical Data. 

  

	6.7	 THIRD PARTY ROYALTY SET-OFF. If Novocodex under Ambrx Third Party
License is required to pay royalty that is necessary for Novocodex’s exercise of its rights hereunder in Territory pursuant to Section 2.3 or obtain a license from a Third Party due to infringement action under Section 7.4, it may
offset any royalty payments actually paid by Novocodex to such Third Party due thereunder with respect to sales of Licensed Products against the royalty payments that are due to Ambrx; provided that in no event shall the royalty payments to Ambrx
with respect to such Licensed Products be reduced by more than [***] ([***]%) of the amount otherwise due. 

  

	6.8	 FUNDING FOR DEVELOPMENT. Novocodex shall be responsible for funding/reimbursing Ambrx’s development costs
through the completion of Phase I Clinical Trials in accordance with the Global Development Plan, as set forth in Section 4.3.2. In the event that Novocodex does not meet its funding obligations as set forth in Section 4.3.2, the royalty
rates at which Ambrx is required to pay Novocodex shall be reduced proportionally. 

  

	6.9	 THIRD PARTY PAYMENTS. Subject to Section 4.3.2, Novocodex shall be responsible for and at its sole expense
shall pay all amounts owing to any Third Party for development activities under the Global Development Plan performed by such Third Party. Any contract with a total value in excess of $[***] shall be signed directly between the Third Party and
Novocodex. Novocodex shall sign such contract promptly and in no case, later than thirty (30) days after the final contract is presented to it. The invoice from any Third Party approved by Novocodex within the Global Development Plan and
incurred by Ambrx for a given Calendar Quarter will be sent to Novocodex within forty-five (45) days following the end of such Calendar Quarter. Such invoice reimbursable by Novocodex shall be paid within thirty (30) days after Novocodex
receives such invoice. 

  

	6.10	 FTE PAYMENTS TO AMBRX. In consideration of technical assistance provided by Ambrx pursuant to Section 5.2,
Novocodex shall fund a minimum of one (1) Ambrx FTEs for the three (3) year period following the Effective Date at the FTE Rate of [***] ($[***]) per FTE per Calendar Year in quarterly

  
 19 

	 	
installments. Novocodex shall make the payment to Ambrx within thirty (30) days after receipt of invoice from Ambrx at the beginning of each Calendar Quarter. 

 

	6.11	 REPORTS. During the Term following the First Commercial Sale of Licensed Product, Novocodex shall furnish to
Ambrx a quarterly written report for the Calendar Quarter showing the gross and Net Sales of all Licensed Products subject to royalty payments sold by Novocodex and its Affiliates in the Territory during the reporting period and the royalties
payable under this Agreement. Reports shall be due on the forty-fifth (45th) day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due.
Novocodex and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. 

  

	6.12	 AUDITS. 

  

	6.12.1	 ACCOUNTING FIRM. Upon the written request of Ambrx and not more than once in each Calendar Year, Novocodex
shall permit a qualified and reputable independent certified public accounting firm selected by Ambrx and approved by Novocodex not unreasonably withhold, at Ambrx’s expense, to have access during normal business hours to such of the records of
Novocodex related to the production and sales of Licensed Products as may be reasonably necessary to verify the accuracy of the royalty reports pursuant to Section 6.11 for any Calendar Year ending not more than thirty six (36) months
prior to the date of such request. The accounting firm shall disclose to Ambrx and Novocodex whether the royalty reports are correct or incorrect and the amount of any discrepancy. 

 

	6.12.2	 ACCESS. In order to fulfill the auditing, the accounting firm so selected shall have the right to access,
examine, review and copy all books or accounts of Novocodex, relevant procurement/distribution agreements and other purchase/sales contracts, purchase/sales orders, operation records, tax paid to local government, and itemized tax for the Licensed
Products, and to discuss the business, operations and conditions of Novocodex with its respective directors, officers, employees, accounts, auditors, financial advisors, legal counsel and investment bankers, to the extent reasonably deemed by Ambrx
as necessary for determining the accuracy of the royalty reports. Novocodex shall not unreasonably restrict the accounting firm’s access to premises of Novocodex during normal business hours. 

 

	6.12.3	 PAYMENT AND FEES. If such accounting firm identifies a discrepancy made during such period, the appropriate
Party shall pay the other Party the amount of the discrepancy within thirty (30) days of the date Ambrx delivers to Novocodex such accounting firm’s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged
by such accounting firm shall be paid by Ambrx, provided however, that if such audit uncovers an underpayment of royalties by Novocodex that exceeds [***] ([***]%) of the total royalties owed for the period in question, the fees of such accounting
firm shall be equally shared by Ambrx and Novocodex. 

  
 20 

	6.12.4	 SUBLICENSES. Novocodex shall include in each sublicense granted by it pursuant to this Agreement a provision
requiring the sublicensee to make reports to Novocodex, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Ambrx’s independent accountant to the same extent required of Novocodex under
this Agreement. 

  

	6.12.5	 CONFIDENTIALITY. Ambrx shall treat all financial information subject to review under this Section 6.12 or
under any sublicense agreement in accordance with the terms of ARTICLE 8 of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Ambrx, or with Novocodex and/or its Affiliates or sublicensee,
obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 

  

	6.13	 PAYMENT EXCHANGE RATE. All royalty payments due hereunder shall be paid in United States dollars by wire
transfer to a bank account designated by Ambrx. Any payments or portions thereof due hereunder which are not paid on the date such payments are due under this Agreement shall bear interest at a rate equal to the lesser of prime rate as reported by
Citibank, New York, New York (or its successor in interest) or the maximum rate permitted by law, calculated on the number of days such payment is delinquent. If the royalty payments are paid in United States Dollar, the Parties shall apply the
[***]. 

  

	6.14	 TAX WITHHOLDING. Ambrx shall be liable for all income and/or other taxes (including interest) imposed upon any
royalty payments made by Novocodex to Ambrx under this Agreement (“Taxes”). In the event Applicable Laws require withholding of Taxes, Novocodex shall notify Ambrx in writing number of tax payable in advance, before it makes such
withholding payments and subtracts the amount thereof from the payments. Novocodex shall submit appropriate proof of payment of the withheld Taxes to Ambrx and shall provide Ambrx with the official receipts within a reasonable period of time.
Notwithstanding the foregoing, to the extent permitted by Applicable Laws and upon request of Ambrx, Novocodex shall use Commercially Reasonable Efforts to apply for approvals from competent PRC tax authorities, on behalf of Ambrx, for reduction or
exemption of applicable PRC taxes over the payments made by Novocodex to Ambrx, before it makes the withholding payments and subtracts the amount thereof from the payments due to Ambrx. 

 

	6.15	 PAYMENT PROCEDURES. Novocodex shall be responsible for obtaining any and all governmental approval/registration
procedures (if legally required) and foreign exchange related procedures/formalities in connection with repatriation of any payments made by Novocodex to Ambrx under the Agreement to the bank accounts designated by Ambrx outside China, and Ambrx
will provide reasonable assistance if necessary. 

 ARTICLE 7 

INTELLECTUAL PROPERTY 

  
 21 

	7.1	 OWNERSHIP. Novocodex is the sole owner of any Novocodex Improvements. Ambrx is the sole owner of any Ambrx
Improvements. Joint Development Technology is co-owned by Novocodex and Ambrx. Other than provided herein, each Party is responsible for filing and prosecuting of Patent Rights stemming from its own
inventions. 

  

	7.2	 FILING, PROSECUTION AND MAINTENANCE OF PATENTS FOR JOINT DEVELOPMENT TECHNOLOGY. 

 

	7.2.1	 JOINT DEVELOPMENT TECHNOLOGY. Ambrx shall have the first right to file patent applications for Joint
Development Technology (in the name of both Novocodex and Ambrx) and thereafter prosecute and maintain Patent Rights for such Joint Development Technology. In the event that Ambrx files such patent applications and thereafter prosecutes and
maintains Patent Rights for such Joint Development Technology, Novocodex shall execute such documents and perform such ministerial acts, at Novocodex’s expense, as may be reasonably necessary for Ambrx to continue such prosecution or
maintenance of Patent Rights claiming such Joint Development Technology. Ambrx shall, in its sole discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Development Technology; provided that
Ambrx’s choice of counsel will not present a conflict of interest for Novocodex. With respect to a given Joint Development Technology, Ambrx may elect not to file or may elect not to file in a particular country and if so, Ambrx shall notify
Novocodex and Novocodex shall have the right to file such patent applications for such Joint Development Technology (in the name of both Novocodex and Ambrx) and thereafter prosecute and maintain Patent Rights for such Joint Development Technology.
In the event that Novocodex files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Development Technology, Ambrx shall execute such documents and perform such ministerial acts, at Ambrx’s expense, as
may be reasonably necessary for Novocodex to continue such prosecution or maintenance of Patent Rights claiming such Joint Development Technology. Novocodex shall, in its sole discretion, have a right to choose external counsel to assist in the
procurement and maintenance of such Joint Development Technology; provided that Novocodex’s choice of counsel will not present a conflict of interest for Ambrx. 

 

	7.2.2	 NOVOCODEX IMPROVEMENTS. Novocodex shall have the first right, at its sole cost and expense, to file patent
applications for Novocodex Improvement and thereafter prosecute and maintain Patent Rights for such Novocodex Improvements. With respect to a given Novocodex Improvement, Novocodex may elect not to file or may elect not to file in a particular
country outside the Territory and if so, Novocodex shall notify Ambrx and Ambrx shall have the right but not the obligation to file such patent applications for such Novocodex Improvement and thereafter prosecute and maintain Patent Rights for such
Novocodex Improvement. In such event, Novocodex shall execute such documents and perform such ministerial acts, at Ambrx’s expense, as may be reasonably necessary for Ambrx to continue such prosecution or maintenance of Patent Rights claiming
such Novocodex Improvements outside the Territory. 

  

	7.2.3	 REVIEW AND CONSULTATION. In each case in connection with the foregoing with respect to Joint Development
Technology and Novocodex Improvement, as applicable, 

  
 22 

	 	
the filing Party (a) shall keep the non-filing Party advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings; (c) shall give the
non-filing Party an opportunity to review the text of the application before filing and shall consult with the non-filing Party with respect thereto; (d) shall give
the non-filing Party an opportunity to review and comment on any documents relating to such patent filings that will be filed in any patent office at least twenty (20) days before such filing and give due
consideration to such substantive, non-cumulative comments; (e) shall supply the non-filing Party with a copy of the application
as-filed, together with notice of its filing date and serial number; and (f) shall promptly give notice to the non-filing Party of the grant, lapse, revocation,
surrender, invalidation or abandonment of any Patent Rights claiming Joint Development Technology and Novocodex Improvement, as applicable) for which it is responsible for the filing, prosecution or maintenance hereunder (provided that the filing
Party shall give at least thirty (30) days prior written notice to the non-filing Party of any desire to cease prosecution and/or maintenance of such Patent Rights). 

 

	7.2.4	 COSTS. The Parties shall [***] costs of filing patent applications and procuring and maintaining Patent Rights
in the United States, Japan, China, Brazil, and with the European Patent Office (including but not limited to all National Phase filing costs and fees) for such Joint Development Technology; Ambrx shall be responsible for [***] of filing patent
applications and procuring and maintaining Patent Rights for such Joint Development Technology in all other jurisdictions outside the Territory, provided however, if, pursuant to Section 7.2.1, Ambrx elects not to file in a particular country
in such other jurisdictions and Novocodex elects to file in such particular country for such Joint Development Technology, then Novocodex shall pay [***]% of the costs to file and maintain said Patent Rights in said elected country. Further, if,
pursuant to Section 7.2.2, Novocodex elects not to file in a particular country outside the Territory and Ambrx elects to file and maintain Patent Rights on such Novocodex Improvements, then Ambrx shall pay [***]% of the costs to file and
maintain said Patent Rights in the elected country(ies). For clarity, Ambrx shall be responsible for prosecuting and maintaining Ambrx Existing Patent Rights and Ambrx Patent Rights in and outside the Territory [***]. 

 

	7.3	 ENFORCEMENT OF PATENT RIGHTS. 

 

	7.3.1	 NOTICE. Each Party shall promptly notify the other Party of any infringement or possible infringement by a
third party of any rights licensed to Novocodex under this Agreement. Further, Ambrx shall give Novocodex, and Novocodex shall give Ambrx, notice of any infringement of (i) any Ambrx Existing Patent Rights in the Territory, or any
misappropriation or misuse of Ambrx Know-How, that may come to Ambrx’s or Novocodex’s attention. Novocodex and Ambrx shall thereafter consult and cooperate fully to determine a course of action,
including but not limited to, the commencement of legal action by Novocodex and/or Ambrx, to terminate any infringement of such Ambrx Existing Patent Rights or any misappropriation or misuse of such Ambrx
Know-How, as applicable. 

  
 23 

	7.3.2	 SUIT BY NOVOCODEX. Novocodex shall have the first right, but not obligation, to initiate and prosecute
such legal action at its own expense and in the name of Novocodex to terminate any infringement relating to such Ambrx Existing Patent Rights or such Ambrx Know-How in the Territory, as applicable. Should
Novocodex elect to bring suit against an infringer, Novocodex shall keep Ambrx reasonably informed of the progress of the action and shall give Ambrx a reasonable opportunity in advance to consult with Novocodex and offer its views about major
decisions affecting the litigation. Novocodex shall give careful consideration to Ambrx views, but shall have the right to control the action; provided, however, that if the validity and/or enforceability of the Ambrx Existing Patent Rights is
raised by the infringer in the action or, or if Novocodex’s license to a Valid Claim in the suit terminates, Ambrx may elect to take control of the action pursuant to Section 7.3.5. Should Novocodex elect to bring suit against an infringer
and Ambrx is joined as party plaintiff in any such suit, Ambrx shall have the right to approve the counsel selected by Novocodex to represent Novocodex and Ambrx, such approval not to be unreasonably withheld. The expenses of such suit or suits that
Novocodex elects to bring, including any expenses of Ambrx incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Novocodex and Novocodex shall hold Ambrx free, clear and harmless from and
against any and all costs of such litigation, including reasonable attorneys’ fees. Novocodex shall not compromise or settle such litigation without the prior written consent of Ambrx, which consent shall not be unreasonably withheld or
delayed. In the event Novocodex exercises its right to sue pursuant to this Section 7.3.2, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character,
including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Ambrx shall receive an amount equal to [***] ([***]%) of
such funds and the remaining [***] ([***]%) of such funds shall be retained by Novocodex. 

  

	7.3.3	 SUIT BY AMBRX. If Novocodex does not take action in the prosecution, prevention, or termination of any
infringement pursuant to Section 7.3.2 above, and has not commenced negotiations with the infringer for the discontinuance of said infringement, within ninety (90) days after receipt of notice to Novocodex by Ambrx of the existence of an
infringement, Ambrx may elect to do so. Should Ambrx elect to bring suit against an infringer and Novocodex is joined as party plaintiff in any such suit, Ambrx shall have the right to select the counsel to represent Ambrx and Novocodex unless
otherwise conflicted out. The expenses of such suit or suits that Ambrx elects to bring, including any expenses of Novocodex incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Ambrx.
In the event Ambrx exercises its right to sue pursuant to this Section 7.3.3, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including
reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Novocodex shall receive an amount equal to [***] ([***]%) of such funds and the
remaining [***] ([***]%) of such funds shall be retained by Ambrx. Notwithstanding the foregoing, Ambrx shall have the right to initiate 

  
 24 

	 	
and prosecute any legal action(s) relating to Licensed Intellectual Property Rights or Ambrx Background Technology outside the Territory at its own expense. 

 

	7.3.4	 COOPERATION. Each party agrees to cooperate fully in any action under this ARTICLE 7 that is controlled
by the other party, provided that the controlling party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance. 

 

	7.3.5	 DECLARATORY JUDGMENT & INVALIDITY CHALLENGE. If a declaratory judgment action is brought naming
Novocodex and/or any of its Affiliates as a defendant, or a claim alleging invalidity or unenforceability of any Valid Claims within the Ambrx Existing Patent Rights, Novocodex shall promptly notify Ambrx in writing and Ambrx may elect, upon written
notice to Novocodex within thirty (30) days after Ambrx receives notice of the commencement of such action, to take over the defense of the invalidity and/or unenforceability aspect of the action solely. 

 

	7.4	 INFRINGEMENT ACTIONS BY THIRD PARTIES. 

 

	7.4.1	 NOTICE. Each Party shall notify the other Party promptly in writing of any claim of, or action for,
infringement of any Patent Rights owned or licensed by Third Parties which is threatened, made or brought against either Party by reason of either Party’s performance of its obligations under this Agreement or development, manufacture, use or
sale of any Licensed Products in the Territory. 

  

	7.4.2	 DEFENSE. In the event that such an action for infringement is commenced by a Third Party solely against a Party
or both Parties jointly and/or any of their respective Affiliates, as the case may be, with respect to a Licensed Product developed and commercialized by Novocodex and/or its Affiliate, Ambrx shall defend such action at its own expense, and
Novocodex hereby agrees to assist and cooperate with Ambrx to the extent necessary in the defense of such suit. Ambrx shall have the right to settle any such action or consent to an adverse judgment thereto, and Novocodex’s consent shall not be
required unless such settlement or consent: (i) imposes any material obligation on Novocodex or limits Ambrx’s obligations to Novocodex under this Agreement or (ii) materially impairs Novocodex’s rights herein. For clarity, any
payment including royalty payments to such Third Party as a result of such settlement shall not require Novocodex’s consent. 

  

	7.4.3	 PAYMENT OBLIGATION. During the pendency of any such action, Novocodex shall continue to pay all royalties and
other payments due hereunder. Ambrx shall retain any award or compensation (including the fair market value of non-monetary compensation) received by Ambrx as a result of any such action (i.e., as a result of
a counterclaim). 

 ARTICLE 8 

CONFIDENTIALITY & PUBLICATIONS 
  

	8.1	 NONDISCLOSURE OBLIGATION. EXCEPTIONS. Except to the extent expressly authorized by this Agreement the Parties
agree that, during the Term of this Agreement 

  
 25 

	 	
and for ten (10) years thereafter, each Party and its Affiliates, if any (collectively, a “receiving Party”), shall use their best efforts to keep Confidential
Information & Materials completely confidential, shall not publish or otherwise disclose to any Third Party and shall not use for any purpose other than the performance of this Agreement both the financial terms of this Agreement and any
information furnished to it by the other Party or its Affiliates, if any (collectively, a “disclosing Party”) (and shall ensure that its and its Affiliates’ respective directors, officers, employees or agents do likewise),
except to the extent that it can be established by the receiving Party by competent proof that such information: (i) is, or hereafter becomes, generally available to the public other than by reason of any default by the receiving Party with
respect to its confidentiality obligations hereunder; (ii) was already known to the receiving Party at the time of disclosure by the disclosing Party; (iii) was lawfully disclosed to the receiving Party by a Third Party not in default of
any confidentiality obligation to the disclosing Party; or (iv) is independently developed by or for the receiving Party without reference to or reliance upon the information furnished by the disclosing Party. 

 

	8.2	 EXCLUSIONS TO CONFIDENTIALITY. The restrictions contained in Section 8.1 shall not apply to any
Confidential Information & Materials in the hands of a receiving Party that (i) is submitted by the receiving Party to governmental authorities to facilitate the issuance of Marketing Authorization for Licensed Products in the
Territory, provided that reasonable measures shall be taken to assure confidential treatment of such information, if practicable, or (ii) is otherwise required to be disclosed in compliance with Applicable Laws (including, without limitation,
to comply with any governmental or stock exchange disclosure requirements) or an order by a court or other regulatory body having competent jurisdiction; provided, however, that if a receiving Party is required to make any such disclosure of the
disclosing Party’s Confidential Information & Materials such receiving Party shall, except where impracticable for necessary disclosures (for example to physicians conducting studies or to health authorities), give reasonable advance
notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications or otherwise, will use its best efforts to secure confidential treatment of such Confidential Information &
Materials required to be disclosed. In addition, any press release or other public announcement permitted by the terms of Section 8.4 hereof shall be excluded from the provisions of Section 8.1. 

 

	8.3	 PUBLICATION. Novocodex and Ambrx each acknowledge the other Party’s interest in publishing the results of
its research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests
and trade secret information. Consequently, except for disclosures permitted pursuant to Section 8.2, either Party, its employees or consultants wishing to make a publication with respect to the development or clinical results regarding the
Licensed Products hereunder shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall
have the right (a) to propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable
information. If the reviewing Party requests a delay, the publishing Party shall 

  
 26 

	 	
delay submission or presentation for a period of one hundred and twenty (120) days to enable patent applications protecting each Party’s rights in such information to be filed in
accordance with Article 7 above. Upon expiration of such one hundred and twenty (120) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or
presentation, the publishing Party shall edit such publication to prevent disclosure of trade secret or proprietary business information prior to submission of the publication or presentation. 

 

	8.4	 PUBLICITY/USE OF NAMES. No disclosure of the existence, or the terms, of this Agreement may be made by either
Party, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter,
without the prior express written permission of the other Party, except as may be required by Applicable Law or as permitted pursuant to Section 8.2; provided that in the event disclosure is required by Applicable Law, the disclosing Party
shall use good-faith efforts to give the non-disclosing Party an opportunity, with reasonable advance notice, to review and comment on any proposed disclosure. Notwithstanding Section 8.4 herein,
Novocodex and Ambrx shall make reasonable effort to issue a mutually agreed joint press releases as shown in Exhibit 8.4 regarding the execution of this Agreement and the cooperation between both Parties, provided further, any further press release
to be issued by one Party mentioning the execution of this Agreement or naming the other Party shall be approved in advance by the other Party. 

  

	8.5	 INJUNCTIVE RELIEF. The Parties acknowledge that monetary damages alone may not adequately compensate the
disclosing Party in the event of a material breach by the receiving Party of this ARTICLE 8, and that, in addition to all other remedies available to the disclosing Party under this Agreement, at law or in equity, to the extent permitted by
Applicable Laws, it shall be entitled to seek injunctive relief for the enforcement of its rights under this ARTICLE 8. 

ARTICLE 9 

REPRESENTATIONS AND WARRANTIES 
  

	9.1	 MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party represents and warrants to the other Party the following as
of the Effective Date: 

  

	9.1.1	 CORPORATE POWER. Such Party is duly organized and validly existing under the laws of the country/state of its
organization, and has full legal and corporate power and authority to enter into this Agreement and to perform its obligations hereunder. 

  

	9.1.2	 DUE AUTHORIZATION AND EXECUTION. The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally
binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that 

  
 27 

	 	
enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and
remedies of creditors. 

  

	9.1.3	 NON-CONTRAVENTION. The execution, delivery and performance by such
Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in any material respect violate any statute, regulation, judgment, order, decree or other restriction of any governmental authority to which
such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or (iii) constitute a material violation or breach by such Party
of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a party. 

  

	9.2	 REPRESENTATIONS BY AMBRX. Ambrx represents and warrants to Novocodex the following as of the Effective Date:

  

	9.2.1	 to Ambrx’s knowledge, the Licensed Intellectual Property Rights exist and are not invalid or
unenforceable, in whole or in part; 

  

	9.2.2	 it has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or
interest in Licensed Intellectual Property Rights related to ARX305 in the Field in the Territory, or (ii) granted any rights to any Third Parties, in either case that would conflict with the rights granted to Novocodex hereunder;

  

	9.2.3	 to Ambrx’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee of Licensed
Intellectual Property Rights related to ARX305 in the Territory, 

  

	9.2.4	 to Ambrx’s knowledge, there are no claims, judgments or settlements against or owed by Ambrx and, no
pending or threatened claims or litigation relating to Licensed Intellectual Property Rights in the Territory. 

  

	9.3	 REPRESENTATIONS BY NOVOCODEX. Novocodex represents, warrants and covenants to Ambrx that:

  

	9.3.1	 All necessary consents, approvals and authorizations of all regulatory authorities and other governmental
authorities and other persons or entities required to be obtained by Novocodex in order to enter into this Agreement have been obtained or, with respect to such consents, approvals and authorizations of regulatory authorities or other governmental
authorities that cannot be obtained before the Effective Date, will be obtained within sixty (60) days after the Effective Date. 

  

	9.3.2	 Novocodex, its Affiliates, and its and their respective principals, owners, officers, directors, employees,
agents, consultants, and joint venture partners, and any other party acting on behalf of Novocodex (collectively as “Novocodex Representatives”), have not and shall not offer, promise, provide, or accept any item of value (broadly
meaning any monetary payment, such as fees or commissions, or nonmonetary benefit, such as employment opportunities, gifts, travel or entertainment), directly or indirectly, to or from any person in exchange for a business advantage; 

  
 28 

	9.3.3	 All Novocodex Representatives shall abide by all applicable anti-bribery and corruption laws, including the
United States Foreign Corrupt Practices Act of 1977 and any other international or local laws of a similar nature or having similar effect now existing or to be enacted in the future; 

 

	9.3.4	 No principal, owner, officer, director, employee or agent of Novocodex or its Affiliates is currently a
“Government Official,” defined as: (a) an officer, agent or employee of a government; or (b) a candidate for government or political office. 

 

	9.3.5	 No Government Official who is closely related to a Novocodex Representative has been or will be, directly or
indirectly, involved in influencing, obtaining, or retaining business on behalf of Novocodex or fulfilling Novocodex’s obligations to Ambrx under this Agreement; 

 

	9.3.6	 No Novocodex Representative (i) is listed on the Office of Foreign Assets Control’s
(“OFAC”) “Specially Designated National and Blocked Person List” (“SDN List”) or otherwise subject to any sanction administered by OFAC (“U.S. Economic Sanctions”); (ii) is owned,
controlled by or acting on behalf of, directly or indirectly, any person, entity, or government listed on the SDN List or otherwise subject to any U.S. Economic Sanction; (iii) has made sales to, contracted with, or otherwise engaged in any
dealing or transaction with or for the benefit of any person, entity, or government listed on the SDN List or otherwise subject to any U.S. Economic Sanction during the previous five years; or (iv) has used, directly or indirectly, any
corporate funds to contribute to or finance the activities of any person, entity, or government listed on the SDN List or otherwise subject to any U.S. Economic Sanction. 

 

	9.3.7	 Novocodex and its Affiliates (i) are in compliance in all material respects with all Applicable Laws
relating to anti-money laundering, and (ii) are not and have not been part of any proceedings (nor is any such proceeding pending or threatened) with respect to any such laws. 

 

	9.3.8	 Both the Ambrx Existing Patent Rights and the Ambrx Know-How are
permitted to be imported into China under PRC law, and none of it falls within the PRC categories for technologies that are restricted or prohibited from being imported. 

 

	9.3.9	 Novocodex and its Affiliates will use the Ambrx Existing Patent Rights and Ambrx
Know-How solely for the purpose of the development, use, manufacture or sale of the Licensed Products in Territory strictly in accordance with the terms of this Agreement and not for any other purpose.

  

	9.3.10	 Novocodex and its Affiliates shall invest sufficient resources and funds and use Commercially Reasonable
Efforts to achieve Novocodex Follow-up Events so as to develop and commercialize Licensed Product in the Territory and obtain Phase I Clinical Data outside the Territory. 

ARTICLE 10 

INDEMNIFICATION & INSURANCE 

  
 29 

	10.1	 INDEMNIFICATION BY NOVOCODEX. Novocodex hereby agrees to indemnify, hold harmless and defend Ambrx, its
Affiliates and their respective officers, directors, agents, employees, successors and assigns (collectively, the “Ambrx Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating
to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out of or relating to (i) the development, manufacture, use, sale or other disposition of Licensed Products by Novocodex
or its Affiliates or sublicensees under this Agreement, (ii) failure to perform its obligations under this Agreement by Novocodex, its Affiliates or their respective officers, directors, agents or employees, (iii) the breach of any of
Novocodex’s covenants, representations or warranties under this Agreement, or (iv) the negligence or willful misconduct by Novocodex, its Affiliates or their respective officers, directors, agents or employees, in performing any
obligations under this Agreement. 

  

	10.2	 INDEMNIFICATION BY AMBRX. Ambrx hereby agrees to indemnify, hold harmless and defend Novocodex, its Affiliates
and their respective officers, directors, agents, employees, successors and assigns (collectively, the “Novocodex Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to
claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out of or relating to (i) failure to perform its obligations under this Agreement by Ambrx, its Affiliates or their
respective officers, directors, agents or employees, (ii) the breach of any of AMBRX’s covenants, representations or warranties under this Agreement, or (iii) the negligence or willful misconduct by Ambrx, its Affiliates or their
respective officers, directors, agents or employees, in performing any obligations under this Agreement. 

  

	10.3	 PROCEDURE. If a Party is seeking indemnification under Article 10 (the “Indemnified Party”),
it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to Article 10 as soon as reasonably practicable after receiving notice of the claim (provided, however, any
delay or failure to provide such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable, Article 10 except to the extent that such delay or failure
materially prejudices the Indemnifying Party’s ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The
Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the
right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any claim without the prior written consent of the
Indemnified Party, which the Indemnifying Party may provide in its sole discretion. The Indemnified Party shall not settle or compromise any such claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld.

  

	10.4	 INSURANCE. 

  
 30 

	10.4.1	 AMOUNT. Beginning the First Commercial Sale of Licensed Product by Novocodex or by an Affiliate, Novocodex
shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts decided by the JSC and naming Ambrx as additional insured. During clinical trials of Licensed Product in the Territory, Novocodex shall, at
its sole cost and expense, procure and maintain commercial general liability insurance in such equal or lesser amount as Ambrx shall require, naming Ambrx as additional insured. During the Phase I clinical trials of Licensed Product outside the
Territory, Ambrx shall procure and maintain commercial general liability insurance in such equal or lesser amount as Novocodex shall require, naming Novocodex as additional insured. Such commercial general liability insurance shall provide:
(a) product liability coverage and (b) broad form contractual liability coverage for Novocodex’s and Ambrx’s indemnification obligations under this Agreement. 

 

	10.4.2	 EVIDENCE. Novocodex shall provide Ambrx with written evidence of such insurance upon request of Ambrx.
Novocodex shall provide Ambrx with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. 

 

	10.4.3	 MAINTENANCE. Novocodex shall maintain such commercial general liability insurance beyond the expiration or
termination of this Agreement during: (a) the period that any Licensed Product is being commercially distributed or sold by Novocodex or its Affiliate and (b) a reasonable period after the period referred to in (a) above which
in no event shall be less than ten (10) years. 

 ARTICLE 11 

TERM & TERMINATION 
  

	11.1	 TERM. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as
provided in this Article 11, shall continue in full force and effect until the expiration of the Royalty Term with respect to Licensed Products in Territory (the “Term”). 

 

	11.2	 EFFECT OF EXPIRATION. Following the expiration of this Agreement with respect to Licensed Product in the
Territory pursuant to Section 11.1, Novocodex shall have the royalty-free, perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export such Licensed Product In the Territory. 

 

	11.3	 TERMINATION BY NOVOCODEX. Novocodex may terminate this Agreement upon six (6) months prior written notice
to Ambrx. 

  

	11.4	 TERMINATION FOR DEFAULT. Each Party shall have the right to terminate this Agreement, upon notice to the other
Party, in the event that: 

  

	11.4.1	 Such other Party materially defaults with respect to any of its material obligations under this Agreement and
does not cure such default within sixty (60) days after the receipt of a notice from the non-breaching Party specifying the nature of, and requiring the remedy of, such default (or, if such default cannot
be cured within such sixty (60)-day period, if 

  
 31 

	 	
the breaching Party does not commence and diligently continue actions to cure same during such sixty (60)-day period); 

 

	11.4.2	 The other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief
under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or
substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or
substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or

  

	11.4.3	 An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a
court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property, under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian,
sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its property, or (iii) the winding-up or liquidation of such other Party; and, in each
case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for thirty (30) days.

  

	11.5	 EFFECT OF TERMINATION. 

 

	11.5.1	 TERMINATION OF RIGHTS. 

 

	 	i.	 Upon termination of this Agreement by Ambrx pursuant to Section 11.4 or by Novocodex pursuant to
Section 11.3, (i) the rights and licenses granted to Novocodex under Sections 2.1, 2.2, 2.3, and 2.4 shall terminate, all rights therein or under will revert to Ambrx and neither Novocodex nor its Affiliates may make, develop, manufacture, have
manufactured, sell, offer for sale and have sold Licensed Products in the Territory; (ii) the rights and licenses granted to Ambrx under Sections 2.6 and 2.7 will revert back to Novocodex, provided however, Novocodex shall not assert against
Ambrx, its Affiliates or sublicensees any claims for infringement of the reverted rights in the event Ambrx and/or its Affiliate and/or sublicensees continue to make, develop, manufacture, have manufactured, sell, offer for sale and have sold
Licensed Products; and (iii) any existing agreements that contain a sublicense shall terminate to the extent of such sublicense; provided, however, that, for each sublicensee, upon termination of the sublicense agreement with such sublicensee,
if the termination is not caused by any action or inaction of the sublicensee, such sublicensee shall have the right to seek a license from Ambrx at Ambrx’s sole discretion. 

 

	 	ii.	 Upon termination of this Agreement by Novocodex pursuant to Section 11.4, (i) the rights and licenses
granted to Novocodex under Sections 2.1, 2.2, 2.3 and 2.4 shall terminate, all rights therein or under will revert to Ambrx and neither 

  
 32 

	 	
Novocodex nor its Affiliates may make any further develop, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products in the Territory; and (ii) rights and licenses
granted to Ambrx under Sections 2.6 and 2.7 will revert to Novocodex. 

  

	11.5.2	 NO RELEASE. Termination of this Agreement for any reason shall not release any Party hereto from any
liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law
or in equity which accrued or are based upon any event occurring prior to such termination. 

  

	11.5.3	 RIGHTS TO SELL STOCK ON HAND. After the date of termination, Novocodex and its Affiliates (a) may sell
Licensed Products then in stock and (b) may complete the production of Licensed Products then in the process of production and sell the same; provided that, in the case of both (a) and (b), Novocodex shall pay the applicable royalties and
payments to Ambrx in accordance with Article 6. 

  

	11.5.4	 TRANSFER OF INFORMATION, MATERIALS AND REGULATORY FILINGS AND. Notwithstanding the foregoing, upon termination
of this Agreement by either party pursuant to Section 11.4 or by Novocodex pursuant to Section 11.3, Novocodex shall promptly transfer and assign to Ambrx ownership of all preclinical data, clinical data, regulatory filings and any other
information and materials as necessary for Ambrx, its Affiliate or successor to continue to develop and commercialize the Licensed Product or ARX305 in the Territory, Phase I Clinical Data in a jurisdiction outside the Territory to the extent
permissible by Applicable Law; if such transfer and assignment is not legally permitted, Novocodex shall provide Ambrx with the right to reference, cross-reference, review, have access to, incorporate and use all documents and other materials filed
by or on behalf of Novocodex and its Affiliates with any Regulatory Authority in furtherance of applications for Marketing Authorization in the Territory or outside the Territory with respect to Licensed Product. Ambrx shall be entitled to freely
and exclusively use and to grant others the right to use all such materials and documents delivered pursuant to this Section 11.5.4. 

  

	11.5.5	 RETURN OF CONFIDENTIAL INFORMATION & MATERIALS. Upon any termination of this Agreement, each Party
shall promptly return to the other Party all Confidential Information & Materials or Know-How received from the other Party, except as reasonably required to exercise any surviving rights or licenses
hereunder. 

  

	11.6	 ACCRUED RIGHTS; SURVIVAL. 

 

	11.6.1	 Termination or expiration of this Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination or expiration. Such termination or expiration shall not relieve either Party from obligations which are expressly indicated to survive termination or expiration of this Agreement.
The rights of the Parties upon termination described in this Agreement shall not be exclusive of any other rights or claims at law or in equity that either Party may have against the other arising out of this Agreement. 

  
 33 

	11.6.2	 Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to
pay all royalties, milestone or follow-up payments and other monetary obligations that may have accrued hereunder prior to such termination. All of the Parties’ rights and obligations under Sections 2.10,
7.1, 7.2, 7.3, and 7.4, and ARTICLE 1, ARTICLE 8, ARTICLE 10, ARTICLE 11, ARTICLE 12, ARTICLE 13 and ARTICLE 14 shall survive termination, relinquishment or expiration hereof. 

ARTICLE 12 
 LIMITATIONS
OF LIABILITY 
  

	12.1	 EXCLUSION OF DAMAGE. EXCEPT WITH RESPECT TO ARTICLE 8 (CONFIDENTIALITY), ARTICLE 9 (REPRESENTATIONS AND
WARRANTIES) AND ARTICLE 10 (INDEMNIFICATION), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES INCURRED BY SUCH PARTY ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE
TERMINATION HEREOF) INCLUDING, BUT NOT LIMITED TO, THE LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OR OTHERWISE, EVEN IF AN AUTHORIZED
REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

  

	12.2	 MAXIMUM LIABILITY. EXCEPT FOR NOVOCODEX’S PAYMENT OBLIGATIONS HEREUNDER AND EXCEPT WITH RESPECT TO ARTICLE
8 (CONFIDENTIALITY), ARTICLE 9 (REPRESENTATIONS AND WARRANTIES) AND ARTICLE 10 (INDEMNIFICATION), EACH PARTY’S MAXIMUM LIABILITY TO THE OTHER PARTY FOR ANY KIND OF LOSS, DAMAGE OR LIABILITY ARISING UNDER OR IN CONNECTION WITH ITS PERFORMANCE OR
BREACH HEREOF, UNDER ANY THEORY OF LIABILITY, SHALL NOT EXCEED [***] ($[***]).  

  

	12.3	 FAILURE OF ESSENTIAL PURPOSE. The limitations specified in this ARTICLE 12 shall survive and apply even if any
limited remedy specified in this Agreement is found to have failed of its essential purpose. 

 ARTICLE 13 

DISPUTE RESOLUTION 
  

	13.1	 DISPUTES. Subject to 13.2, upon the written request of either Party to the other Party, any claim, dispute, or
controversy as to the breach, enforcement, interpretation or validity 

  
 34 

	 	
of this Agreement (a “Dispute”) will be referred to the Executive Officers (or such Executive Officer’s designee with decision-making authority) for attempted resolution. In
the event such executives are unable to resolve such Dispute within 30 days after the initial written request, then, upon the written demand of either Party, the Dispute shall be subject to arbitration, as provided in Section 13.2, except
as expressly set forth in 13.2. 

  

	13.2	 ARBITRATION. Any Dispute that cannot be resolved pursuant to Section 13.1 will be referred to and finally
resolved by arbitration in accordance with the International Chamber of Commerce (the “Rules”) by the Hong Kong International Arbitration Centre (“HKIAC”), by an arbitral tribunal composed of three
(3) arbitrators, with each Party appointing one (1) arbitrator and the third arbitrator to be selected by mutual agreement of the two (2) arbitrators appointed by the Parties. The foregoing arbitration proceedings may be commenced by
either Party by notice to the other Party. All arbitration proceedings will be conducted in the English language. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrators, or, in
the absence of such determination, each Party will pay its own expenses. All rulings by the arbitrators will be final. 

  

	13.3	 EXCEPTIONS. Nothing contained in this Agreement shall deny either Party the right to seek, upon good cause,
injunctive or other equitable relief from a court of competent jurisdiction in the context of an emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing dispute resolution discussions or
arbitration proceedings. In addition, either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of Patent Rights or
other intellectual property rights, and no such claim shall be subject to arbitration pursuant to 13.2. 

 ARTICLE 14

 MISCELLANEOUS 
  

	14.1	 FORCE MAJEURE. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including,
embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any
governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure
circumstances. 

  

	14.2	 ASSIGNMENT. Except as provided in this Section 14.2, this Agreement may not be assigned or otherwise
transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party. Notwithstanding 

  
 35 

	 	
the foregoing, either Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; provided, however,
that the assigning party must notify the other party at least twenty (20) days prior to completion of any such assignment. Further, each party may assign this Agreement to any assignee of all or substantially all of such Party’s business
to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which this Agreement relates, or in the event of such Party’s merger, consolidation or similar transaction. Any
permitted assignee shall assume all obligations of its assignor under this Agreement. This Agreement is binding upon the permitted successors and assigns of the Parties. Any attempted assignment not in accordance with this Section 14.2 shall be
void. 

  

	14.3	 SEVERABILITY. If any one or more of the provisions contained in this Agreement is held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the
substantive rights of the Parties. The Parties shall in such an instance use their good faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement
the purposes of this Agreement. 

  

	14.4	 NOTICES. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered
personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return
receipt requested, addressed as follows: 

  

					
	If to Ambrx, to:	 		  	Ambrx, Inc.
		 		  	10975 North Torrey Pines Road
		 		  	La Jolla, CA 92037
		 		  	Attn: Office of General Counsel
		 	          	  	Facsimile No.:
		
		 	With a copy to:
		 		  	Goodwin Procter LLP
		 		  	One Exchange Square
		 		  	Suite 2801, 8 Connaught Place
		 		  	Central, Hong Kong
		 		  	Attn: Wenseng “Wendy” Pan, Esq.
		 		  	Facsimile No.:
			
	If to Novocodex, to:	 		  	NovoCodex Biopharmaceuticals Ltd.,
		 		  	 398 Mahuan Road, Binhaixincheng, Shaoxing,

Zhejiang 312366, the People’s Republic of China

		 		  	Attn: Zhenlan Hu
		 		  	Facsimile No.:

  
 36 

 or to such other address(es) as the Party to whom notice is to be given may have furnished
to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch, if sent by internationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of
mailing, if sent by mail. 
  

	14.5	 APPLICABLE LAW. This Agreement shall be governed by and construed in accordance with the laws of the Hong Kong
Special Administrative Region, without reference to any rules of conflict of laws or renvoi. The United Nations Convention on the Sale of Goods shall not apply to this Agreement. All disputes arising from or in connection with this Agreement
shall be submitted for arbitration in accordance with the UNCITRAL Arbitration Rules in accordance with the HKIAC Procedures for the Administration of International Arbitration in force at the date of this Agreement. The place of arbitration shall
be in Hong Kong at Hong Kong International Arbitration Centre. 

  

	14.6	 ENTIRE AGREEMENT; AMENDMENTS. This Agreement together with the Schedules hereto contains the entire
understanding of the Parties with respect to the subject matter hereof, including the research program and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either
oral or written, with regard to the subject matter hereof, including the research program and/or the licenses granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by reference and
shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. 

 

	14.7	 HEADINGS AND INTERPRETATION. The captions to the several Articles and Sections and subsections hereof are not a
part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit shall be
deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words
of any gender include each other gender, (b) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear,
(c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term “including” (or “includes” or words of similar import), such term shall not be limiting
and such term shall be deemed to mean “including without limitation” (or “includes without limitation”), (e) the word “or” shall not be construed as exclusive, and (f) references to any Articles or Sections include
Sections and subsections that are part of the reference Article or section (e.g., a section numbered “Section 2.2.1” would be part of “Section 2.2.”, and references to “Article 2” or
“Section 2.2.” would refer to material contained in the subsection described as “Section 2.2.2”). 

  
 37 

	14.8	 INDEPENDENT CONTRACTORS. It is expressly agreed that Ambrx and Novocodex shall be independent contractors and
that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Ambrx nor Novocodex shall have the authority to make any statements, representations or commitments of any kind, or to take any action,
which shall be binding on the other Party, without the prior written consent of the other Party. 

  

	14.9	 WAIVER. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to
perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 

 

	14.10	 CUMULATIVE REMEDIES. No remedy referred to in this Agreement is intended to be exclusive, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  

	14.11	 WAIVER OF RULE OF CONSTRUCTION. Each Party has had the opportunity to consult with counsel in connection with
the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	14.12	 BUSINESS DAY REQUIREMENTS. In the event that any notice or other action or omission is required to be taken by
a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. 

 

	14.13	 COUNTERPARTS. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original. 

 

	14.14	 PRC REGULATORY MATTERS. Novocodex shall be responsible for any and all PRC related regulatory approvals,
registrations and/or filings in connection with performance of this Agreement, including without limitation registering this Agreement with competent commission of commerce and providing registration certificate to Ambrx within sixty (60) days
after execution of this Agreement. Before Novocodex’s filing or submission of any reports or other documents with any PRC governmental authority or securities exchange, it shall provide copies of any such reports or documents to be filed or
submitted to Ambrx for its prior consents; after regulatory approvals, registrations and/or filings are completed, Novocodex shall provide a copy of relevant certificates to Ambrx immediately. 

 

	14.15	 EXPORT LAWS. Notwithstanding anything to the contrary contained herein, all obligations of Ambrx and Novocodex
are subject to prior compliance with the export regulations of the United States and any other relevant country and such other laws and regulations in effect in the United States and/or any other relevant country as may be applicable, and to
obtaining all necessary approvals required by the applicable agencies 

  
 38 

	 	
of the governments of the United States and any other relevant countries. Ambrx and Novocodex shall cooperate with each other and shall provide assistance to the other as reasonably necessary to
obtain any required approvals. 

  

	14.16	 FURTHER ACTIONS. Each Party will execute, acknowledge and deliver such further instruments, and to do all such
other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	14.17	 NO THIRD PARTY RIGHTS. The provisions of this Agreement are for the exclusive benefit of the Parties, and no
other person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. 

 

	14.18	 EXPENSES. Except as otherwise specifically provided in this Agreement, each Party (and its Affiliates) shall
bear its own costs and expenses in connection with entering into this Agreement and the consummation of the transactions and performance of its obligations contemplated hereby. 

 

	14.19	 EXTENSION TO AFFILIATES. Novocodex shall have the right to extend the rights, licenses, immunities and
obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions
apply to Novocodex. Novocodex shall remain fully liable for any acts or omissions of such Affiliates. 

  

	14.20	 LANGUAGE. The official text of this Agreement is in the English language as written and spoken in the United
States of America. Any text or version of this Agreement in another language, even if such text or version is made by translation or prepared by or executed by one or both of the Parties for a Party’s convenience shall not be binding and shall
have no force or effect. Without limiting the foregoing, in the event of any conflict or inconsistency between the English text of this Agreement and any text or version of this Agreement in another language, the English text of this Agreement will
prevail. 

 [Remainder of this page is left intentionally blank] 

  
 39 

 IN WITNESS WHEREOF, the Parties have executed this
Co-Development and License Agreement as of the Effective Date. 
  

			
	NOVOCODEX BIOPHARMACEUTICALS LTD.
		
	By: 签字:	 	 /s/ Xuejun Liang

		
	Name: 姓名 :	 	 Xuejun Liang

		
	Title: 职位:	 	

  

			
	AMBRX, INC.
		
	By: 签字:	 	 /s/ Feng Tian

		
	Name: 姓名 :	 	 Feng Tian

		
	Title: 职位:	 	 CEO

  
 40 

 Exhibits 

Exhibit 1.1: Structure of ARX305 

[***] 
 [***]AS269 

[***] 
 [***] 

[***] 

 Exhibit 1.5: List of Ambrx Existing Patent Rights 

[See attached] 

 Exhibit 1.28: Global Development Plan 

To be adopted by the JSC within 60 days after the Effective Date. 

 Exhibit 3.1: Initial Members of Joint Steering Committee 

 

			
	Ambrx	  	NovoCodex
	Shawn Zhang	  	Gang Xia
	Ying Buechler	  	Hongjun Jiang
	Sulan Yao	  	Jingjing Zhu

 Exhibit 8.4: Draft Joint Press Release 

Ambrx and NovoCodex form Second Collaboration to Develop and 

Commercialize Ambrx’s Antibody Drug Conjugates 

SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ — Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned
company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates (ADCs). Under the agreement, Ambrx and NovoCodex
will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70 positive cancers. 
 Under the terms
of the agreement, NovoCodex is responsible for developing and commercializing ARX305 in China while Ambrx is responsible for developing and commercializing ARX305 outside of China. NovoCodex will fund global development activities to the end of
Phase 1 clinical trials and pay Ambrx an undisclosed upfront payment, development milestones, and a double digit royalty on product sales in China. NovoCodex is also eligible to share in undisclosed portion of ARX305 product sales outside of China.

 “We are excited to initiate our second collaboration with NovoCodex following our successful collaboration with ARX788, which is
currently in Phase 1 clinical trials for HER2 positive breast and gastric cancers. ARX305 is a natural extension to the first collaboration with the inclusion of another Ambrx enabled ADC that is intended to treat CD70 positive cancers such as Renal
Cell Carcinoma and Multiple Myeloma. Further, we continue to align ourselves with China’s leading pharmaceutical companies” said Feng Tian, Ph.D., Chief Executive Officer of Ambrx. “ARX305, which is expected to start Phase 1 clinical
trials in early 2021, allows Ambrx to expand its ADC pipeline into multiple cancer types while gaining access to the China market through our partnership with NovoCodex.” 

Chunbo Li, Chairman of Zhejiang Medicine, commented, “The smooth progress of our first ZMC-Ambrx
collaborated ADC project, ARX788, proves that Ambrx’ technology is one of the best methods to make an ADC drug. The new alliance with Ambrx on ARX305 will strengthen our leading position on ADC research, and hopefully will bring new treatment
to related cancer patients.” 
 About Ambrx 

Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create first- and/or
best-in-class biotherapeutics, including antibody drug conjugates (ADC), immunomodulating proteins, bispecific antibodies and other therapeutic proteins with improved
pharmacologic properties. Leveraging the Ambrx proprietary technology platforms, Ambrx has collaborations with Bristol-Myers Squibb, Astellas, BeiGene, Elanco and ZMC, with drug products generated using Ambrx technology in different stages of
clinical trials. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas. For additional information, visit www.ambrx.com 

 About ARX305 

CD70 is highly expressed in multiple solid and liquid tumors such as Renal Cell Carcinoma, Multiple Myeloma,
Non-Hodgkin’s Lymphoma, AML, and etc. ARX305 is a best-in-class anti-CD70 ADC that was precision-engineered using Ambrx
proprietary antibody and clinically validated drug payload. Strong in vitro and in vivo efficacy have been demonstrated in multiple tumor cells and models. It is expected to deliver a direct killing to CD70-overexpressing tumor and improvement of
the immune suppression in the tumor microenvironment. 
 About NovoCodex 

NovoCodex is a majority owned company of Zhejiang Medicine Co., Ltd. (stock code: SH.600216), mainly committed to the research and development
of biological products. The company’s laboratory has experience and capabilities in genetic engineering, cell culture, toxin synthesis, conjugation, formulation & filling, preclinical study and clinical study. ARX788 project has been
successfully advanced to the later stage of phase 1 clinical trial in China. The company is building a protein drug development platform with the insertion of unnatural amino acids as the core technology to develop a variety of long-acting protein
drugs. For additional information, visit http://www.novocodex.cn/.EX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 CO-DEVELOPMENT AND LICENSE
AGREEMENT 
 between 
 SINO
BIOPHARMACEUTICAL CO., LTD. 
 and 

AMBRX, INC. 
 Dated as of
January 13, 2020 

  
 1 

 This CO-DEVELOPMENT AND LICENSE
AGREEMENT (this “Agreement”), effective as of January 13, 2020 (the “Effective Date”), is between Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North Torrey Pines
Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and Sino Biopharmaceutical Co., Ltd., a company registered under the laws of the Cayman Islands, with its
registered address in Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands, for and on behalf of itself and its Affiliates (together with its Affiliates,
“Sino”). Ambrx and Sino may each be referred to herein individually as a “Party” or, collectively, as the “Parties.” 

RECITALS 

WHEREAS, Ambrx owns and/or controls Ambrx Background Technology (as hereinafter defined) and has rights to Licensed
Intellectual Property Rights (as hereinafter defined) with respect to the Research Program (as hereinafter defined); 

WHEREAS, Sino is a pharmaceutical company engaged in research, Development, and Commercialization of pharmaceutical
products, including the human therapeutic products in the Sino Territory (as hereinafter defined); 
 WHEREAS, Sino
desires to obtain an exclusive license under the Licensed Intellectual Property Rights (as defined below) in the Sino Territory upon the terms and conditions set forth herein, and Ambrx desires to grant such a license, in order for Sino to Develop,
make, use, sell and offer for sale the Licensed Products (as hereinafter defined) for the prevention or treatment of human diseases and human conditions in the Sino Territory; and 

WHEREAS, Sino desires to obtain assistance from Ambrx and Ambrx desires to offer such assistance to Sino to Develop the
Research Program and the Licensed Products in the Sino Territory under world-class standards. 
 NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 As used in this Agreement, the following terms shall have those meanings set forth in this Article 1 unless the context dictates
otherwise. 
  

	1.1	 “Affiliate” shall mean, with respect to any Person, any other Person that directly or
indirectly controls, is controlled by, or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of
such Person, 

  
 2 

	 	
whether through the ownership of fifty percent (50%) or more of the voting securities of such Person by voting agreement, by contract or otherwise. 

 

	1.2	 “Agreement” shall have the meaning set forth in the introductory paragraph.

  

	1.3	 “Ambrx” shall have the meaning set forth in the introductory paragraph. 

 

	1.4	 “Ambrx Background Technology” shall mean Know-How and
Patent Rights that are owned and/or Controlled by Ambrx or any of its Affiliates as of the Effective Date or during the Term of this Agreement that is not Ambrx Research Program IP, including Ambrx Core Technology IP and the Ambrx Core Technology
Platform. 

  

	1.5	 “Ambrx Cell Materials” shall mean (a) the CHO cell lines Controlled by Ambrx that [***],
(b) the E. coli strains Controlled by Ambrx that express [***], and (c) the special and proprietary supporting materials for (a) and (b) Controlled and provided by Ambrx. For clarity, Ambrx Cell Materials shall not include proprietary
mammalian and bacterial cell lines used to create the Ambrx Cell Materials. 

  

	1.6	 “Ambrx Core Technology IP” shall mean Ambrx Core Technology Patents and Ambrx Core Technology Know-How. 

  

	1.7	 “Ambrx Core Technology Know-How” shall mean all Know-How owned or Controlled by Ambrx that is related to Ambrx Core Technology Platform. 

  

	1.8	 “Ambrx Core Technology Patents” shall mean all Patent Rights that are Controlled by Ambrx that
claim the Ambrx Core Technology Platform. 

  

	1.9	 “Ambrx Core Technology Platform” shall mean Ambrx’s proprietary platform technology, as
described in more detail in Exhibit 1.9, which includes but is not limited to: (i) Ambrx’s proprietary mammalian and bacterial cell lines used to create the Ambrx Cell Materials; (ii) the ReCODETM platform; (iii) the EuCODETM platform; and (iv) other technologies, such as conjugation chemistry technology.

  

	1.10	 “Ambrx Indemnified Parties” shall have the meaning set forth in Section 9.1.

  

	1.11	 “Ambrx Research Program Invention” shall mean any Research Program Invention discovered,
generated, made or reduced to practice solely by Ambrx’s employees, independent contractors or consultants. 

  

	1.12	 “Ambrx Research Program IP” shall mean all Ambrx Research Program Patents and Ambrx Research
Program Know-How. 

  

	1.13	 “Ambrx Research Program Know-How” shall mean all Know-How that is related to and arises from an Ambrx Research Program Invention. 

  

	1.14	 “Ambrx Research Program Patents” shall mean any Patent Right that claims an Ambrx Research
Program Invention. 

  
 3 

	1.15	 “Ambrx Territory” shall mean all parts of the world except the Sino Territory.

  

	1.16	 “Ambrx Third Party License” shall have the meaning set forth in Section 2.4.1.

  

	1.17	 “Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to
any of the Parties or their respective Affiliates in carrying out activities hereunder or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject by law or by agreement, and shall include all
statutes, enactments, acts of legislature, laws, ordinances, rules, Regulations, notifications, guidelines, policies, directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local
authority or other governmental entity in such jurisdictions. 

  

	1.18	 “Biosimilar Product” means, with respect to a Licensed Product, a biologic product:
(a) for which Regulatory Approval is obtained by referencing Regulatory Filings of such Licensed Product; (b) that is approved for use in such country (or region) pursuant to a Regulatory Approval process governing approval of
interchangeable or biosimilar biologics as described in 42 U.S.C. § 262, or a similar process for Regulatory Approval in any country (or region) outside the United States, or any other similar provision that comes into force, or
is the subject of a notice with respect to such Licensed Product under 42 U.S.C. § 262(l)(2) or any other similar provision that comes into force in such country (or region); and (c) is sold in the same country as such
Licensed Product by any Third Party that is not a Sublicensee of Sino or its Affiliates with respect to the Ambrx Research Program IP and Joint Research Program IP. 

 

	1.19	 “Bispecific Molecule” shall mean any molecule that only binds to two biological targets
simultaneously, and shall exclude any molecule that binds more than two biological targets or less than two biological targets simultaneously. 

  

	1.20	 “BLA” means a Biologics License Application filed with the FDA in the United States, as
defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et seq., or any non-U.S. counterpart of the foregoing. 

 

	1.21	 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar
months ending on March 31, June 30, September 30 and December 31. 

  

	1.22	 “Calendar Year” shall mean each successive period of twelve (12) months commencing on
January 1 and ending on December 31. 

  

	1.23	 “cGMP” or “Current Good Manufacturing Practice” shall mean the applicable
then-current good manufacturing practice standards for manufacturing of pharmaceuticals or biologicals, as set forth in the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301, as amended from time to time, together with
any similar standards of good manufacturing practice as required by the FDA and other relevant Regulatory Authority. 

  
 4 

	1.24	 “China GAAP” shall mean Generally Accepted Accounting Principles for the People’s
Republic of China. 

  

	1.25	 “Claimant” shall have the meaning set forth in Section 6.4.1. 

 

	1.26	 “Claimant License Fee” shall have the meaning set forth in Section 6.5.

  

	1.27	 “Clinical Trial” means any Phase I Clinical Trial, Phase II Clinical Trial, or Phase III
Clinical Trial. 

  

	1.28	 “CMC Data” means any data included in the “Chemistry, Manufacturing and Controls”
portion of a Regulatory Filings or in any supporting Development reports thereto, in each case, with respect to any Licensed Product in any country in the world. 

 

	1.29	 “Commercialize” or “Commercialization” means any and all activities directed
to the marketing and commercialization of the Licensed Product after Regulatory Approval, including pre-launch and post-launch marketing, promoting, distribution, detailing or commercially selling the Licensed
Product (as well as importing and exporting activities in connection therewith). 

  

	1.30	 “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a
Party [***]. 

  

	1.31	 “Compensation” shall have the meaning set forth in Section 6.5. 

 

	1.32	 “Confidential Information & Materials” shall mean any and all
proprietary and/or confidential information, materials and data, including all scientific, pre-clinical, clinical, regulatory, process, formulation, manufacturing, marketing, financial and commercial
information or data, compounds, cells and cell lines, whether communicated in writing or orally or by any other method, which are provided by one Party to the other Party prior to or during the Term of this Agreement. The fact that an item is known
to the public shall not be taken to exclude the possibility that a compilation including the item, and/or a Development relating to the item, is (and remains) not known to the public. 

 

	1.33	 “Control,” “Controls” or “Controlled by” shall mean, with
respect to any Patent Rights, Know-How, Confidential Information & Materials, or other intellectual property assets or other items or rights, as applicable, possession by the Party granting the
applicable right, license, access or release to the other Party as provided herein of the power and authority, whether arising by ownership, license, or other authorization, to disclose and deliver such
Know-How, Confidential Information & Materials, and to grant and authorize under such Patent Rights, Know-How, Confidential Information & Materials the
right, license, access or release, as applicable of the scope granted to such other Party in this Agreement without giving rise to any violation of the term of any written agreement with any Third Party existing at the time such disclosure is first
made or such right, license access or release first comes into effect hereunder. Notwithstanding anything to the contrary in this Agreement, in the event that a Third Party merges or consolidates with or acquires a Party or an Affiliate of a Party,
or a Party or an Affiliate of a Party transfers to a Third Party all or substantially 

  
 5 

	 	
all of its assets to which this Agreement relates (such Third Party and its Affiliates immediately prior to such merger, consolidation or transfer (the “Acquisition Transaction”,
collectively, the “Acquiring Entities”), then (a) any intellectual property or materials owned or Controlled by any Acquiring Entity (and not Controlled by such Party or its Affiliates) immediately prior to the effective date
of such Acquisition Transaction, and (b) any intellectual property or materials independently developed or acquired by or on behalf of any Acquiring Entity after an Acquisition Transaction without accessing or practicing any Patent Rights, Know-How, Confidential Information & Materials made available to such Party under this Agreement, shall not be deemed be Controlled by such Party or its Affiliates after the effective date of such
Acquisition Transaction for purposes of this Agreement. 

  

	1.34	 “Cover” shall mean, with respect to Patent Rights and materials, products and services, that
the research, Development, making, using, offering to sell, selling, importing, or exporting of such materials, products and services, would, but for the a license under such Patent Rights, infringe a Valid Claim of such Patent Rights in the Sino
Territory. 

  

	1.35	 “Development” or “Develop” means any and all research and development
activities necessary or useful to obtain Regulatory Approval for a Licensed Product, including but not limited to all non-clinical, Scientific Development, Pre-Clinical
development and clinical activities, research and development of companion diagnostics for use in connection with Clinical Trials of Licensed Products, as well as approved Licensed Products, drug development activities, animal pharmacology,
toxicology, statistical analysis and report writing, activities to generate chemistry-manufacturing-and-control information, the distribution of Licensed Products for
use in Clinical Trials (including placebos and comparators), Licensed Product approval and registration, and regulatory affairs related to the foregoing. When used as a verb, “Develop” means to engage in development.

  

	1.36	 “Development Plan” shall mean the plan setting forth the Scientific Development, Pre-Clinical Development, clinical, manufacturing and regulatory activities and timelines relating to the Development of Licensed Products in the Field to the completion of the Phase I Clinical Trials to be
performed by Sino in the Sino Territory and by Ambrx in the Ambrx Territory for each of the Licensed Products, which plan shall be updated by the Joint Steering Committee from time to time. 

 

	1.37	 “Disclosing Party” shall have the meaning set forth in Section 7.1.

  

	1.38	 “Dispute” shall have the meaning set forth in Section 10.7. 

 

	1.39	 “Due Diligence Period” shall have the meaning set forth in Section 11.1.

  

	1.40	 “Effective Date” shall mean the date first set forth in the introductory paragraph.

  

	1.41	 “Exclusive Existing Third Party Licenses” shall have the meaning set forth in
Section 2.4.2. 

  
 6 

	1.42	 “Existing Third Party License” shall have the meaning set forth in Section 2.4.2.

  

	1.43	 “FDA” shall mean the United States Food and Drug Administration, or any successor thereto.

  

	1.44	 “Field” shall mean all indications and uses, including all human disease indications
and therapeutic uses. 

  

	1.45	 “Filing Party” shall have the meaning set forth in Section 6.2.1(I).

  

	1.46	 “First Commercial Sale” shall mean, with respect to any Licensed Product, the first sale to
the general public of such Licensed Product in the Sino Territory after all required marketing and pricing approvals have been granted, or otherwise permitted, by the governing health authority of Sino Territory such as NMPA. “First
Commercial Sale” shall not include the provision of any Licensed Product for use in Clinical Trials or for compassionate use, in each case, if such use is not compensated, prior to the receipt of necessary Marketing Authorization.

  

	1.47	 “Future Improvements” shall have the meaning set forth in Section 4.3.3.

  

	1.48	 “Future Third Party License” shall have the meaning set forth in Section 2.4.1.

  

	1.49	 “Generic Competition” shall mean the sale of Biosimilar Products in the Sino Territory by a
Third Party. 

  

	1.50	 “GLP” means the applicable then-current good laboratory practice standards as are required by
applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States, those promulgated or endorsed by the FDA in U.S. 21 C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by the
applicable Regulatory Authorities outside of the United States. 

  

	1.51	 “HKIAC” shall have the meaning set forth in Section 10.8. 

 

	1.52	 “IND” shall mean (a) an investigational new drug application filed with the FDA for
authorization for the investigation of a product, and (b) any of its foreign equivalents as filed with the applicable Regulatory Authorities in other countries or regulatory jurisdictions in the Sino Territory, as applicable.

  

	1.53	 “Indemnified Party” shall have the meaning set forth in Section 9.3.

  

	1.54	 “Indemnifying Party” shall have the meaning set forth in Section 9.3.

  

	1.55	 “Infringement” shall have the meaning set forth in Section 6.3.1. 

 

	1.56	 “Initial Compounds” shall mean (a) the [***], and (b) the [***]. For clarity, in the
circumstances of a Reload Compound under Section 3.2, with respect to any Initial Compound selected as a PCC by the Parties for Pre-Clinical Development and subsequently agreed by the Parties to cease
Development under Section 3.2, any 

  
 7 

	 	
improvements, modifications or upgrades of such ceased Initial Compound confirmed and accepted by the Parties as a Reload Compound shall forthwith not be considered as an Initial Compound.

  

	1.57	 “Initial PCC Requirements” shall have the meaning set forth in Section 4.2.2.

  

	1.58	 “Invention” shall mean any process, method, composition of matter, article of manufacture,
discovery or finding that is conceived or reduced to practice. 

  

	1.59	 “Joint Research Program Invention” shall mean any Research Program Inventions discovered,
generated, made or reduced to practice in the performance of the Development Plan jointly by the Parties or any of their employees, independent contractors or consultants. 

 

	1.60	 “Joint Research Program IP” shall mean all Joint Research Program Patents and Joint Research
Program Know-How. 

  

	1.61	 “Joint Research Program Know-How” shall mean all Know-How that is related to or arises from a Joint Research Program Invention. 

  

	1.62	 “Joint Research Program Patents” shall mean any Patent Right that claims a Joint Research
Program Invention. 

  

	1.63	 “Joint Steering Committee” shall mean the entity organized and acting pursuant to Article 3.

  

	1.64	 “Know-How” shall mean all existing and future
unpatented technical and other information or materials which are not in the public domain including information comprising or relating to discoveries, Inventions, data, designs, formulae, methods, models, assays, Development Plans, procedures,
designs for experiments and tests and results of experimentation and testing, information related to cells or cell lines, processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological,
toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries and information contained in submissions to and information from ethical committees and regulatory authorities. Know-How includes rights protecting Know-How. 

  

	1.65	 “License” shall mean all of the rights granted by Ambrx to Sino by this Agreement under the
Licensed Intellectual Property Rights pursuant to Section 2.2.1. 

  

	1.66	 “Licensed Compounds” shall mean (a) the Initial Compounds and (b) any Reload
Compound that is selected by the unanimous decision of the Joint Steering Committee as a PCC in accordance with Section 3.2, which unanimous decision shall be reached without invoking casting vote of its chairperson under Section 3.4.2.

  

	1.67	 “Licensed Intellectual Property Rights” shall mean all existing (as of the Effective Date) and
future Patent Rights and Know-How that are Controlled by Ambrx that are necessary or useful for the manufacture, Development or Commercialization of the Licensed

  
 8 

	 	
Compounds and the Reload Compound (if any), including but not limited to the Ambrx Background Technology, Platform Improvements, and any Patent Rights and
Know-How Controlled by Ambrx under the Existing Third Party Licenses, Ambrx Third Party Licenses and Future Third Party Licenses. 

 

	1.68	 “Licensed Product” shall mean any pharmaceutical product containing a Licensed Compound as an
active pharmaceutical ingredient. 

  

	1.69	 “Losses” shall have the meaning set forth in Section 9.1. 

 

	1.70	 “MAA” means a Marketing Authorization Application, BLA, NDA, or similar application, as
applicable, and all amendments and supplements thereto, submitted to the FDA, European Medicines Agency, or any equivalent filing in a country or regulatory jurisdiction other than the United States or the European Union with the applicable
Regulatory Authority (including the NMPA), to obtain marketing approval for a pharmaceutical, biological, or diagnostic product, in a country or in a group of countries. 

 

	1.71	 “Marketing Authorization” shall mean all approvals from NMPA necessary to market and sell a
Licensed Product in the Sino Territory or a Regulatory Authority in a corresponding jurisdiction outside the Sino Territory. 

  

	1.72	 “Milestone Events” shall have the meaning set forth in Section 5.2.

  

	1.73	 “Milestone Payments” shall have the meaning set forth in Section 5.2.

  

	1.74	 “NDA” means a New Drug Application submitted to the FDA, or any successor application or
procedure, as more fully defined in 21 C.F.R. § 314.50 et seq. 

  

	1.75	 “Negotiation Period” shall have the meaning set forth in Section 11.1.

  

	1.76	 “Net Sales” shall mean with respect to a Licensed Product, the total gross amounts invoiced by
or on behalf of Sino or its Affiliate or Sublicensee for sales of such Licensed product after deducting, if not previously deducted, from the amount invoiced or received: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  
 9 

	 	(h)	 [***]; 

  

	 	(i)	 [***]; and 

  

	 	(j)	 [***]. 

Any individual items that are estimated and deducted in calculating Net Sales shall be periodically (but at least on a Calendar Quarter basis)
trued up and adjusted by Sino consistent with its customary practices and in accordance with China GAAP. Any deductions subsequently reversed shall be included in Net Sales for the royalty period in which such deductions are reversed. In no event
shall the total amount of deductions made in accordance with Items 1.76(f) through 1.76(j) above during any period exceed [***] ([***]) of the gross invoice price for such period. The calculation of Net Sales hereunder shall be in accordance
with China GAAP and Sino’s and/or its Affiliates’ customary accounting policies, applied consistently across periods, and: 
 (1)
Transfer or sale of a Licensed Product within Sino, between Sino and an Affiliate, or between Sino and a non-Affiliate Third Party in which Sino has equity interest shall not be considered a sale, commercial
use or disposition for the purpose of the foregoing paragraphs; 
 (2) in the event that Sino has to transfer or sell any Licensed Product to
a non-Affiliate Third Party in which Sino has equity interest, Sino and Ambrx shall jointly discuss and determine the value of Net Sales; and 

(3) in the event that Sino receives consideration for any Licensed Products in the case of transactions not at arm’s length with a non-Affiliate of Sino, Net Sales will be calculated based on the fair market value of such consideration or transaction, assuming an arm’s length transaction made in the ordinary course of business. 

 

	1.77	 “NMPA” shall mean National Medical and Pharmaceutical Administration in the People’s
Republic of China, or any successor thereto. 

  

	1.78	 “Non-Exclusive Existing Third Party License”
shall have the meaning set forth in Section 2.4.2. 

  

	1.79	 “Originating Licensor” shall have the meaning set forth in Section 2.7.1.

  

	1.80	 “Party” or “Parties” shall have the meaning set forth in the introductory
paragraph. 

  

	1.81	 “Patent Rights” shall mean any and all rights under any of the following, whether existing now
or in the future, and whether or not filed: (i) a United States, international or foreign patent, utility model, design registration, certificate of invention, patent of addition or substitution, or other governmental grant for the protection
of Inventions or industrial designs anywhere in the world, including any reissue, renewal, re-examination or extension thereof; and (ii) any application for any of the foregoing, including any
international, provisional, divisional, continuation, continuation-in-part or continued prosecution application. 

  
 10 

	1.82	 “[***]” shall mean the Bispecific Molecules set forth in Exhibit 1.82 wherein (a) [***] and
(b) [***]. 

  

	1.83	 “PEGylated IL-2 Molecule” shall mean the pegylated
version of biological molecule Interleukin-2 through the site-specific conjugation with the incorporated unnatural amino acid set forth in Exhibit 1.83 modified by Ambrx under this Agreement meant to have reduced or abolished binding to alpha
receptor (CD25). 

  

	1.84	 “Pending Product Specific Patent Rights” shall have the meaning set forth in
Section 2.1.4. 

  

	1.85	 “Person” shall mean any natural person, corporation, firm, business trust, joint venture,
association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. 

  

	1.86	 “Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 C.F.R. § 312.21(a), as may be amended, or the foreign equivalent thereof. 

  

	1.87	 “Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 C.F.R. § 312.21(b), as may be amended, or the foreign equivalent thereof. 

  

	1.88	 “Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy
the requirements of 21 C.F.R. § 312.21(c), as may be amended, or the foreign equivalent thereof. 

  

	1.89	 “Platform Improvements” shall have the meaning set forth in Section 6.1.4.

  

	1.90	 “PRC” shall mean the People’s Republic of China. 

 

	1.91	 “Pre-Clinical Candidate” or “PCC”
shall mean (a) each Initial Compound that meets the Initial PCC Requirements that is selected by the Joint Steering Committee in accordance with Section 3.2 and developed under the Development Plan; and (b) the Reload Compound (if
any) that meets the Initial PCC Requirements and the further criteria set by the unanimous decision of Joint Steering Committee without invoking casting vote of its chairperson under Section 3.4.2, in each case to start the Development
activities under Section 3.2 to enable IND filing by the Parties in their respective territories, including for completion of the Scientific Development by Ambrx and the subsequent Pre-Clinical
Development by Sino in scale-up production, process optimization and other Development activities in regulatory aspects for Successful Dual IND Filing with Regulatory Authority. 

 

	1.92	 “Pre-Clinical Data” shall mean data and information
generated in the performance of Pre-Clinical Development. 

  

	1.93	 “Pre-Clinical Development” shall mean those
Development activities occurring in the Research Term subsequent to Scientific Development that are essential in preparation for 

  
 11 

	 	
a Successful Dual IND Filing, commencing from delivery of a PCC to a Successful Dual IND Filing in all cases as provided in the applicable Development Plan. 

 

	1.94	 “Product Specific Patent Rights” shall have the meaning set forth in Section 2.1.1.

  

	1.95	 “Receiving Party” shall have the meaning set forth in Section 7.1. 

 

	1.96	 “Regulations” means regulations, statutes, rules, guidelines and procedures promulgated by any
Regulatory Authority pursuant to Applicable Laws, including current GLP and current cGMP. 

  

	1.97	 “Regulatory Approval” means all approvals, licenses, and authorizations of the applicable
Regulatory Authority necessary for the marketing and sale of a pharmaceutical, biological, or diagnostic product for a particular indication in a country or region, including MAAs (if any). 

 

	1.98	 “Regulatory Authority” shall mean any applicable government regulatory authority involved in
granting approvals for the manufacturing, marketing, reimbursement and/or pricing of the Licensed Product or Licensed Compound in the Sino Territory or outside the Sino Territory, including, in the Sino Territory, NMPA, and, in the United States,
the FDA and any successor governmental authority having substantially the same function. 

  

	1.99	 “Regulatory Data” means any and all research data, pharmacology data, CMC Data, Safety Data, Pre-Clinical Data, clinical data and all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with Regulatory Filings and Regulatory Approvals for Licensed Products
(including any applicable drug master files or similar documentation). 

  

	1.100	 “Regulatory Filing” means, with respect to the Licensed Compounds/Licensed Products,
any submission to a Regulatory Authority of any appropriate regulation applications specific to the Licensed Compounds/Licensed Products, and shall include any submission to a regulatory advisory board any supplement or amendment thereto, regulatory
registrations, applications, authorizations, and approvals (including approvals of MAAs, supplements and amendments, pre- and post-approvals, pricing approvals, and labeling approvals), Regulatory Approvals,
and other submissions made to or with any Regulatory Authority for research, Development, manufacture, or Commercialization of a pharmaceutical, biological, or diagnostic product in a regulatory jurisdiction, together with all related correspondence
to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each MAA, including all drug master files (if any), INDs, BLAs, and NDAs, and foreign equivalents of any of the foregoing.

  

	1.101	 “Reload Compound” shall have the meaning set forth in Section 3.2. 

 

	1.102	 “Reload Patent Rights” shall have the meaning set forth in Section 3.2.

  
 12 

	1.103	 “Remaining Compensation” shall have the meaning set forth in Section 6.5.

  

	1.104	 “Research Program” shall mean the research and Development program for the [***] and Reload
Compound (if any) conducted under this Agreement, including, for clarity, under the Development Plan. 

  

	1.105	 “Research Program Invention” shall mean any Invention discovered, generated, made or reduced
to practice in the performance of the Research Program by the Parties that are not improvements to the Ambrx Core Technology Platform. 

  

	1.106	 “Research Term” shall mean the period commencing on the Effective Date, and, unless this
Agreement is earlier terminated, ending on the later to occur of (a) the fourth (4th) anniversary of the Effective Date, or (b) the sixth (6th) anniversary of the Effective Date in case of Development of a Reload Compound; and (c) the
first Successful Dual IND Filing for a Licensed Product. 

  

	1.107	 “Review Period” shall have the meaning set forth in Section 11.1. 

 

	1.108	 “Right of Reference” means the “right of reference or use” defined in 21 C.F.R.
§ 314.3(b), or its equivalents outside the United States, and shall include the right to allow the applicable Regulatory Authority in a country to have access to relevant information (by cross-reference, incorporation by reference or otherwise)
contained in Regulatory Filings (and any data contained or referenced therein) filed with such Regulatory Authority. 

  

	1.109	 “Royalty Term” shall have the meaning set forth in Section 5.5. 

 

	1.110	 “Rules” shall have the meaning set forth in Section 10.8. 

 

	1.111	 “Safety Data” means any adverse event (as such term is used in the meaning set forth in Title
21 of the United States Code of Federal Regulations § 312.32 or its equivalents in the Sino Territory) information from human trials and all results from non-clinical safety studies, including toxicology
and safety pharmacology data, with respect to a Licensed Product required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under Applicable Laws, but excluding any information related to the
efficacy of the Licensed Product. 

  

	1.112	 “Scientific Development” means the activities to be undertaken by Ambrx under the Research
Program to generate the Pre-Clinical Candidates for the Licensed Compounds. 

  

	1.113	 “Selected Improvements” shall have the meaning set forth in Section 4.3.3.

  

	1.114	 “Sino” shall have the meaning set forth in the introductory paragraph. 

 

	1.115	 “Sino Indemnified Parties” shall have the meaning set forth in Section 9.2.

  
 13 

	1.116	 “Sino Investee” shall have the meaning set forth in Section 11.3. 

 

	1.117	 “Sino Paid-up Amount” shall have the meaning set forth
in Section 6.5. 

  

	1.118	 “Sino Research Program Invention” shall mean any Research Program Invention discovered,
generated, made or reduced to practice solely by Sino’s employees, independent contractors or consultants. 

  

	1.119	 “Sino Research Program IP” shall mean all Sino Research Program Patents and Sino
Research Program Know-How. 

  

	1.120	 “Sino Research Program Know-How” shall mean all Know-How that is related to or arises from a Sino Research Program Invention. 

  

	1.121	 “Sino Research Program Patents” shall mean any Patent Right that claims a Sino Research
Program Invention. 

  

	1.122	 “Sino Territory” shall mean all cities, zones, provinces, territories and other divisions or
regions in and throughout the People’s Republic of China, and for the purpose of this Agreement, shall include the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan. 

 

	1.123	 “Sublicense” shall have the meaning set forth in Section 2.7.1. 

 

	1.124	 “Sublicensee” shall have the meaning set forth in Section 2.7.1. 

 

	1.125	 “Sublicensor” shall have the meaning set forth in Section 2.7.1. 

 

	1.126	 “Successful Dual IND Filing” means an IND that is suitable for filing with and
complies with the Regulations of both the NMPA and the FDA and which within thirty (30) days after submission to the FDA is not placed on clinical hold due to any concerns regarding Pre-Clinical Data or
the sufficiency thereof. 

  

	1.127	 “Taxes” shall have the meaning set forth in Section 5.11. 

 

	1.128	 “Term” shall have the meaning set forth in Section 10.1. 

 

	1.129	 “Third Party” shall mean a Person or entity other than Ambrx, Sino or their Affiliates.

  

	1.130	 “Third Party Manufacturer” shall have the meaning set forth in Section 4.6.1.

  

	1.131	 “Valid Claim” shall mean: (a) a claim of an issued and unexpired patent within a Patent
Right that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
(ii) rendered unenforceable through disclaimer or otherwise, (iii) abandoned or (iv) permanently lost through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending
patent application within the Patent Rights that (i) has been 

  
 14 

	 	
asserted and continues to be prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling. 

 

	1.132	 “Withdrawal Notice” shall have the meaning set forth in Section 3.6.

 ARTICLE 2 

ASSIGNMENTS, LICENSE, DEVELOP, COMMERCIALIZATION 
  

	2.1	 ASSIGNMENTS OF PRODUCT SPECIFIC PATENT RIGHTS IN THE SINO TERRITORY. 

 

	2.1.1	 In consideration of and subject to payment of the upfront payment under Section 5.1, and subject to the
assignment provisions of Section 3.2, Ambrx hereby irrevocably undertakes to assign and transfer to Sino or its designated Affiliate, at no additional consideration, any existing and future Patent Rights Controlled by Ambrx (or its Affiliates)
in the Sino Territory that Cover solely the Licensed Compounds and/or the Licensed Products, including but not limited to any Patent Rights that claim the modifications, or method of use of any of the Licensed Compounds and/or the Licensed Products
in the Sino Territory and the right to claim priority in Patent Right applications in the Sino Territory, but in each case excluding Ambrx Background Technology and any Patent Rights Controlled by Ambrx that claim any product or composition of
matter other than a Licensed Compound and/or a Licensed Product (the “Product Specific Patent Rights”), to the full end of the term for which such Product Specific Patent Rights may be granted by the relevant government department
or administration in charge of patent registrations in the Sino Territory, to the effect that Sino or its designated Affiliate shall become the sole registered owner or applicant (as applicable) of the Product Specific Patent Rights in the Sino
Territory. A list of the existing Product Specific Patent Rights is set forth on Exhibit 2.1.1. 

  

	2.1.2	 Upon Sino’s presentation of proof of upfront payment under Section 5.1, Ambrx shall sign an
assignment agreement and/or all other necessary documents required for assignment of Patent Rights applications or change of applicant of the existing Product Specific Patent Rights in the Sino Territory to Sino or it designated Affiliate.

  

	2.1.3	 With respect to the Product Specific Patent Rights that are pending or issued in the Sino Territory, Ambrx
shall assign the Product Specific Patent Rights pending or issued in the Sino Territory to Sino or its designated Affiliate within 60 days from the Effective Date to the extent assignable under Applicable Law, and as promptly as possible thereafter
if not permitted to be assigned by Applicable Law within such 60 days. 

  

	2.1.4	 With respect to the Patent Rights that are pending (including Patent Cooperation Treaty patent applications and
provisional patent applications) or provisional that are eligible to claim priority to Product Specific Patent Rights in the Sino Territory (“Pending Product Specific Patent Rights”), Ambrx shall, within twenty (20) days after
receipt of the registration or application numbers of such Pending Product Specific Patent Rights, notify Sino in writing of such pending or provisional Pending Product Specific Patent Rights. Upon Sino’s written request, Ambrx shall execute
all documents and instruments, provide copy of all documents relating to the Pending Product Specific Patent Rights and shall do 

  
 15 

	 	
all lawful acts, as may be reasonably necessary for assignment of Patent Right applications or change of applicant of the Pending Product Specific Patent Rights in the Sino Territory to Sino, so
as to enable Sino or its designated Affiliate to make Patent Right applications or priority claims of such Pending Product Specific Patent Rights in the Sino Territory. 

 

	2.2	 GRANT OF EXCLUSIVE LICENSES TO USE THE LICENSED INTELLECTUAL PROPERTY RIGHTS. 

 

	2.2.1	 In consideration of and subject to the terms and conditions of this Agreement (including payment of the upfront
payment under Section 4.1 5.1), Ambrx hereby grants to Sino exclusive right and license, with the right to grant Sublicenses subject to Section 2.7, under all existing and future the Licensed Intellectual Property Rights to Develop, make,
have made and manufacture solely the Licensed Compounds and Licensed Products solely for use in the Field in the Sino Territory during the Term of this Agreement, provided that (a) for the Licensed Intellectual Property Rights self-owned by
Ambrx, such grant shall be for a perpetual right with royalties payable in accordance with Article 5; (b) for Licensed Intellectual Property Rights constituted under the Existing Third Party Licenses, [***] (i) to the full end of the term
or extension or renewed term under the relevant Existing Third Party Licenses; and (ii) in the event of a new agreement with the same Third Party licensor the subject matter of which include license for Patent Rights covered under the Existing
Third Party Licenses, for the term or any extension or renewed term under such new agreement; and (c) for Licensed Intellectual Property Rights constituted under the Ambrx Third Party Licenses and the Future Third Party Licenses, such grant
shall be (i) to the full end of the term or any extension or renewal under such agreements; and (ii) in the event of a new agreement with the same Third Party licensor the subject matter of which include license for Patent Rights covered
under the Ambrx Third Party Licenses or the Future Third Party Licenses, for the term or extension or renewed term under the new agreement, in each case with royalty fees only payable upon First Commercial Sale of any Licensed Products and subject
to royalty set-off in accordance with Section 5.6 (Third Party Royalty Set-off), in each case for so long as Ambrx Controls such Patent Rights. A list of the
Licensed Intellectual Property Rights in existence as of the Effective Date is set forth in Exhibit 2.2.1 (Licensed Intellectual Property Rights self-owned by Ambrx) and Exhibit 2.4.2 (Existing Third Party Licenses). 

 

	2.2.2	 Subject to the terms and conditions of this Agreement and as partial consideration for the rights granted by
Ambrx under the License, Sino hereby grants to Ambrx an exclusive, perpetual, sub-licensable, royalty-free right and license in the Ambrx Territory, under Sino Research Program IP and the Product Specific
Patent Rights, to make, use, sell, offer for sale, import and export products in the Ambrx Territory during the Term of this Agreement. 

  

	2.2.3	 Ambrx agrees that during the Term of this Agreement, it will not grant any exclusive right and license under
the Licensed Intellectual Property Rights to any Third Party to Develop, have Developed, use, manufacture, have manufactured, sell, offer for sale and have sold any product containing any Licensed Products for use in the Field and in the Sino
Territory. 

  

	2.3	 AMBRX RETAINED RIGHTS. The License granted by Ambrx to Sino under Section 2.2.1 is exclusive for use in
the Field in the Sino Territory. Nothing in this 

  
 16 

	 	
Agreement shall preclude Ambrx from granting license to use the Ambrx Background Technology and Ambrx Core Technology Platform for use not falling within scope of the Field in the Sino Territory.

  

	2.4	 THIRD PARTY LICENSE. 

 

	2.4.1	 In the event that, during the Term of this Agreement and after the Effective Date, Ambrx (as licensee) enters
into agreement(s) with any Third Party (as licensor) in respect of Licenses for rights in the Field to any Valid Claim of any issued Patent Right or Patent Right application issued to such Third Party that may be necessary for Sino’s exercise
of its rights pursuant to Section 2.2 herein in the Sino Territory (an “Ambrx Third Party License”), for future Third Parties, Ambrx shall secure the right (a) to grant the Sublicense under this Section in any Ambrx Third
Party License, (b) for licenses to Patent Rights that, but for such license, would be infringed by the making, using, selling, offering for sale or importation of a Licensed Product at the time and in the country in the Sino Territory in which
such activity occurs (“Future Third Party License”). If Sino is required to pay certain royalty payments to such a Third Party under any such Ambrx Third Party License or Future Third Party License, either directly to the Third
Party or indirectly to such Third Party through Ambrx, [***]. 

  

	2.4.2	 A list of Ambrx’s existing Third Party licenses (“Existing Third Party License”) that are
exclusive (“Exclusive Existing Third Party Licenses”) and non-exclusive (“Non-Exclusive Existing Third Party Licenses”) in each case that are essential for Development
of each of the Licensed Compounds in the Territory is set forth in Exhibit 2.4.2. 

  

	2.5	 NO ASSERTION BY AMBRX. So long as Sino is in compliance with the terms and conditions of this Agreement, Ambrx
shall not assert against any claims for infringement of any Licensed Intellectual Property Rights by Sino’s permitted exercise of its rights hereunder solely for the purpose of Developing, making, having made, using, selling, offering for sale
or having sold any Licensed Product in the Field in the Sino Territory during the Term of this Agreement. 

  

	2.6	 RIGHTS OF REFERENCE; CLINICAL DATA RIGHTS. 

 

	2.6.1	 Subject to the terms of this Agreement, Ambrx hereby grants Sino, its Affiliates and Sublicensees (solely to
the extent permitted to make or own any Regulatory Filings or Regulatory Approvals) access to, and a Right of Reference with respect to (a) Regulatory Filings, Regulatory Approvals and all corresponding documentation, and (b) all
Regulatory Data (including Safety Data and CMC Data contained or referenced in any Regulatory Filings), and all corresponding documentation, in each case ((a) and (b)) (i) to the extent Controlled by Ambrx or its Affiliates at any time during the
Term, (ii) associated with the Pre-Clinical Development and/or the Phase I Clinical Trial conducted hereunder for a Licensed Product in the Field and (iii) for the sole purpose of Sino
exercising its rights under the License in the Sino Territory during the Term. Upon written request from Sino, Ambrx shall provide to Sino or its Affiliates or Sublicensees (if permitted) a
cross-

  
 17 

	 	
reference letter or similar communication to the applicable Regulatory Authority to effectuate such Right of Reference. 

 

	2.6.2	 Subject to the terms of this Agreement and effective on the Effective Date, Sino hereby grants Ambrx, its
Affiliates and their Sublicensees access to, and a Right of Reference with respect to: (a) Sino’s and its Affiliates’ and their Sublicensees’ Regulatory Filings and Regulatory Approvals and all corresponding documentation
Controlled by Sino or its Affiliates or their Sublicensees at any time during the Term; and (b) all Regulatory Data (including Safety Data and CMC Data contained or referenced in any Regulatory Filings), and all corresponding documentation, in
each case ((a) and (b)) (i) to the extent Controlled by Sino or its Affiliates at any time during the Term, (ii) associated with Pre-Clinical Development and/or the Phase I Clinical Trial
conducted hereunder for a Licensed Product, and (iii) for the sole purpose of researching, Developing, making, having made, manufacturing, seeking and securing Regulatory Approval for and importing, exporting, selling and commercializing the
Licensed Products in the Ambrx Territory. Upon written request from Ambrx, Sino shall provide to Ambrx, its Affiliates and Sublicensees (as applicable) a cross-reference letter or similar communication to the applicable Regulatory Authority to
effectuate such Right of Reference. Notwithstanding anything in this Agreement to the contrary, the foregoing right of access and Right of Reference in this Section 2.6.2 shall survive any expiration or early termination of this Agreement for
any reason. 

  

	2.7	 SUBLICENSES. 

  

	2.7.1	 Any Sublicense by either Party as sublicensor (the “Sublicensor”) of the rights granted to
such Party under this Agreement to a Third Party or an Affiliate as sublicensee (“Sublicensee”) shall (a) require prior written approval from the party granting the originating license (“Originating Licensor”),
such approval not to be unreasonably conditioned, withheld or delayed, (b) be consistent with the terms of this Agreement, and (c) shall include an obligation for the Sublicensee to comply with the applicable obligations of the
sublicensing Party set forth in this Agreement. The Sublicensor shall be responsible and liable for the conduct and activities of each Sublicensee as if performed by the Sublicensor hereunder. The Sublicensor shall not grant any Sublicense hereunder
that would impose obligations on the Sublicensee greater than those obligations of the Originating Licensor. The Sublicensor shall provide to the Originating Licensor a copy of each sublicense hereunder (“Sublicense”) promptly after
entering into such Sublicense, which shall permit verification by the Originating Licensor of compliance with the provisions of this Agreement. 

  

	2.8	 NO OTHER GRANT OF RIGHTS. Except as expressly provided herein, nothing in this Agreement will be construed to
confer any ownership interest, license or other rights upon Sino by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of Ambrx, or any other entity, regardless of whether such
technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Ambrx Background Technology or Licensed Intellectual Property Rights. 

  
 18 

 ARTICLE 3 

JOINT STEERING COMMITTEE 
  

	3.1	 MEMBERS. The Parties shall establish a Joint Steering Committee (the “Joint Steering
Committee”), which shall comprise six (6) members, three (3) designated by Sino and three (3) by Ambrx (or such other number as the Parties may agree in writing). The initial members of the Joint Steering Committee are set
forth on Exhibit 3.1. Any member of the Joint Steering Committee may be represented at any meeting by a designee who is appointed by the Party designating such member for such meeting and who has authority to act on behalf of such member, as
evidenced by written notice from the Party designating such member to the chairperson of the Joint Steering Committee. The chairperson of the Joint Steering Committee shall be designated by Ambrx. The initial chairperson is designated on Exhibit
3.1. Each Party shall be free to replace its representative members with new appointees who have authority to act on behalf of such Party on the Joint Steering Committee, on prior written notice to the other Party. 

 

	3.2	 RESPONSIBILITIES. The Joint Steering Committee shall be responsible for providing oversight and coordinating
the Scientific Development, Pre-Clinical Development, clinical Development and cGMP activities related to the Research Program and Development Plan, including: (a) maximizing the global opportunity and
profitability of the Licensed Product while aligning the strategic, logistical and financial considerations of each Party; (b) reviewing and discussing the implementation of the Development Plan; (c) reviewing, discussing and approving
amendments and updates to the Development Plan; (d) directing Development activities for the Licensed Product in accordance with the Development Plan; (e) aligning cGMP manufacturing activities and investments to provide the Licensed
Compounds and Licensed Products for Clinical Trials and commercial supply in accordance with the Development Plan; and (f) selecting [***] and [***]. If the Parties mutually agreed to cease Development of a PCC after the relevant IND-enabling activities (including manufacture of such PCC for use in such IND-enabling activities) have been completed under the applicable Development Plan, then the Parties
shall replace such PCC, no more than [***] during the Term, each time with a molecule that is Controlled by Ambrx upon mutual agreement, (“Reload Compound”) for Development under this Agreement, including with respect to a
Successful Dual IND Filing for such Reload Compound, for no additional consideration under Section 5.1 (Upfront Payment). For clarity, (a) such replacement may only occur up to [***] during the Term, which may be (i) [***]; or
(ii) [***]; and (b) any modifications, reworkings, improvements or upgrades of the Initial Compound for which the Parties mutually agreed to cease Development after the relevant IND-enabling
activities can be considered as a Reload Compound. After completion of the due diligence of the Patent Rights that Cover such Reload Compound (“Reload Patent Rights”) to the satisfaction of Sino, Sino shall reassign the Product
Specific Patents Rights for the replaced Licensed Compound to Ambrx, and concurrently Ambrx shall assign Reload Patent Rights to Sino. 

  

	3.3	 MEETINGS. The Joint Steering Committee shall meet as frequently as the Parties deem appropriate during the
first four (4)-year period following the Effective Date but no less frequently than once a Calendar Quarter (or more frequently, as agreed upon by the Parties) 

  
 19 

	 	
thereafter, on such dates and at such times as the Parties shall agree, on ten (10) days’ written notice to the other Party unless such notice is waived by the other Party. The Joint
Steering Committee may convene or be polled or consulted from time to time by means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate by the Parties. To the extent that meetings are held in person, they
shall alternate between the offices of the Parties unless the Parties otherwise agree. The chairperson shall be responsible for sending notices of meetings to all members. 

 

	3.4	 DECISIONS. 

  

	3.4.1	 A quorum for a meeting of the Joint Steering Committee shall require the presence of at least two
(2) Ambrx members (or designees) and at least two (2) Sino members (or designees) in person or by telephone. All decisions made or actions taken by the Joint Steering Committee shall be made by consensus by its members, with the Ambrx
members present at a meeting cumulatively having one (1) vote and the Sino members present at a meeting cumulatively having one (1) vote. 

  

	3.4.2	 In the event that a consensus cannot be reached by the Joint Steering Committee with respect to a matter that
is a subject of its decision-making authority within thirty (30) days after the matter is first brought before the Joint Steering Committee, then the matter shall be decided unanimously by the CEO of Ambrx and the CEO of Sino or by their
designated representative. If the CEO of Ambrx and the CEO of Sino or their designated representative cannot reach a unanimous decision, then the chairperson of the Joint Steering Committee shall have the final decision-making authority; provided
that (a) [***]; and (b) [***]. Notwithstanding the foregoing, in no event shall final decision-making authority be used (i) to require the other Party to violate any Applicable Law or any agreement it may have with any Third Party, (ii) to
amend the terms and conditions of the Agreement, or (iii) to require the other Party to conduct any activities outside the scope of the Development Plan. 

 

	3.5	 MINUTES. Within fifteen (15) days after each Joint Steering Committee meeting, the chairperson of the
Joint Steering Committee shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint
Steering Committee at such meeting. The chairperson of the Joint Steering Committee shall be responsible for circulation of all draft and final minutes. Draft minutes shall be circulated to all members of the Joint Steering Committee sufficiently in
advance of the next meeting to allow review and comment prior to the meeting. Minutes shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee.

  

	3.6	 WITHDRAWAL. At any time during the Term and for any reason, either Party shall have the right to withdraw from
participation in the Joint Steering Committee upon written notice to the other Party (a “Withdrawal Notice”), which shall be effective immediately upon receipt. Following the issuance of a Withdrawal Notice and subject to this
Section 3.6, the withdrawing Party’s representatives on the Joint Steering Committee shall not participate in any meetings of the Joint Steering Committee. If, at any time, following

  
 20 

	 	
the issuance of a Withdrawal Notice, the withdrawing Party wishes to resume participation in the Joint Steering Committee, the withdrawing Party shall notify the other Party in writing and,
thereafter, the withdrawing Party’s representatives on the Joint Steering Committee shall be entitled to attend any subsequent meeting of, and to participate in the activities of, the Joint Steering Committee as if a Withdrawal Notice had not
been issued by the withdrawing Party. Following the withdrawing Party’s issuance of a Withdrawal Notice, unless and until the withdrawing Party resumes participation in the Joint Steering Committee in accordance with this Section 3.6:
(i) all meetings of the Joint Steering Committee shall be held at the other Party’s facilities; and (ii) all decisions of the Joint Steering Committee shall be made by the remaining Party; (iii) the withdrawing Party shall have
the right to continue to receive the minutes of the meetings of the Joint Steering Committee, but shall not have the right to approve the minutes for any such meeting held after the withdrawing Party’s issuance of the Withdrawal Notice. In any
event, withdrawal from the Joint Steering Committee shall not impair Sino and Ambrx’s rights to receive reports or disclosures under Section 3.5. 

  

	3.7	 TERM. The Joint Steering Committee shall exist until completion of Phase I Clinical Trial for a Licensed
Product. Afterwards, each Party shall nominate an alliance manager to communicate and mutually coordinate activities. 

ARTICLE 4 
 DEVELOPMENT,
REGULATORY, MANUFACTURING AND COMMERCIALIZATION 
  

	4.1	 DEVELOPMENT OVERVIEW. The Parties shall collaborate in the Development of Licensed Products under this
Agreement in order to achieve a Successful Dual IND Filing for each of the [***], [***], and Reload Compound (if any), and thereafter, up until the completion of the Phase I Clinical Trial in the Field set forth in and in accordance with the
Development Plan and Section 4.3 below. In the course of performance of its obligations under this Agreement, each Party shall co-operate and provide assistance to the other Party to achieve the common
intent of successful Commercialization of the Licensed Products for sale in the respective territories of the Parties. Thereafter, the Parties may continue the Research Program or conduct Development activities in their respective territories
separately in accordance with Section 4.4 below. 

  

	4.2	 DEVELOPMENT RESPONSIBILITIES AND DEVELOPMENT PLAN. 

 

	4.2.1	 As of the Effective Date, the Parties have agreed to undertake Scientific Development, Pre-Clinical Development and clinical Development under the Development Plan up until the completion of the Phase I Clinical Trials in the Field described therein in a collaborative manner, including with respect to
(i) the indication(s) to be Developed; (ii) the proposed Development activities and allocation thereof between the Parties, (iii) the timeline for initiation and completion of activities, including target milestones,
(iv) manufacturing process development, (v) clinical supply arrangements, and (vi) the Phase I Clinical Trial activities. Either Party may propose to the Joint Steering Committee and the other Party revisions to the Development
Plan, with supporting evidence, such as technical, clinical or regulatory reasons that underline the proposed revisions. The Joint Steering Committee 

  
 21 

	 	
shall approve the Development Plan within sixty (60) days after the Effective Date, and may amend the Development Plan from time to time after the Effective Date, pursuant to the
decision-making mechanism as set forth in Section 3.4.2. The Parties shall use Commercially Reasonable Efforts to achieve the Successful Dual IND Filing. 

  

	4.2.2	 Subject to further allocation of responsibilities under the Development Plan in Section 4.2.1 above, the
Parties have agreed that Ambrx shall be responsible for Scientific Development of the Licensed Compounds and shall use Commercially Reasonable Efforts to provide PCCs of the Licensed Compounds that meet the requirements set forth in
Exhibit 4.2.2 (“Initial PCC Requirements”), provided that, the Reload Compounds (if any) shall meet the additional and further success criteria set by the unanimous decision of the Joint Steering Committee without invoking
casting vote by its chairperson under Section 3.4.2. 

  

	4.2.3	 Except as expressly stated elsewhere in this Agreement (including Section 4.3.1), each Party shall bear
the internal costs incurred by such Party in undertaking its activities under this Agreement, including under the Development Plan and with respect to the creation and submission of any Regulatory Filings for use by such Party. For clarity, Ambrx
shall bear all the costs incurred by Ambrx for the Scientific Development of the PCCs of the Licensed Compounds and Sino shall bear all the costs for preparing the regulatory docket for dual IND filing of the Licensed Compounds in the PRC and the
United States, as well as the costs for Pre-Clinical Development of the Initial Compounds, or as otherwise agreed to by the Parties.

 

	4.2.4	 The Parties anticipate that the Pre-Clinical Development for Licensed
Compounds will be undertaken in stages by a contract research organization selected by Sino, which shall be suitably qualified and experienced in handling dual IND filing in the PRC and the United States. If, during such Pre-Clinical Development for a Licensed Compound, such Licensed Compound generates negative safety or efficacy signals or fails to meet the Initial PCC Requirements, a Reload Compound may be selected as a
replacement in accordance with Section 3.2, and such Reload Compound may undergo Pre-Clinical Development with Ambrx and Sino sharing the costs equally until the end of
Pre-Clinical Development. 

  

	4.3	 RESEARCH PROGRAMS UNDER THE DEVELOPMENT PLAN; FUNDING. 

 

	4.3.1	 Up until completion of the Phase I Clinical Trial for the Licensed Product described in the Development Plan,
the Parties shall collaborate in the Development of the Licensed Product in accordance with the Development Plan, including budgets (if any) and timelines set forth in the Development Plan. Each Party shall use Commercially Reasonable Efforts to
carry out the activities assigned to it under the Development Plan. 

  

	4.3.2	 AMBRX CELL MATERIALS. Ambrx shall provide the Ambrx Cell Materials to Sino in accordance with the Development
Plan. Sino shall use the Ambrx Cell Materials solely to further develop a manufacturing process for the Licensed Compounds and Licensed Products (including for cGMP scale-up) in accordance with the Development
Plan. Sino shall not reverse engineer, chemically analyze, disassemble, or modify the Ambrx Cell Materials. Sino shall only have the right to provide the Ambrx Cell Materials to Third

  
 22 

	 	
Party contract manufacturers that are manufacturing the Licensed Products in connection with Sino exercising its rights under the License or to fulfill Sino’s supply obligations to Ambrx
under this Agreement. Other than such Third Party contract manufacturers, Sino shall not provide the Ambrx Cell Materials to any Third Party without Ambrx’s prior written consent. 

 

	4.3.3	 OPT OUT AND OPT IN SELECTED IMPROVEMENTS. Subject to the Licensed Intellectual Property Rights granted to Sino
under Section 2.1.2 2.2.1, for any future improvements in (i) the Licensed Intellectual Property Rights; (ii) the Patent Rights constituted under Ambrx Third Party License; (iii) the Patent Rights constituted under Future Third
Party Licenses; and (iv) the Ambrx Cell Material cell lines used by Ambrx to Manufacture Licensed Products for use in Clinical Trials or Commercialization by Ambrx, ((i), (ii), (iii) and (iv) collectively referred to as “Future
Improvements”), Ambrx shall notify Sino in writing of such Future Improvements and Sino shall have an option, exercisable in its sole discretion from time to time during the Term, to opt out of or into such Future Improvements for
Development of any of the Licensed Compounds or the Licensed Products during the Term in the Sino Territory. For clarity, (i) Future Improvements for which Sino has exercised its option to opt out shall not be included in Licensed Intellectual
Property Rights; (ii) Future Improvements for which Sino has exercised its option to opt-in (“Selected Improvements”) shall be included in the Licensed Intellectual Property Rights
in accordance with Section 2.2.1, effective as from the date of the Sino opt-in notice. Ambrx shall provide personnel and assistance to support Sino’s implementation of the Selected Improvements, and
Sino shall only be liable to pay the full time equivalent cost of such support to Ambrx, calculated based on the number of days spent on the support and by reference to the basic salary of such supporting personnel without regard to other benefits.
Except for the full time equivalent costs of the Ambrx personnel support and subject to royalties that may be payable under Section 5.3 and offsettable under Section 5.6, Sino shall not be liable to pay any additional fees and costs to
Ambrx or to any Third Party for the Selected Improvements. 

  

	4.4	 OUTSIDE THE DEVELOPMENT PLAN. Other than rights and obligations set forth in the Development Plan, Sino shall
be solely responsible for conducting and paying for all Development and Commercialization of the Licensed Products in or for the Sino Territory, and Ambrx shall be solely responsible for conducting and paying for the Development and
Commercialization of the Licensed Products outside the Sino Territory. Subject to Section 3.4.2, Sino shall have decision-making authority for (and an obligation to fund) additional activities not included in the Development Plan that Sino
deems necessary or desirable for the Sino Territory; provided that such additional activities would not be reasonably likely to affect the Development or Commercialization of the Licensed Product outside the Sino Territory or outside the Field.

  

	4.5	 REGULATORY. Sino shall file and own all INDs and other Regulatory Filings required in connection with
Sino’s Development of the Licensed Compounds and Licensed Products in the Sino Territory. Ambrx shall have the right to conduct Development and file and own INDs and other Regulatory Filings for the Development of the Licensed Compounds and

  
 23 

	 	
Licensed Products and to make its own filings with Regulatory Authorities outside the Sino Territory with respect thereto. 

 

	4.5.1	 SAFETY DATA EXCHANGE. No later than initiation by Sino of a Clinical Trial in the Sino Territory, Sino shall
enter into a Safety Data exchange agreement with Ambrx and/or its other licensee regarding the Licensed Product, which shall set forth standard operating procedures governing the collection, investigation, reporting and exchange of information
concerning adverse drug reactions/experiences sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes. Such Safety Data exchange agreement shall identify which Party shall be
responsible for the timely reporting of all relevant adverse drug reactions/experiences, product quality, product complaints and Safety Data relating to the Licensed Product to the appropriate Regulatory Authorities in and outside the Sino Territory
in accordance with all Applicable Law. Such agreement shall allow each Party to comply with all regulatory and legal requirements regarding the management of Safety Data by providing for the exchange of relevant information in the appropriate format
within applicable timeframes. Unless otherwise mutually agreed by the Parties, Ambrx or its other licensee shall maintain a global safety database for the Licensed Product, and Sino shall maintain one or more safety database(s) for the Licensed
Product in the Field and the Sino Territory. 

  

	4.6	 MANUFACTURING. 

  

	4.6.1	 With respect to each Licensed Compound, prior to the initiation of Phase I Clinical Trial to be conducted under
the Development Plan, Ambrx shall provide Pre-Clinical Candidate for each such Licensed Compound, having completed the Scientific Development of the PCC as agreed by the unanimous decision of the Joint
Steering Committee without invoking casting vote of its chairperson under Section 3.4.2. Sino shall be responsible for and shall perform all cGMP manufacturing activities and Pre-Clinical Development
(including cGMP scale-up) related to manufacturing the Licensed Compounds and Licensed Products in a manner in order to achieve a Successful Dual IND Filing, and the Parties shall co-operate and provide assistance to each other in support of seeking Successful Dual IND Filing. Sino (by itself or through its Affiliate or a Third Party contract manufacturer appointed by Sino)
(“Third Party Manufacturer”) shall manufacture all Licensed Compounds and Licensed Products in accordance with cGMP applicable to the United States and the equivalent standard or Current Good Manufacturing Practice in the PRC
in order to support a Successful Dual IND Filing. Sino’s Affiliate or the Third Party Manufacturer shall perform the technology transfer of the manufacturing process for each of the Licensed Products in accordance with the Development Plan
[***], provided that any activities in addition to the activities described in the Development Plan would be [***]. Ambrx shall provide technical support (including upon mutual agreement on-site assistance)
relating to the Ambrx Cell Materials, and Licensed Compounds with respect to manufacturing Licensed Compound and Licensed Products to Sino or its Affiliate or the Third Party Manufacturer [***]. 

 

	4.6.2	 Upon request by Sino during the Research Term and for the period prior to the First Commercial Sale of a
Licensed Product, for purposes of establishing manufacturing capability for each Licensed Compound and/or Licensed Product, Ambrx shall enable a 

  
 24 

	 	
technology transfer to Sino or its Affiliate or the Third Party Manufacturer the manufacturing process required to manufacture the Licensed Compounds and/or the Licensed Products in the Sino
Territory. Such enablement shall include a written description of the technology, together a copy of all relevant documents (including, without limitation, production manuals and experiment protocols), as well as
on-site technical assistance at the facility designated by Sino, provided that [***]. 

  

	4.6.3	 Sino shall be responsible for manufacturing the Licensed Compound and Licensed Products for the Phase I
Clinical Trials conducted by Sino under this Agreement in support of Regulatory Approval in the Sino Territory through a Third Party Manufacturer. The Third Party Manufacturer costs, all fees and costs arising from engagement of the Third Party
Manufacturer or manufacturing activities in the Sino Territory shall be borne by the Parties in accordance with Sections 4.2.3 and 4.2.4. Sino shall provide Ambrx with sufficient clinical supply to [***]. For the purpose of advancing
Development and Commercialization of the Licensed Compounds and/or the Licensed Products in their respective territories, Sino and Ambrx agree to share all Regulatory Data and Regulatory Filings within sixty (60) days after the relevant
submission to or obtaining of the grant of Regulatory Approval from the Regulatory Authority in their respective territories. Upon expiry of the Research Term, the Parties shall negotiate in good faith terms for a supply agreement under which Sino
would fulfill Ambrx’s clinical and commercial needs for each Licensed Product and further Clinical Trials. 

  

	4.7	 COMMERCIALIZATION. 

  

	4.7.1	 Sino (itself and through its Affiliates and Sublicensees, as applicable) shall be solely responsible, at its
own expense, for marketing, selling, offering for sale, distributing, promoting and otherwise commercializing the Licensed Product in the Field in the Sino Territory. 

 

	4.7.2	 Sino shall use Commercially Reasonable Efforts to obtain Regulatory Approval for and Commercialize each
Licensed Compound and Licensed Product in each country in the Sino Territory. 

  

	4.8	 COMPLIANCE WITH APPLICABLE LAWS. Sino shall conduct, and shall cause its Affiliates and Sublicensees to
conduct, all Development, regulatory, manufacturing and Commercialization activities with respect to Licensed Compounds and Licensed Products in the Field in the Sino Territory in compliance with all Applicable Laws, including good scientific and
clinical practices under the Applicable Laws of the country in which such activities are conducted. 

  

	4.9	 EXCLUSIVITY. Subject to the terms and conditions of this Agreement, during the Term (a) Ambrx and its
Affiliates shall not in the Sino Territory, and (b) Sino itself, any Sino Affiliate or the Sino Investee, each that has been assigned any rights or obligations under this Agreement, and each anywhere in the world shall not, in each case
(a) and (b) research, Develop, manufacture or Commercialize, directly or indirectly, by itself or with a Third Party, any of the following: (i) [***]; (ii) any project related to a Bispecific Molecule that [***]; (iii) [***]; and
(iv) a biological molecule that is [***]. For the avoidance of doubt, 

  
 25 

	 	
the above restrictions on the Sino Affiliate and/or the Sino Investee shall only cover the period during which the rights and obligations under this Agreement are effectively assigned and assumed
by the relevant Sino Affiliate and/or the Sino Investee. In the event that there is any re-assignment of rights and obligations from the relevant Sino Affiliate and/or Sino Investee (in each case as an
assignor) to a new permitted assignee designated by Sino, the above restrictions shall no longer apply to the assigning Sino Affiliate and/or the Sino Investee as from the date on which such re-assignment of
the rights or obligations are made effective. For clarity, the foregoing does not restrict either Party from researching, Developing, manufacturing or Commercializing any of the following: (1) [***], (2) [***], (3) [***],
(4) [***], (5) [***], and (6) [***]. 

 ARTICLE 5 

MONETARY OBLIGATIONS, REPORTS AND AUDITS 
  

	5.1	 UPFRONT PAYMENT. Sino shall pay to Ambrx, within [***] ([***]) business days of the Effective Date, a one-time payment in cash of Ten Million Dollars ($10,000,000 USD), which payment shall be non-refundable (other than as set forth in Section 6.5 and Section 10.3A)
and non-creditable and not subject to set off. 

  

	5.2	 MILESTONE PAYMENTS. As set forth in the following table, Sino shall make the following payments in cash (the
“Milestone Payments”) to Ambrx upon achievement of each of the milestone events set forth in the tables below (the “Milestone Events”) for any Licensed Products by Sino or its Affiliates or Sublicensees. Each
Milestone Payment shall be payable by Sino to Ambrx within thirty (30) days after the achievement of the corresponding Milestone Event and receipt of invoice from Ambrx with respect to each of the Licensed Products. Such payments shall be non-refundable and non-creditable and not subject to set-off (other than as set forth in Section 6.5). 

The following Milestone Payments shall apply for each Licensed Product: 

 

			
	 Milestone Event
	  	Milestone Payment
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  

	5.3	 ROYALTIES PAYABLE BY SINO. Subject to the terms and conditions of this Agreement, Sino shall pay Ambrx
royalties in an amount equal to the following percentage of Net Sales of each Licensed Product sold by Sino, its Affiliates or Sublicensees: 

  

	5.3.1	 [***] ([***]) of such Net Sales of each Licensed Product in the Sino Territory in each Calendar Year up to and
including Net Sales of [***] ([***]); 

  
 26 

	5.3.2	 [***] ([***]) of such Net Sales of each Licensed Product in the Sino Territory in each Calendar Year for the
portion of such Net Sales exceeding [***] ([***]) up to and including [***] ([***]); and 

  

	5.3.3	 [***] ([***]) of such Net Sales of each Licensed Product in the Sino Territory in each Calendar Year for the
portion of such Net Sales exceeding [***] ([***]). 

  

	5.4	 KNOW-HOW ROYALTY. Notwithstanding the provisions of Section 5.3
above, in the event that (a) the manufacture, use or sale of Licensed Products by Sino or its Affiliates in a country in the Sino Territory is not Covered by a Valid Claim of the Patent Right within the Licensed Intellectual Property Rights or
Sino Research Program Patents or Ambrx Research Program Patents in such country, or (b) Generic Competition occurs in a country in the Sino Territory, then the royalty payments due to Ambrx [***]. For clarity, upon the first occurrence of
(a) or (b) above, the royalty payments due to Ambrx shall be [***]. 

  

	5.5	 ROYALTY TERM. Royalties on the Licensed Product at the rates set forth above in Section 5.3 shall be
calculated, reported and paid by Sino on a quarterly basis during the period commencing with the First Commercial Sale of such Licensed Product in a country in the Sino Territory and continue until the expiration of [***] ([***]) years after such
First Commercial Sale of the Licensed Product in such country (the “Royalty Term”). 

  

	5.6	 THIRD PARTY ROYALTY SET-OFF. If Sino, under an agreement with a Third
Party for licenses to Patent Rights that, but for such license, would be infringed by the making, using, selling, offering for sale or importation of a Licensed Product at the time and in the country in which such activity occurs, is required to pay
any royalty that is as a result of Sino’s exercise of its rights under such Third Party license, Sino may offset [***] ([***]) of any royalty payments actually paid by Sino to all such Third Parties due under such licenses in the aggregate with
respect to sales of Licensed Products against the royalty payments that are due to Ambrx; provided that in no event shall the royalty payments to Ambrx with respect to such Licensed Products be [***] ([***]) of the amount otherwise due (“Set-Off Limit”). 

  

	5.7	 THIRD PARTY PAYMENTS. Subject to the terms of this Agreement and Sections 4.2.3 and 4.2.4, each Party shall be
responsible for and at its sole expense shall pay all amounts owing by such Party to any Third Party for Development activities under the Development Plan performed by Third Parties. 

 

	5.8	 REPORTS. During the Term following the First Commercial Sale of the Licensed Product, Sino shall furnish to
Ambrx a quarterly written report for the Calendar Quarter showing the gross and Net Sales of all Licensed Products subject to royalty payments sold by Sino and its Affiliates in the Sino Territory during the reporting period and the royalties
payable under this Agreement. Reports shall be due on the forty-fifth (45th) day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due.
Sino and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. 

  
 27 

	5.9	 AUDITS. 

  

	5.9.1	 ACCOUNTING FIRM. Upon the written request of Ambrx and not more than once in each Calendar Year, Sino shall
permit a qualified and reputable independent certified public accounting firm selected by Ambrx and approved by Sino, such approval not to be unreasonably withheld, at Ambrx’s expense, to have access during normal business hours to such of the
records of Sino’s designated Affiliate that is Developing and/or Commercializing Licensed Products that are related to the production and sales of Licensed Products as may be reasonably necessary to verify the accuracy of the royalty reports
pursuant to Section 5.8 for any Calendar Year ending not more than thirty-six (36) months prior to the date of such request. The accounting firm shall disclose to Ambrx and Sino whether the royalty
reports are correct or incorrect and the amount of any discrepancy. 

  

	5.9.2	 ACCESS. In order to fulfill the auditing, the accounting firm so selected shall have the right to access,
examine, review and copy, the books or accounts of any Affiliate designated by Sino for sales of the Licensed Products, such access shall be restricted to the extent relevant to determine the accuracy of the royalty reports, and shall include the
relevant procurement/distribution agreements and other purchase/sales contracts, purchase/sales orders, operation records, tax paid to local government, and itemized tax for the Licensed Products, and to make enquiries with respect to such Sino
Affiliate, to the extent reasonably necessary for determining the accuracy of the royalty reports. The relevant Sino Affiliate shall not unreasonably restrict the accounting firm’s access to its premises during normal business hours.

  

	5.9.3	 PAYMENT AND FEES. If such accounting firm identifies a discrepancy made during such period, the appropriate
Party shall pay the other Party the amount of the discrepancy within thirty (30) days of the date Ambrx delivers to Sino such accounting firm’s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by
such accounting firm shall be paid by Ambrx, provided, however, that if such audit uncovers an underpayment of royalties by Sino that exceeds [***] ([***]) of the total royalties owed for the period in question, the fees of such accounting firm
shall be equally shared by Ambrx and Sino. 

  

	5.9.4	 SUBLICENSES. Sino shall include in each Sublicense granted by it pursuant to this Agreement a provision
requiring the Sublicensee to make reports to Sino, to keep and maintain records of sales made pursuant to such Sublicense and to grant access to such records by Ambrx’s independent accountant to the same extent required of Sino under this
Agreement. 

  

	5.9.5	 CONFIDENTIALITY. Ambrx shall treat all financial information subject to review under this Section 5.9.5 or
under any Sublicense agreement in accordance with the terms of Article 7 of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Ambrx, or with Sino and/or its Affiliates or Sublicensee,
obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 

  
 28 

	5.10	 PAYMENT EXCHANGE RATE; LATE PAYMENTS. All royalty payments due hereunder shall be paid in United States dollars
by wire transfer to a bank account designated by Ambrx. Any payments or portions thereof due hereunder which are not paid on the date such payments are due under this Agreement shall bear interest [***], calculated on the number of days such payment
is delinquent. If the royalty payments are paid in any currency other than United States Dollars, the Parties shall apply the [***]. 

  

	5.11	 TAX WITHHOLDING. All payments under this Agreement shall be net of any taxes or duties, other than income taxes
of Ambrx, owed thereon, which taxes (other than Ambrx income taxes) shall be the responsibility of Sino (“Taxes”). Ambrx shall be liable for all income and/or other taxes (including interest) imposed upon any royalty payments made
by Sino to Ambrx under this Agreement. In the event Applicable Laws require withholding of Taxes, Sino shall notify Ambrx in writing of the amount of tax payable in advance, before it makes such withholding payments and subtracts the amount thereof
from the payments. Sino shall submit appropriate proof of payment of the withheld Taxes to Ambrx and shall provide Ambrx with the official receipts within a reasonable period of time. Notwithstanding the foregoing, to the extent permitted by
Applicable Laws and upon the request of Ambrx, Sino shall use Commercially Reasonable Efforts to apply for approvals from competent PRC tax authorities, on behalf of Ambrx, for reduction or exemption of applicable PRC taxes on the payments made by
Sino to Ambrx, before it makes the withholding payments and subtracts the amount thereof from the payments due to Ambrx. 

  

	5.12	 PAYMENT PROCEDURES. Sino shall be responsible for obtaining any and all governmental approval/registration
procedures (if legally required) and foreign exchange-related procedures/formalities in connection with repatriation of any payments made by Sino to Ambrx under the Agreement to the bank accounts designated by Ambrx outside China, and Ambrx will
provide reasonable assistance if necessary. 

 ARTICLE 6 

INTELLECTUAL PROPERTY 
  

	6.1	 OWNERSHIP OF INTELLECTUAL PROPERTY. 

 

	6.1.1	 OWNERSHIP OF SELF-CONTROLLED IP OUTSIDE THIS AGREEMENT. As between the Parties, each Party will retain
ownership of all Patent Rights, Know-How and other intellectual property rights that are Controlled by such Party prior to the Effective Date or are otherwise developed, made, conceived of or reduced to
practice by such Party. 

  

	6.1.2	 OWNERSHIP OF LICENSED COMPOUNDS, LICENSED PRODUCTS AND PRODUCT SPECIFIC PATENTS. As between Sino and Ambrx,
Sino is the sole owner of all existing and future rights, titles and interests in and to the Licensed Compounds, the Licensed Products and the Product Specific Patent Rights in each case in the Sino Territory, and Ambrx is the sole owner of all
existing and future rights, titles and interests in the Licensed Compounds and the Licensed Products in each case in the Ambrx Territory. 

  
 29 

	6.1.3	 OWNERSHIP OF RESEARCH PROGRAM IP INDEPENDENTLY DEVELOPED BY EACH PARTY. 

 

	 	(I)	 Sino is the sole owner: 

 

	 	(a)	 any Sino Research Program Patents in the Sino Territory; and 

 

	 	(b)	 any Ambrx Research Program Patents in the Sino Territory. 

 

	 	(II)	 Ambrx is the sole owner of any Ambrx Background Technology and: 

 

	 	(a)	 any Sino Research Program Patents in the Ambrx Territory; and 

 

	 	(b)	 any Ambrx Research Program Patents in the Ambrx Territory. 

 

	6.1.4	 OWNERSHIP OF PLATFORM IMPROVEMENTS. Ambrx is the sole owner of any improvements to the Ambrx Core Technology
Platform made, conceived of, reduced to practice, or generated by either or both of the Parties (such improvements “Platform Improvements”). So long as the Ambrx Core Technology Patents relevant to the Platform Improvements remains
valid, Sino hereby assigns to Ambrx all of Sino’s right, title and interest in, to and under all Platform Improvements and all intellectual property rights therein.

 

	6.1.5	 OWNERSHIP OF JOINT RESEARCH PROGRAM PATENTS. 

 

	 	(a)	 With respect to interests in Joint Research Program Patents in the Sino Territory, Sino is the sole owner; and

  

	 	(b)	 With respect to interests in Joint Research Program Patents in the Ambrx Territory, Ambrx is the sole owner.

  

	6.1.6	 OWNERSHIP OF INVENTION OUTSIDE THE FIELD. Ownership of Invention by each Party outside the Field shall be owned
by the Parties in the following manner: 

  

	 	(a)	 With respect to any interests arising from any Invention outside the Field, which is discovered, generated,
made or reduced to practice solely by Sino’s employees, independent contractors or employees in the course of performance of the Research Program, such interests in the Sino Territory shall be solely owned by Sino and such interests in the
Ambrx Territory shall be solely owned by Ambrx. 

  

	 	(b)	 With respect to any interests arising from any Invention outside the Field, which is discovered, generated,
made or reduced to practice solely by Ambrx’ s employees, independent contractors or employees in the course of performance of the Research Program, such interests in the Sino Territory shall be solely owned by Sino and such interests in the
Ambrx Territory shall be solely owned by Ambrx. 

  
 30 

	6.1.7	 ASSIGNMENT. Each Party shall assign and hereby assigns to the other Party such Party’s right title and
interest in, to and under the intellectual property rights (including Patent Rights) that are assigned to such other Party under this Section 6.1. 

  

	6.2	 FILING, PROSECUTION AND MAINTENANCE OF PATENTS. 

 

	6.2.1	 

(I) JOINT RESEARCH PROGRAM IP. Each Party shall have the right to file Patent Right applications for Joint Research Program Patents, with
respect to Sino in the Sino Territory, and with respect to Ambrx in the Ambrx Territory and thereafter prosecute and maintain Patent Rights for such Joint Research Program Patents in its territory. In the event that any Party files such Patent Right
applications and thereafter prosecutes and maintains Patent Rights for such Joint Research Program Patents in its territory (such Party, the “Filing Party”), upon the request of the Filing Party, the other Party shall co-operate and shall execute such documents and perform such ministerial acts, at the costs and expenses of the Filing Party, as may be reasonably necessary for the Filing Party to continue such prosecution or
maintenance of Patent Rights claiming such Joint Research Program Patents. With respect to a given Joint Research Program Patent, the Filing Party may elect to file or may elect not to file in a particular country and, if so, the Filing Party shall
notify the other Party. 
 (II) PATENT RIGHTS FOR RESEARCH PROGRAM IP. Sino shall have the right, at its sole cost and expense, to file
Patent Right applications in the Sino Territory for (i) Patent Rights for Sino Research Program IP; (ii) Patent Rights for Ambrx Research Program IP; and (iii) Product Specific Patent Rights; and Ambrx shall have the right, at its
sole cost and expense, to file Patent Right applications in the Ambrx Territory for (iv) Patent Rights for Ambrx Research Program IP; and (v) Patent Rights for Sino Research Program IP. In the event that any Filing Party files such Patent
Right applications and thereafter prosecutes and maintains Patent Rights for such Patent Rights under this (i) to (v) of this paragraph, upon the request of the Filing Party, the other Party shall
co-operate and shall execute such documents and perform such ministerial acts, at the costs and expenses of the Filing Party, as may be reasonably necessary to continue such prosecution or maintenance of such
Sino Research Program Patents and Ambrx Research Program. 
  

	6.2.2	 REVIEW AND CONSULTATION. In each case in connection with the foregoing with respect to Patent Rights, as
applicable, the Filing Party (a) shall keep the other Party advised of the status of the actual and prospective patent filings; (b) upon the other Party’s written request, shall provide advance copies of any papers related to the
filing, prosecution and maintenance of such patent filings; (c) shall give the other Party an opportunity to review the text of the application before filing and shall consult with the other Party with respect thereto; (d) shall give the
other Party an opportunity to review and comment on any documents relating to such patent filings that will be filed in any patent office at least twenty (20) days before such filing and give due consideration to such substantive, non-cumulative comments; (e) shall supply the other Party with a copy of the application as-filed, together with notice of its filing date and serial number; and
(f) shall promptly give notice to the other Party of the grant, lapse, revocation, surrender, invalidation or 

  
 31 

	 	
abandonment of any Patent Rights for which it is responsible for the filing, prosecution or maintenance hereunder (provided that the filing Party shall give at least thirty (30) days’
prior written notice to the other Party of any desire to cease prosecution and/or maintenance of such Patent Rights). With respect to a given Patent Right, the Filing Party may elect not to prosecute and maintain such Patent Right, and, if so, the
Filing Party shall notify the other Party and the other Party shall have the right (but not the obligation) to prosecute and maintain such Patent Right. 

  

	6.2.3	 COSTS. The Filing Party shall be responsible for the costs of filing Patent Right applications and procuring
and maintaining Patent Rights for such Joint Research Program Patents, Ambrx Research Program Patents and Sino Research Program Patents that it has a right to file, prosecute and maintain under this Article 6. 

 

	6.3	 ENFORCEMENT OF PATENT RIGHTS. 

 

	6.3.1	 NOTICE. Each Party shall promptly notify the other Party of any infringement or possible infringement by a
Third Party of any Patent Rights licensed or assigned to Sino under this Agreement. Further, Ambrx shall give Sino, and Sino shall give Ambrx, notice of any infringement of any Patent Rights that a Filing Party has the right to prosecute and
maintain in the Sino Territory, or any misappropriation or misuse of Joint Research Program Know-How, Ambrx Research Program Know-How or Sino Research Program Know-How, that may come to Ambrx’s or Sino’s attention (“Infringement”). Sino and Ambrx shall thereafter consult and cooperate fully to determine a course of action, including, but not
limited to, the commencement of legal action by Sino and/or Ambrx, to terminate any Infringement of such Patent Rights or any misappropriation or misuse of such Know-How, as applicable. 

 

	6.3.2	 SUIT BY SINO. Sino shall have the first right, but not the obligation, to initiate and prosecute such legal
action at its own expense and in the name of Sino to terminate any Infringement in the Sino Territory, as applicable. Should Sino elect to bring suit against an infringer, Sino shall keep Ambrx reasonably informed of the progress of the action and
shall give Ambrx a reasonable opportunity in advance to consult with Sino and offer its views about major decisions affecting the litigation. Sino shall give careful consideration to Ambrx’s views, but shall have the right to Control the
action; provided, however, that if the validity and/or enforceability of the Ambrx Background Technology (including the Ambrx Core Technology IP) is raised by the infringer in the action, or if Sino’s License to a Valid Claim in the suit
terminates, Ambrx may elect to take control of the action pursuant to Section 6.3.3. Should Sino elect to bring suit against an infringer and Ambrx is joined as party plaintiff in any such suit, Sino shall have the right to approve the counsel
selected by Sino to represent Sino and Ambrx, such approval not to be unreasonably withheld. The expenses of such suit or suits that Sino elects to bring, including any expenses of Ambrx incurred in conjunction with the prosecution of such suits or
the settlement thereof, shall be paid for entirely by Sino and Sino shall hold Ambrx free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. Sino shall not compromise or settle such
litigation without the prior written consent of Ambrx, which consent shall not be unreasonably withheld or delayed. In the event Sino exercises its right to sue pursuant to this Section 6.3.2, it shall first reimburse itself out of any sums
recovered 

  
 32 

	 	
in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit.
If, after such reimbursement, any funds shall remain from said recovery, then Ambrx shall receive an amount equal to [***] ([***]) of such funds and the remaining [***] ([***]) of such funds shall be retained by Sino. 

 

	6.3.3	 SUIT BY AMBRX. If Sino does not take action in the prosecution, prevention or termination of any infringement
pursuant to Section 6.3.2 above, and has not commenced negotiations with the infringer for the discontinuance of said infringement, within ninety (90) days after receipt of notice to Sino by Ambrx of the existence of an Infringement, Ambrx
may elect to do so. Should Ambrx elect to bring suit against an infringer and Sino is joined as party plaintiff in any such suit, Ambrx shall have the right to select the counsel to represent Ambrx and Sino unless otherwise conflicted out. The
expenses of such suit or suits that Ambrx elects to bring, including any expenses of Sino incurred in conjunction with the prosecution of such suits or the settlement thereof, [***]. In the event Ambrx exercises its right to sue pursuant to this
Section 6.3.3 it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the
prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Sino shall receive an amount equal to [***] ([***]) of such funds and the remaining [***] ([***]) of such funds shall be retained by Ambrx.
Notwithstanding the foregoing, Ambrx shall have the right to initiate and prosecute any legal action(s) relating to Licensed Intellectual Property Rights or Ambrx Background Technology outside the Sino Territory at its own expense.

  

	6.3.4	 COOPERATION. Each Party agrees to cooperate fully in any action under this Article 6 that is controlled by the
other Party, provided that the controlling Party reimburses the cooperating Party promptly for any costs and expenses incurred by the cooperating Party in connection with providing such assistance. 

 

	6.3.5	 DECLARATORY JUDGMENT & INVALIDITY CHALLENGE. If a declaratory judgment action is brought naming Sino
and/or any of its Affiliates as a defendant, or a claim alleging invalidity or unenforceability of any Valid Claims within the in Ambrx Research Program Patents or Sino Research Program Patents or Joint Research Program Patents in the Sino
Territory, it shall be handled in the same manner as set forth in Section 6.4. 

  

	6.4	 INFRINGEMENT ACTIONS BY THIRD PARTIES. 

 

	6.4.1	 NOTICE. Each Party shall notify the other Party promptly in writing of any claim of, or action for,
infringement of any Patent Rights owned or licensed by Third Parties (“Claimant”) which is threatened, made or brought against either Party by reason of either Party’s performance of its obligations under this Agreement or
Development, manufacture, use or sale of any Licensed Products in the Sino Territory. 

  

	6.4.2	 DEFENSE. In the event that such an action for infringement is commenced by a Claimant solely against a Party or
both Parties jointly and/or any of their respective Affiliates, as the 

  
 33 

	 	
case may be, with respect to a Licensed Product Developed and Commercialized by Sino and/or its Affiliate in the Sino Territory, Sino shall use best efforts to defend such action at its own
expense, and Ambrx hereby agrees to use best efforts to assist and cooperate with Sino in the defense of such suit, including but not limited to providing the necessary information and materials Controlled by Ambrx for preparing the defense and
counter-claim. 

  

	6.4.3	 PAYMENT OBLIGATION. During the pendency of any such action, Sino shall continue to pay all royalties and other
payments due hereunder, provided that no injunctive relief has been declared by the relevant court which prohibit use of the relevant Product Specific Patent Rights or the relevant Licensed Intellectual Property Rights in the Sino Territory.

  

	6.5	 UNSUCCESSFUL DEFENSE AND SETTLEMENT. In the event that Sino loses an action for infringement of Patent Rights
brought by a Claimant, Ambrx shall, within 30 days of the Court’s award of damages to the Claimant, [***]. Alternatively, if a settlement agreement is reached between Sino and the Claimant to pay the Claimant (i) [***]; (ii) [***]: (a) [***];
(b) [***] (i) [***]; and (ii) [***]. For clarity, the [***] and the [***] aggregating with the [***] shall not exceed [***] of the total royalties payable to Ambrx during the Term. 

ARTICLE 7 

CONFIDENTIALITY & PUBLICATIONS 
  

	7.1	 NONDISCLOSURE OBLIGATION. Except to the extent expressly authorized by this Agreement, the Parties agree that,
during the Term of this Agreement and for seven (7) years thereafter, each Party and its Affiliates, if any (collectively, a “Receiving Party”), shall use their best efforts to keep Confidential Information & Materials
completely confidential, shall not publish or otherwise disclose to any Third Party and shall not use for any purpose other than the performance of this Agreement both the financial terms of this Agreement and any information furnished to it by the
other Party or its Affiliates, if any (collectively, a “Disclosing Party”) (and shall ensure that its and its Affiliates’ respective directors, officers, employees or agents do likewise), except to the extent that it can be
established by the Receiving Party by competent proof that such information: (i) is, or hereafter becomes, generally available to the public other than by reason of any default by the Receiving Party with respect to its confidentiality
obligations hereunder; (ii) was already known to the Receiving Party at the time of disclosure by the Disclosing Party; (iii) was lawfully disclosed to the Receiving Party by a Third Party not in default of any confidentiality obligation
to the Disclosing Party; or (iv) is independently Developed by or for the Receiving Party without reference to or reliance upon the information furnished by the Disclosing Party. 

 

	7.2	 EXCLUSIONS TO CONFIDENTIALITY. The restrictions contained in Section 7.1 shall not apply to any
Confidential Information & Materials in the hands of a Receiving Party that (i) are submitted by the Receiving Party to governmental authorities to facilitate the issuance of Marketing Authorization for Licensed Products in the Sino
Territory, provided that reasonable measures shall be taken to assure confidential treatment of such information, if practicable, or (ii) are otherwise required to be disclosed in compliance with

  
 34 

	 	
Applicable Laws (including, without limitation, to comply with any governmental or stock exchange disclosure requirements) or an order by a court or other regulatory body having competent
jurisdiction; provided, however, that if a Receiving Party is required to make any such disclosure of the Disclosing Party’s Confidential Information & Materials, such Receiving Party shall, except where impracticable for necessary
disclosures (for example to physicians conducting studies or to health authorities), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of Patent Right applications or
otherwise, will use its best efforts to secure confidential treatment of such Confidential Information & Materials required to be disclosed. In addition, any press release or other public announcement permitted by the terms of
Section 7.4 hereof shall be excluded from the provisions of Section 7.1. 

  

	7.3	 PUBLICATION. Sino and Ambrx each acknowledge the other Party’s interest in publishing the results of its
research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and
trade secret information. Consequently, except for disclosures permitted pursuant to Section 7.2, either Party, its employees or its consultants wishing to make a publication with respect to the Development or clinical results regarding the
Licensed Products hereunder shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall
have the right (a) to propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable
information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of one hundred and twenty (120) days to enable Patent Right applications protecting each Party’s rights in such
information to be filed in accordance with Article 67 above. Upon expiration of such one hundred and twenty (120) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests
modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure of trade secret or proprietary business information prior to submission of the publication or presentation.

  

	7.4	 PUBLICITY/USE OF NAMES. No disclosure of the existence, or the terms, of this Agreement may be made by either
Party. Notwithstanding the foregoing, disclosure by either Party to its business partners or other institutions in the ordinary and usual course of business or with the bona fide intent to pursue the objective of this Agreement shall be permitted,
provided that such disclosure shall be to the minimum extent possible and a confidentiality agreement shall be entered into with the recipient on terms no less exacting than the confidentiality provisions set forth in this Agreement. Neither Party
shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express
written permission of the other Party, except as may be required by Applicable Law or as permitted pursuant to Section 7.2; provided that in the event disclosure is required by Applicable Law, the

  
 35 

	 	
Disclosing Party shall use good-faith efforts to give the non-Disclosing Party an opportunity, with reasonable advance notice, to review and comment on any
proposed disclosure. Notwithstanding Section 7.4 herein, Sino and Ambrx shall make reasonable effort to issue a mutually agreed joint press release as shown in Exhibit 7.4 regarding the execution of this Agreement and the cooperation
between both Parties, provided, further, that any further press release to be issued by one Party mentioning the execution of this Agreement or naming the other Party shall be approved in advance by the other Party. 

 

	7.5	 INJUNCTIVE RELIEF. The Parties acknowledge that monetary damages alone may not adequately compensate the
Disclosing Party in the event of a material breach by the Receiving Party of this Article 7, and that, in addition to all other remedies available to the Disclosing Party under this Agreement, at law or in equity, to the extent permitted by
Applicable Laws, it shall be entitled to seek injunctive relief for the enforcement of its rights under this Article 7. 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 
  

	8.1	 MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party represents and warrants to the other Party the following as
of the Effective Date and covenants during the Term that: 

  

	8.1.1	 CORPORATE POWER. Such Party is duly organized and validly existing under the laws of the country/state of its
organization, and has full legal and corporate power and authority to enter into this Agreement and to perform its obligations hereunder. 

  

	8.1.2	 DUE AUTHORIZATION AND EXECUTION. The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally
binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and
other similar laws of general application affecting the rights and remedies of creditors. 

  

	8.1.3	 NON-CONTRAVENTION. The execution, delivery and performance by such
Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in any material respect violate any statute, Regulation, judgment, order, decree or other restriction of any governmental authority to which
such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or (iii) constitute a material violation or breach by such Party
of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a party. 

  
 36 

	8.2	 REPRESENTATIONS BY AMBRX. Ambrx represents and warrants to Sino the following as of the Effective Date:

  

	8.2.1	 to Ambrx’s knowledge, the Licensed Intellectual Property Rights exist and are not invalid or
unenforceable, in whole or in part; 

  

	8.2.2	 it has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or
interest in Licensed Intellectual Property Rights related to the [***] in the Field in the Sino Territory, or (ii) granted any rights to any Third Parties, in either case that would conflict with the rights granted to Sino hereunder;

  

	8.2.3	 to Ambrx’s knowledge, it is (a) the sole and exclusive owner of the Licensed Intellectual Property
Rights, (b) the sole and exclusive licensee of the Exclusive Existing Third Party Licenses, and (c) the non-exclusive licensee of the Non-Exclusive Existing
Third Party Licenses, in each case related to the [***] in the Sino Territory and the Ambrx Territory; 

  

	8.2.4	 the Exclusive Existing Third Party Licenses are in force and effect, and Ambrx has not received any notice of
breach or termination with respect to any Existing Third Party License; 

  

	8.2.5	 to Ambrx’s knowledge, there are no claims, judgments or settlements against or owed by Ambrx and no
pending or threatened claims or litigation relating to Licensed Intellectual Property Rights in the Sino Territory and the Ambrx Territory; and Ambrx is not aware of any infringement or misappropriation of the intellectual property rights of any
Third Party in the Sino Territory and the Ambrx Territory arising from any research and development of the Licensed Compounds by Ambrx prior to the Effective Date; 

 

	8.2.6	 to Ambrx’s knowledge, there are no claims, judgments or settlements against or owed by the licensor of the
Existing Third Party License relating to the Third Party License in the Sino Territory and the Ambrx Territory; and 

  

	8.2.7	 save and except the Existing Third Party Licenses set forth in Exhibit 2.4.2, there are no other Existing Third
Party Licenses to which Ambrx is a licensee for use of any Patent Rights or Know-How that are necessary or useful for the manufacture, Development or Commercialization of the Licensed Compounds and the
Licensed Products. Ambrx shall update the Existing Third Party License exhibit for any changes and addition of Ambrx Third Party Licenses and Future Third Party Licenses on a regular basis. 

 

	8.3	 REPRESENTATIONS BY SINO. Sino represents and warrants to Ambrx as of the Effective Date and covenants
thereafter, to Ambrx that: 

  

	8.3.1	 Sino and its Affiliates will use the Licensed Intellectual Property Rights and Ambrx Core Technology IP solely
for the purpose of the Development, use, manufacture or sale of the Licensed Products in the Sino Territory strictly in accordance with the terms of this Agreement and not for any other purpose. 

  
 37 

	8.3.2	 Sino and its Affiliates shall invest sufficient resources and funds and use Commercially Reasonable Efforts to
achieve Milestone Events so as to Develop and Commercialize Licensed Products in the Sino Territory. 

 ARTICLE 9

 INDEMNIFICATION & INSURANCE 
  

	9.1	 INDEMNIFICATION BY SINO. Sino hereby agrees to indemnify, hold harmless and defend Ambrx, its Affiliates and
their respective officers, directors, agents, employees, successors and assigns (collectively, the “Ambrx Indemnified Parties”) against any and all direct losses, costs, expenses, fees or damages arising out of or relating to
claims, allegations, suits, actions or proceedings (collectively, “Losses”) asserted by any Third Party, whether governmental or private, arising out of or relating to (i) the Development, manufacture, use, sale or other
disposition of Licensed Products by Sino or its Affiliates or Sublicensees under this Agreement, (ii) failure to perform its obligations under this Agreement by Sino, its Affiliates or their respective officers, directors, agents or employees,
(iii) the breach of any of Sino’s covenants, representations or warranties under this Agreement, or (iv) the negligence or willful misconduct by Sino, its Affiliates or their respective officers, directors, agents or employees, in
performing any obligations under this Agreement, except in each case ((i) to (iv)) for those Losses as to which Ambrx has an obligation to indemnify Sino pursuant to Section 9.2, as to which Losses each Party shall indemnify the other to the
extent of their respective liability; provided, however, that Sino shall not be obligated to indemnify Ambrx for any Losses to the extent that such Losses arises as a result of gross negligence or wilful misconduct on the part of Ambrx or any of its
Affiliates. 

  

	9.2	 INDEMNIFICATION BY AMBRX. Ambrx hereby agrees to indemnify, hold harmless and defend Sino, its Affiliates and
their respective officers, directors, agents, employees, successors and assigns (collectively, the “Sino Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims,
allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out of or relating to (i) failure to perform its obligations under this Agreement by Ambrx, its Affiliates or their respective
officers, directors, agents or employees, (ii) the breach of any of Ambrx’s covenants, representations or warranties under this Agreement, or (iii) the negligence or willful misconduct by Ambrx, its Affiliates or their respective
officers, directors, agents or employees, in performing any obligations under this Agreement, except in each case ((i) to (iii)) for those Losses as to which Sino has an obligation to indemnify Ambrx pursuant to Section 9.1, as to which Losses
each Party shall indemnify the other to the extent of their respective liability; provided, however, that Ambrx shall not be obligated to indemnify Sino for any Losses to the extent that such Losses arises as a result of gross negligence or wilful
misconduct on the part of Sino or any of its Affiliates. 

  

	9.3	 PROCEDURE. If a Party is seeking indemnification under this Article 9 (the “Indemnified
Party”), it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to this Article 9 as soon as reasonably practicable after receiving notice of the claim
(provided, however, any delay or 

  
 38 

	 	
failure to provide such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable, this Article 9 except
to the extent that such delay or failure materially prejudices the Indemnifying Party’s ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is
obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and
expense. The Indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any
claim without the prior written consent of the Indemnified Party, which the Indemnifying Party may provide in its sole discretion. The Indemnified Party shall not settle or compromise any such claim without the prior written consent of the
Indemnifying Party, not to be unreasonably withheld. 

  

	9.4	 INSURANCE. Each Party shall obtain and acquire customary and reasonable insurance for activities conducted
under Clinical Trials, in accordance with applicable laws and regulations in the territory of each Party. 

 ARTICLE 10

 TERM & TERMINATION 
  

	10.1	 TERM. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as
provided in this Article 10, shall continue in full force and effect until the expiration of the Royalty Term with respect to Licensed Products in the Sino Territory (the “Term”). 

 

	10.2	 EFFECT OF EXPIRATION. Following the expiration of this Agreement with respect to a Licensed Product in the Sino
Territory pursuant to Section 10.1, (a) the License granted to Sino under Section 2.2.1, comprising (i) the Licensed Intellectual Property Rights self-owned by Ambrx, (ii) the Licensed Intellectual Property Rights constituted
under the Existing Third Party Licenses, and (iii) the Licensed Intellectual Property Rights constituted under the Ambrx Third Party Licenses and Future Third Party Licenses shall continue to be in full force and effect for Sino to make, have
made, use, sell, offer for sale, have sold and export such Licensed Product in the Sino Territory, in accordance with the terms under Section 2.2.1; (b) the License granted to Ambrx under Section 2.2.2 shall continue to be in full
force and effect for Ambrx to make, have made, use, sell, offer for sale, have sold and export such Licensed Product in the Ambrx Territory; and (c) Sino shall continue to retain all of Sino’s right, title and interest in, to and under the
Product Specific Patent Rights and Reload Patent Rights (if any) acquired during the Term of this Agreement. 

  

	10.3	 TERMINATION BY SINO WITHOUT CAUSE. Sino may terminate this Agreement upon six (6) months’ prior
written notice to Ambrx. 

  

	10.3A	 REQUEST FOR REFUND AND TERMINATION BY SINO DUE TO AMBRX’S FAILURE TO DELIVER PCC ON TIME.

  
 39 

	10.3A(1)	 In the event that Ambrx fails to provide any one PCCs of the Licensed Compounds that meet the Initial PCC
Requirements on or before June 30, 2020 or such later date as further agreed by the Parties, Sino shall have the right to request a refund of [***] of the upfront payment under Section 5.1 (being [***] ([***])) by serving a refund notice
to Ambrx. If Sino exercises such a discretion, Ambrx shall return [***] of the upfront payment to Sino within [***] business days from the date of the refund notice; and Sino shall reassign all the Product Specific Patent Rights that is/are specific
only to the delayed PCC to Ambrx within [***] days upon receipt of [***] of the upfront payment. All fees and costs related to the reassignment of such Product Specific Patent Rights shall be borne by Ambrx. For clarity, Product Specific Patent
Rights that are useful for Development and Commercialization of PCC delivered on-time shall not be reassigned. 

  

	10.3A(2)	 In the event that Ambrx fails to provide the PCCs of the Licensed Compounds that meet the Initial PCC
Requirements on or before June 30, 2020 or such later date as further agreed by the Parties, Sino shall have the right to terminate this Agreement unilaterally by serving a termination notice to Ambrx. If Sino exercises such a discretion, Ambrx
shall return the upfront payment under Section 5.1 to Sino within 10 business days from the date of the termination notice; and Sino shall reassign all the Product Specific Patents Rights to Ambrx within 60 days upon receipt of the
upfront payment. All fees and costs related to the reassignment of the Product Specific Patent Rights shall be borne by Ambrx. 

  

	10.4	 TERMINATION FOR DEFAULT. Each Party shall have the right to terminate this Agreement, upon notice to the other
Party, in the event that: 

  

	10.4.1	 Such other Party materially defaults with respect to any of its material obligations under this Agreement and
does not cure such default within sixty (60) days after the receipt of a notice from the non-breaching Party specifying the nature of, and requiring the remedy of, such default (or, if such default cannot
be cured within such sixty (60)-day period, if the breaching Party does not commence and diligently continue actions to cure same during such sixty (60)-day period);

  

	10.4.2	 Such other Party fails to use Commercially Reasonable Efforts to perform its respective obligations under the
Agreement in accordance with the timelines set forth therein; 

  

	10.4.3	 The other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief
under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or
substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or
substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or

  

	10.4.4	 An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a
court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property, under the bankruptcy, insolvency or similar laws of any 

  
 40 

	 	
jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its
property, or (iii) the winding-up or liquidation of such other Party; and, in each case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree
approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for thirty (30) days. 

  

	10.5	 EFFECT OF TERMINATION. 

 

	10.5.1	 TERMINATION OF RIGHTS. Effect of Termination of this Agreement shall be in accordance with Section 10.5
and Section 10.6. 

 (I) Upon termination of this Agreement by Ambrx pursuant to Section 10.4 or by Sino pursuant
to Section 10.3, (a) all rights and Licenses granted to Sino under Article 2 shall continue to be in full force and effect (excluding Ambrx Territory), (b) the License granted to Ambrx under Section 2.2.2 shall continue to be in
full force and effect (excluding the Sino Territory), and (c) Sino shall continue to retain all of Sino’s right, title and interest in, to and under the Product Specific Patent Rights and the Reload Patent Rights (if any). 

(II) Upon termination of this Agreement by Sino pursuant to Section 10.4, the rights and Licenses granted to Ambrx under
Section 2.2.2 shall be retained by Ambrx. 
 (III) Upon termination of this Agreement by Sino pursuant to Section 10.3A(2) and
subject to the refund of the upfront payment by Ambrx to Sino, the Product Specific Patent Rights assigned to Sino shall be reassigned and reverted to Ambrx in accordance with Section 10.3A(2) and the Licenses granted to Sino under Article 2
shall be null and void. 
  

	10.5.2	 NO RELEASE. Termination of this Agreement for any reason shall not release any Party hereto from any liability
which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination, nor shall such termination preclude either Party from pursuing any rights and remedies it may have
hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination. 

  

	10.5.3	 SINO’S RETAINED RIGHTS AFTER TERMINATION. After the date of termination by either party pursuant to
Section 10.4 or by Sino pursuant to Section 10.3, Sino and its Affiliates shall have the right to (a) [***]; and (b) [***] and (c) [***]; provided that, [***]. For clarity, this Section 10.5.3 does not apply to termination
pursuant to Section 10.3A(2). 

  

	10.5.4	 TRANSFER OF INFORMATION, MATERIALS AND REGULATORY FILINGS. Notwithstanding the foregoing, upon termination of
this Agreement by either party pursuant to Section 10.4 or by Sino pursuant to Section 10.3, each Party shall provide the other Party with the right to reference, cross-reference, review, have access to, incorporate and use all documents
and other materials filed by or on behalf of the other Party and its Affiliates with any Regulatory Authority in furtherance of applications for Marketing Authorization of the Parties in their respective territories with respect to the Licensed
Product. Each Party shall be entitled to freely and exclusively use and to grant others the 

  
 41 

	 	
right to use all such materials and documents delivered pursuant to this Section 10.5.4 for use outside their respective territories. For clarity, this Section 10.5.4 does not apply to
termination pursuant to Section 10.3A(2). 

  

	10.5.5	 RETURN OF CONFIDENTIAL INFORMATION & MATERIALS. Subject to Section 10.5.1, upon any termination
of this Agreement, each Party shall promptly return to the other Party all Confidential Information & Materials or Know-How received from the other Party, except as reasonably required to exercise any
surviving rights or licenses hereunder. 

  

	10.6	 ACCRUED RIGHTS; SURVIVAL. 

 

	10.6.1	 Termination or expiration of this Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination or expiration. Such termination or expiration shall not relieve either Party from obligations which are expressly indicated to survive termination or expiration of this Agreement.
The rights of the Parties upon termination described in this Agreement shall not be exclusive of any other rights or claims at law or in equity that either Party may have against the other arising out of this Agreement. 

 

	10.6.2	 Termination, relinquishment or expiration of this Agreement pursuant to Section 10.3 (Termination by Sino
Without Cause) and Section 10.4 (Termination for Default) shall not terminate each Party’s obligation to pay all royalties, Milestone Payments and other monetary obligations that may have accrued hereunder prior to such termination. All of
the Parties’ respective rights and obligations under Section 2.1.1 (Assignments of Product Specific Patent Rights in the Sino Territory); Section 2.2 (Grant of Exclusive Licenses to Use the Licensed Intellectual Property Rights);
Section 2.6 (Rights of Reference; Clinical Data Rights), Section 6.1 (Ownership of Intellectual Property), Section 10.5 (Effect of Termination) and Section 11.5 (Notices), Article 1 (Definitions), Article 7
(Confidentiality & Publications), Article 9 (Indemnification & Insurance), Section 10.2 (Effect of Expiration), Section 10.6 (Accrued Rights; Survival), Section 10.7 (Dispute Resolution), and Section 11.6
(Applicable Law) shall survive termination, relinquishment or expiration hereof. 

  

	10.6.3	 Termination, relinquishment or expiration of this Agreement pursuant to Section 10.3A(2) shall not
terminate Article 1 (Definitions), Article 7 (Confidentiality & Publications), Article 9 (Indemnification & Insurance), Section 10.6 (Accrued Rights; Survival), Section 10.7 (Dispute Resolution), and Section 11.6
(Applicable Law), which Sections shall survive termination and relinquishment hereof. 

 DISPUTE RESOLUTION 

 

	10.7	 DISPUTES. Subject to Section 10.8, upon the written request of either Party to the other Party, any claim,
dispute or controversy as to the breach, enforcement, interpretation or validity of this Agreement (a “Dispute”) will be referred to the executive officers (or such executive officer’s designee with decision-making authority)
for attempted resolution. In the event such executives are unable to resolve such Dispute within thirty (30) days after 

  
 42 

	 	
the initial written request, then, upon the written demand of either Party, the Dispute shall be subject to arbitration, as provided in Section 10.8, except as expressly set forth in
Section 10.8. 

  

	10.8	 ARBITRATION. Any Dispute that cannot be resolved pursuant to Section 10.7 will be referred to and finally
resolved by arbitration in accordance with the International Chamber of Commerce (the “Rules”) by the Hong Kong International Arbitration Centre (“HKIAC”), by an arbitral tribunal composed of three
(3) arbitrators, with each Party appointing one (1) arbitrator and the third arbitrator to be selected by mutual agreement of the two (2) arbitrators appointed by the Parties. The foregoing arbitration proceedings may be commenced by
either Party by notice to the other Party. All arbitration proceedings will be conducted in the English language. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrators, or, in
the absence of such determination, each Party will pay its own expenses. All rulings by the arbitrators will be final. 

  

	10.9	 EXCEPTIONS. Nothing contained in this Agreement shall deny either Party the right to seek, upon good cause,
injunctive or other equitable relief from a court of competent jurisdiction in the context of an emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing Dispute resolution discussions or
arbitration proceedings. In addition, either Party may bring an action in any court of competent jurisdiction to resolve Disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of Patent Rights or
other intellectual property rights, and no such claim shall be subject to arbitration pursuant to Section 10.8. 

ARTICLE 11 

MISCELLANEOUS 
  

	11.1	 RIGHT OF FIRST OFFER FOR CHINA OPPORTUNITIES. In the event that Ambrx (for itself and on behalf of its
Affiliates) consider to develop [***] in China, Ambrx shall first notify Sino in writing, and Sino shall have [***] ([***]) days (“Review Period”) to notify Ambrx in writing that Sino wishes to negotiate for rights to [***] in
China. If Sino delivers such written notice prior to the expiration of the Review Period, followed by Sino’s performance of due-diligence investigation on [***] in no more than [***] days
(“Due Diligence Period”), then Ambrx and Sino shall [***] (either inside or outside the Field) in China for a period of [***] ([***]) days (“Negotiation Period”). Ambrx (for itself and on behalf of its
Affiliates) shall not enter into any [***] for any such [***] in China unless and until the Review Period and, if applicable, the Due Diligence Period and the Negotiation Period have expired without the Parties coming to terms under this
Section 11.1.

  

	11.2	 FORCE MAJEURE. Neither Party shall be held liable to the other Party or be deemed to have defaulted under or
breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including
embargoes, war, acts of war (whether war shall be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor 

  
 43 

	 	
disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such
force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. 

 

	11.3	 ASSIGNMENT. Except as provided in this Section 11.3, this Agreement may not be assigned or otherwise
transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party. Notwithstanding the foregoing, (i) Sino may assign this Agreement and its obligations hereunder in whole
or in part to an entity in which Sino owns not less than [***] equity interest (“Sino Investee”), provided that Sino shall be jointly and severally liable under this Agreement upon such assignment taking effect, (ii) either
Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; provided, however, that (a) the assigning Party must notify the other Party at least twenty
(20) days prior to completion of any such assignment, and (b) in the event of an assignment to an Affiliate, the assigning Party shall be jointly and severally liable for all activities of such Affiliate pursuant to this Agreement.
Further, each Party may assign this Agreement to any assignee of all or substantially all of such Party’s business to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which
this Agreement relates, or in the event of such Party’s merger, consolidation or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. This Agreement is binding upon the permitted
successors and assigns of the Parties. Any attempted assignment not in accordance with this Section 11.3 shall be void. 

  

	11.4	 SEVERABILITY. If any one or more of the provisions contained in this Agreement is held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the
substantive rights of the Parties. The Parties shall in such an instance use their good faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement
the purposes of this Agreement. 

  

	11.5	 NOTICES. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered
personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return
receipt requested, addressed as follows: 

  

			
	If to Ambrx, to:	 	Ambrx, Inc.
		 	10975 North Torrey Pines Road
		 	La Jolla, CA 92037
		 	Attn: Office of General Counsel
		 	Facsimile No.: (858) 453-9511

 With a copy to: 

  
 44 

			
		 	 Sidley Austin LLP
 555 California
Street

		 	Suite 2000
		 	San Francisco, California 94104
		 	USA
		 	Attn: Tom Duley, Partner
		 	Facsimile No.: +1 415-772-7400

 If to Sino, to: 

Unit 4109, Office Tower, Convention Plaza, 
  

			
		 	 Sino Biopharmaceutical Limited

1 Harbour Road, Wanchai,

		 	 Hong Kong

		 	 Attention: Mabel Leung

		 	 Facsimile No.: +852 2880 0847

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party
in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a
non-business day, then on the next business day); (b) on the business day after dispatch, if sent by internationally recognized overnight courier; or (c) on the fifth (5th) business day
following the date of mailing, if sent by mail. 
  

	11.6	 APPLICABLE LAW. This Agreement shall be governed by and construed in accordance with the laws of the Hong Kong
Special Administrative Region, without reference to any rules of conflict of laws or renvoi. The United Nations Convention on the Sale of Goods shall not apply to this Agreement. All Disputes arising from or in connection with this Agreement
shall be submitted for arbitration in accordance with the United Nations Commission on International Trade Law Arbitration Rules in accordance with the HKIAC Procedures for the Administration of International Arbitration in force at the date of this
Agreement. The place of arbitration shall be in Hong Kong at HKIAC. 

  

	11.7	 ENTIRE AGREEMENT; AMENDMENTS. This Agreement together with the Schedules hereto contains the entire
understanding of the Parties with respect to the subject matter hereof, including the Research Program and the Licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either
oral or written, with regard to the subject matter hereof, including the Research Program and/or the Licenses granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by reference and
shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. 

  
 45 

	11.8	 HEADINGS AND INTERPRETATION. The captions to the several Articles and Sections and subsections hereof are not a
part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit shall be
deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words
of any gender include each other gender, (b) words such as “herein,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words
using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term “including” (or “includes” or words of similar import), such term shall not be limiting and such term
shall be deemed to mean “including without limitation” (or “includes without limitation”), (e) the word “or” shall not be construed as exclusive, and (f) references to any Articles or Sections include Sections and
subsections that are part of the reference Article or section (e.g., a section numbered “Section 2.2.1” would be part of “Section 2.2,” and references to “Article 2” or “Section 2.2”
would refer to material contained in the subsection described as “Section 2”). 

  

	11.9	 INDEPENDENT CONTRACTORS. It is expressly agreed that Ambrx and Sino shall be independent contractors and that
the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Ambrx nor Sino shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall
be binding on the other Party, without the prior written consent of the other Party. 

  

	11.10	 WAIVER. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to
perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 

 

	11.11	 CUMULATIVE REMEDIES. No remedy referred to in this Agreement is intended to be exclusive, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  

	11.12	 WAIVER OF RULE OF CONSTRUCTION. Each Party has had the opportunity to consult with counsel in connection with
the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	11.13	 BUSINESS DAY REQUIREMENTS. In the event that any notice or other action or omission is required to be taken by
a Party under this Agreement on a day that is not a business day, then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. 

 

	11.14	 COUNTERPARTS. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the 

  
 46 

	 	
same instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original. 

 

	11.15	 PRC REGULATORY MATTERS. If required under applicable laws and regulations, Sino shall be responsible for any
and all PRC-related Regulatory Approvals, registrations and/or filings in connection with performance of this Agreement, including without limitation registering this Agreement with competent commission of
commerce and providing registration certificate to Ambrx within sixty (60) days after execution of this Agreement; after Regulatory Approvals, registrations and/or filings are completed, Sino shall provide a copy of relevant certificates to
Ambrx within thirty (30) days after obtaining such relevant certificates. 

  

	11.16	 EXPORT LAWS. Notwithstanding anything to the contrary contained herein, all obligations of Ambrx and Sino are
subject to prior compliance with the export Regulations of the United States and any other relevant country and such other laws and Regulations in effect in the United States and/or any other relevant country as may be applicable, and to obtaining
all necessary approvals required by the applicable agencies of the governments of the United States and any other relevant countries. Ambrx and Sino shall cooperate with each other and shall provide assistance to the other as reasonably necessary to
obtain any required approvals. 

  

	11.17	 FURTHER ACTIONS. Each Party will execute, acknowledge and deliver such further instruments, and do all such
other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	11.18	 NO THIRD PARTY RIGHTS. The provisions of this Agreement are for the exclusive benefit of the Parties, and no
other Person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. 

 

	11.19	 EXPENSES. Except as otherwise specifically provided in this Agreement, each Party (and its Affiliates) shall
bear its own costs and expenses in connection with entering into this Agreement and the consummation of the transactions and performance of its obligations contemplated hereby. 

 

	11.20	 EXTENSION TO AFFILIATES. Sino shall have the right to extend the rights, licenses, immunities and obligations
granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to
Sino. Sino shall remain fully liable for any acts or omissions of such Affiliates. 

  

	11.21	 LANGUAGE. The official text of this Agreement is in the English language as written and spoken in the United
States of America. Any text or version of this Agreement in another language, even if such text or version is made by translation or prepared by or executed by one or both of the Parties for a Party’s convenience, shall not be binding and shall
have no force or effect. Without limiting the foregoing, in the event of any conflict 

  
 47 

	 	
or inconsistency between the English text of this Agreement and any text or version of this Agreement in another language, the English text of this Agreement will prevail. 

[Remainder of this page is left intentionally blank] 

  
 48 

 IN WITNESS WHEREOF, the Parties have executed this
Co-Development and License Agreement as of the Effective Date. 
  

			
	SINO BIOPHARMACEUTICAL CO., LTD.

			
		
	By:	 	/s/ Theresa Tse

			
	Name: Tse, Theresa Y Y
	Title: Chairwoman
	
	AMBRX, INC.

			
		
	By:	 	/s/ Feng Tian

			
	Name: Tian, Feng
	Title: Chief Executive Officer

  
 49 

 List of Exhibits 

Exhibit 1.9: Ambrx Core Technology Platform 
 Exhibit 1.36:
Development Plan 
 Exhibit 1.82: [***] 
 Exhibit 1.83: [***]

 Exhibit 2.1.1: Product Specific Patent Rights 
 Exhibit
2.2.1: Licensed Intellectual Property Rights 
 Exhibit 2.4.2: Existing Third Party Licenses 

Exhibit 3.1: Joint Steering Committee 
 Exhibit 4.2.2 : Initial
PCC Requirements 
 Exhibit 7.4: Joint Press Release 

 Exhibit 1.9: Ambrx Core Technology Platform 

 
 

 
  
 

 

  
 Exhibit 1.9 - 1 

 Exhibit 1.36: Development Plan 

Clinical Plan will be updated (with Rodent Non-GLP toxicology plan) 

 
 

 
  
 

 

  
 Exhibit 1.36 - 1 

 Exhibit 1.82: [***] 

The diagram and description below set forth the structure of the [***] as of the Effective Date, which may be modified by mutual agreement to the satisfaction
of both Parties. 
  
 

 
 B. Amino Acid Sequence of Humanized Anti-CD3 Fab Lead Molecule 

[***] 
 [***] 

[***] 
 [***] 

[***] 

  
 Exhibit 1.82 - 1 

 Exhibit 1.83: [***] 

The diagram and description below set forth the structure of the [***] as of the Effective Date, which may be modified by mutual agreement to the satisfaction
of both Parties. 
  
 

 
  
 

 

  
 Exhibit 1.83 - 1 

 Exhibit 2.1.1: Product Specific Patent Rights 

 

															
	 Ambrx

Docket
 Number
	  	 Title
	  	 Country
	  	 Serial No.

(Filing
 Date)
	  	 Publication

No.
 (Date)
	  	 Patent No.

(Issue Date)
	  	 Priority
	  	 Status

Estimated
Expiry

	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  		  		  		  	 [***]

[***]

	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  		  		  		  	 [***]

[***]

	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  		  		  		  	 [***]

[***]

	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  		  		  		  	[***]

  
 Exhibit 2.1.1 - 1 

 Exhibit 2.2.1: Licensed Intellectual Property Rights 

Section A: List of Ambrx Core Technology Patents (Attached list) 

Section B: List of Ambrx Non-Core Patents (Attached list) 

Section C: List of Know-How 
  

	 	•	 	 Know-How is reflected/ covered in Sections A and B 

  
 Exhibit 2.1.2 - 1 

 Exhibit 2.4.2: Existing Third Party Licenses 

The agreements set forth herein have been provided by Ambrx with certain content redacted or omitted intentionally for confidentiality reasons. Sino is not
aware of the full content of the agreements set forth herein. 
  

															
	 Reference
	  	 Agreement
	  	 Description
	  	 Signed
	  	 Exclusivity
	  	 Term
	  	 Expiry Date
	  	 Royalty to be
paid by Sino

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	 [***]

[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 [***]

[***]
	  	[***]

  
 Exhibit 2.4.2 - 1 

 Exhibit 3.1: Joint Steering Committee 

Ambrx 
 Shawn Zhang, VP Research 

Ying Buechler, VP Development 
 Sukumar Sakamuri, VP and Head of
Chemistry 
 SINO 
 Names of 3 members from Sino’s side
to be provided. 

  
 Exhibit 3.1 - 1 

 Exhibit 4.2.2: Initial PCC Requirements 

[***] 
 PD study: [***]. 

PK study: [***]. 
 Safety: [***]. 

2. [***] 
 In vitro studies: [***] 

[***] 
 PK studies: [***]. 

PD studies: [***]. 
 Safety: [***]. 

  
 Exhibit 4.2.2 - 1 

 Ambrx Patent Rights – Core IP (December 2019) 

Exhibit 7.4: Draft Joint Press Release 
 To be
mutually agreed prior to release 

  
 Exhibit 7.4 - 1 

 Ambrx Patent Rights – Core IP (December 2019) 

 

															
	 Ambrx
Docket
Number
	  	Title	 	Country	 	Serial No.
(Filing Date)	 	Publication
No. (Date)	 	Patent No.
(Issue Date)	 	Priority	 	Status
Estimated
Expiry
	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
 Exhibit 7.4 - 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]